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Abstract 
Macrophages are a subset of myeloid cells showing phenotypic and functional plasticity. 
Tumor cells secrete chemokines which attract macrophages resulting in their accumulation 
within the tumor microenvironment. Depending on the environmental signals they receive, 
these tumor associated macrophages (TAMs) can differentiate into M1-like or M2-like TAMs 
with different phenotype and function. M1-like TAMs produce proinflammatory cytokines and 
display tumoricidal activity, whereas M2-like TAMs have an immunosuppressive phenotype 
typically associated with enhanced tumor growth. At later stages of tumor development, the 
majority of TAMs resemble the M2-like phenotype, thereby contributing to the establishment 
of an immunosuppressive tumor microenvironment. As M2-like TAMs are generally 
associated with poor prognosis in most tumor entities, they are considered as a suitable 
target for cancer therapy. In this study, we reprogrammed M2-like macrophages by cognate 
interaction with CD4+ T cells, transcription factor knockdown and miRNA transfection. 
Within the first part of the thesis, we demonstrate by comprehensive gene and protein 
expression analyses as well as functional assays that M2-like (IL-4 treated) peritoneal 
exudate cells (PECs) can be repolarized in vitro into immunostimulatory M1-like 
macrophages through cognate interaction with CD4+ T cells. Moreover, a MHC II (IAb) 
deficient, ovalbumin (OVA) expressing B16F10 clone (M2KO/OVA) was established to 
investigate the effect of adoptively transferred OVA specific CD4+ T cells on TAM 
polarization in a mouse model where MHC II restricted interaction between tumor cells and 
T cells is precluded. Adoptive transfer of CD4+ T cells into M2KO/OVA tumor bearing mice 
resulted in a decreased expression of the M2-associated protein CD206 and an increased 
expression of M1-associated genes (Il1b, Cd86, Cxcl10 and Nos2) in TAMs freshly isolated 
from M2KO/OVA tumors, pointing towards reprogramming of M2-like TAMs. In the second 
part of the project we combined transcription factor (TF) binding information with RNA 
expression profiles of in vitro polarized PECs and identified five transcription factors (CTCF, 
E2F1, MYC, PPARү and STAT6) involved in the induction and maintenance of the M2-like 
phenotype. siRNA mediated knockdown of these TFs in M2 polarized PECs induced the 
expression of M1-associated genes, whereas the expression of M2-associated genes was 
significantly reduced. In addition, the expression of proinflammatory cytokines (IL-1α, IL-6, 
MCP-1 and TNFα) was upregulated upon siRNA mediated TF knockdown, demonstrating a 
successful reprogramming of M2-like macrophages. In the third part of the project we were 
aiming at the identification of miRNAs involved in macrophage polarization. Therefore, we 
performed small RNA sequencing of in vitro polarized PECs, leading to the identification of 
19 miRNAs which were differentially expressed between M1-like and M2-like macrophages. 
Based on their expression level and their expression fold changes, six miRNAs significantly 
upregulated in M1-like PECs were selected for subsequent validation. The expression 
analysis of M2-like and untreated PECs upon co-transfection of these miRNAs revealed 
enhanced expression levels of M1-associated genes and decreased expression levels of 
M2-associated genes, indicating a polarization towards the M1-like phenotype. Taken 
together, our results reveal new insights into the transcriptional, post-transcriptional and 
T cell mediated reprogramming of macrophages and might be useful for the identification of 
novel therapeutic targets to repolarize M2-like TAMs. 
Zusammenfassung 
vii 
 
Zusammenfassung 
Makrophagen sind myeloide Zellen, die eine große phänotypische und funktionale Plastizität 
aufweisen. Tumorzellen sekretieren Chemokine, die eine Akkumulation von Makrophagen 
im Tumormikromilieu induzieren können. In Abhängigkeit von den umgebenden Signalen 
können diese Tumor-assoziierten Makrophagen (TAMs) in M1 oder M2 Makrophagen mit 
unterschiedlichem Phänotyp differenzieren. M1 TAMs produzieren proinflammatorische 
Zytokine und haben eine tumorizide Aktivität, während M2 TAMs einen 
immunsupprimierenden Phänotyp aufweisen und mit verstärktem Tumorwachstum assoziiert 
sind. In späteren Tumorstadien weisen die meisten infiltrierten Makrophagen einen M2 
Phänotyp auf und tragen dadurch zu der Etablierung eines immunsupprimierenden 
Tumormikromilieus bei. M2 polarisierte Makrophagen sind in den meisten Tumorentitäten 
mit einer schlechten Prognose assoziiert und stellen daher ein geeignetes Ziel für 
Krebstherapien dar. In dieser Arbeit konnten M2 Makrophagen durch die MHC II restringierte 
Interaktion mit CD4+ T-Zellen, die Herabregulation von Transkriptionsfaktoren (TFs) oder 
durch die Transfektion von miRNAs zu M1 Makrophagen reprogrammiert werden.  
Im ersten Teil der Arbeit wird anhand umfassender Genexpressionsanalysen und mithilfe 
funktionaler Testverfahren gezeigt, dass M2 polarisierte (IL-4 induziert) peritoneale 
Exsudatzellen (PECs) durch eine antigen-spezifische Interaktion mit CD4+ T-Zellen in vitro in 
M1 Makrophagen repolarisiert werden können. Außerdem wurde ein IAb defizienter, 
Ovalbumin (OVA) exprimierender B16F10 Klon etabliert (M2KO/OVA), um die Effekte von 
adoptiv transferierten CD4+ T-Zellen auf TAMs unter Ausschluss einer direkten MHC II 
restringierten Interaktion zwischen Tumorzellen und T-Zellen in vivo untersuchen zu können. 
Der adoptive Transfer von CD4+ T-Zellen in M2KO/OVA tumortragende Mäuse resultierte in 
einer verminderten Expression des M2-assoziierten Proteins CD206 und einer erhöhten 
Expression von M1-assoziierten Genen (Il1b, Cd86, Cxcl10 and Nos2) in frisch isolierten 
TAMs aus M2KO/OVA Tumoren. Im zweiten Teil der Arbeit wurden, auf Grundlage 
vorhergesagter TF Bindungsstellen und experimentell ermittelten RNA Expressionsprofilen 
von in vitro polarisierten PECs, fünf TFs identifiziert (CTCF, E2F1, MYC, PPARү and 
STAT6), die für die Induktion und Aufrechterhaltung eines M2 Phänotyps von Bedeutung 
sind. Eine siRNA vermittelte Herunterregulation dieser TFs induzierte die Expression von 
M1-assoziierten Genen, wohingegen die Expression von M2-assoziierten Genen signifikant 
reduziert war. Zusätzlich war die Expression von proinflammatorischen Zytokinen (IL-1α, 
IL-6 and TNFα) nach siRNA Transfektion erhöht, wodurch die erfolgreiche Repolarisierung 
der M2 Makrophagen zusätzlich bestätigt werden konnte. Im dritten Teil des Projektes 
wurden basierend auf miRNA Sequenzierdaten von in vitro polarisierten PECs 19 miRNAs 
detektiert, die zwischen M1 und M2 polarisierten Makrophagen differentiell exprimiert waren. 
Basierend auf deren Expressionsstärke wurden sechs miRNAs mit hoher Expression in M1 
Makrophagen für die weitere Validierung ausgewählt. Nach Ko-Transfektion aller sechs 
miRNAs in M2 PECs oder in unbehandelte PECs wurde eine erhöhte Expression von M1-
assoziierten Genen und ein reduziertes Expressionsniveau von M2-assoziierten Genen 
detektiert, was auf eine Polarisation in Richtung des M1 Phänotyps hindeutet. Unsere 
Ergebnisse gewähren neue Einblicke in die transkriptionelle, post-transkriptionelle und durch 
T-Zellen vermittelte Umprogrammierung von Makrophagen und könnten für die Entwicklung 
neuer therapeutischer Ansätze zur Repolarisation von M2 TAMs nützlich sein.
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1 Introduction 
1.1 The immune system and cancer 
1.1.1 General principles of the immune system  
The human body is constantly exposed to putative pathogenic microorganisms and has 
evolved immune defense mechanisms to eliminate intruding pathogens. The human immune 
system is composed of many different effector cells and effector molecules that enable the 
human body to differentiate between foreign and self-antigens. In addition, the generation of 
memory cells upon primary infection allows an accelerated and more robust immune 
response in case of re-infection. At least as important as the establishment of an appropriate 
immune reaction, is the termination of such a response, returning the immune system to a 
basal state after the antigen has been cleared. Disorders in one of the described 
mechanisms can result in autoimmune diseases, inflammatory diseases and cancer. 
The human immune system is divided in two branches: innate and adaptive immunity. The 
innate immune system represents the first line defense against pathogens and is responsible 
for the discrimination between self and a variety of pathogens. The innate immune system 
consists of specialized cells such as macrophages, mast cells, granulocytes and dendritic 
cells (DCs) that recognize microorganisms with a limited number of germline-encoded 
pattern recognition receptors (PRRs). These include toll-like receptors (TLRs), cytosolic 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and retinoic acid-
inducible gene (RIG)-I-like receptors. All PRRs recognize so called pathogen-associated 
molecular patterns (PAMPs) which are conserved microbial components indispensable for 
the survival of microorganisms. Once activated through PRRs, a series of signaling events 
lead to the production of immune mediators such as interleukins (ILs) that have the potential 
to regulate an immune response. Another first line defense mechanism of innate immune 
cells is the expression and secretion of antimicrobial peptides, which either weaken or even 
kill pathogens [1]. The upregulation of both, major histocompatibility complex (MHC)/peptide 
complexes as well as costimulatory molecules (e.g. B7-1 and B7-2) on the surface of antigen 
presenting cells (APCs; e.g. macrophages and dendritic cells) allow subsequent priming of 
naive T cells and thereby activation of adaptive immunity. The adaptive immune system is 
characterized by high specificity, develops by clonal selection from a vast repertoire of B and 
T lymphocytes bearing antigen-specific receptors and has the capacity to establish an 
immunological memory. Three signals are required for a naïve T cell to become fully 
activated [2, 3]. The interaction between the unique T cell receptor (TCR) and its ligand 
(MHC/peptide complex) presented on the surface of an APC represents the first signal. The 
second signal is provided by an interaction between costimulatory molecules on the same 
APC and their corresponding ligands on the T cell surface (e.g. cluster of 
differentiation (CD) 28). Thereafter, CD4+ T cells can differentiate into a variety of effector 
subsets (e.g. Th1, Th2, Th17, regulatory T cells (Tregs)) which fulfill different effector 
functions. The differentiation decision is mainly triggered by the cytokines in the 
microenvironment produced by cells of the innate immune system (“signal 3”) [4, 5]. Primed 
T helper cells can for instance trigger B cell differentiation into antibody secreting plasma 
cells [6]. In contrast, CD8+ T cells differentiate into cytotoxic T lymphocytes (CTLs), which 
are able to kill target cells directly through the release of cytotoxic granules.  
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1.1.2 Cancer immunoediting 
Whether the immune system has the capacity to control tumor growth was debated for over 
a century. Based on an enhanced understanding of the human immune system and the 
demonstration that tumor antigens do exist [7], Burnet and Thomas constructed the 
hypothesis of immunosurveillance in the 1950s. According to their hypothesis the 
development of cancer is controlled or even prevented in immunocompetent hosts by the 
adaptive immune system [8, 9]. However, this concept was abandoned shortly afterwards as 
subsequent studies in nude mice (major but not totally immunodeficient) demonstrated 
similar susceptibility to carcinogen induced tumor development compared to 
immunocompetent mice [10].  
In the 1990s, immunodeficiency mouse models on pure genetic backgrounds became 
available and facilitated more precise experimental validations of the immunosurveillance 
hypothesis. Kaplan et al. demonstrated in an interferon-gamma receptor (IFNGR) deficient 
mouse model that spontaneously arising and chemically induced tumors are controlled by 
the endogenous production of interferon-gamma (IFNү). They furthermore showed that 
tumors developed faster and more frequently in signal transduced and activator of 
transcription protein (Stat) 1 deficient mice, lacking sensitivity to all IFN family members, 
compared to wild type (WT) mice [11]. Three years later, similar experiments were 
performed in recombination-activating gene-2 (Rag2) immunodeficient mice that fail to 
generate mature T or B lymphocytes [12]. These results demonstrated that lymphocytes and 
IFNү are required to induce an effective anti-tumor immune response. Furthermore, the 
authors showed that the immune system selects for those tumor cells which have reduced 
immunogenicity. The awareness, that the immune system not only protects the host from the 
cancer development, but also modulates the immunogenicity of tumor cells was the basis for 
the cancer immunoediting hypothesis. The process of immunoediting was divided into three 
consecutive phases termed “elimination”, “equilibrium” and “escape” (three “Es”) as 
illustrated in Figure 1.1 [13]. In the elimination phase, innate and adaptive immunity are 
capable to recognize and destroy transformed cells before a tumor becomes clinically 
apparent. Tumor cells that survive the elimination phase enter into the equilibrium phase in 
which the adaptive immune system controls tumor development and shapes the tumor cells 
immunogenicity. Experimental evidence for the existence of the equilibrium phase arose 
from experiments in immunocompetent mice [14]. If those mice were treated with low dose 
carcinogen but did not develop a palpable tumor, they still harbored occult cancer cells 
which started to grow out when T cells and IFNү were depleted by the administration of 
monoclonal antibodies. The cells isolated from these tumors were highly immunogenic. 
Further investigations demonstrated that keeping occult tumor cells in the equilibrium phase 
is exclusively mediated by the adaptive immune system, more precisely by IL-12, IFNү, 
CD4+ and CD8+ T cells. The equilibrium phase is assumed to be the longest phase within 
the process of immunoediting and may even persist throughout the life of the host. However, 
due to the constant immune selection pressure the tumor cell population changes and 
altered variants may arise and enter the escape phase. These altered tumor cell variants 
often show a reduced immunogenicity and at the same time an increased resistance to 
immune mediated cytotoxicity, which eventually facilitates tumor outgrowth. The loss of 
antigens is one of the best studied escape mechanisms resulting in a reduced susceptibility 
of tumor cells to CD8+ T cell recognition. Different mechanisms, all driven by the process of 
immunoselection and the inherent genetic instability of tumor cells, are known to be 
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responsible for the loss of tumor antigen expression. Some tumor cells lose expression 
either of strong rejection antigens [15] or of MHC I molecules which are necessary to present 
antigen derived epitopes [16]. Another possible way of losing epitope presentation are 
defects in the antigen processing machinery (e.g. low molecular mass protein (LMP) 7, 
transporter associated with antigen processing (TAP) 1 or TAP2), which is essential to 
produce the epitopes and load them on MHC molecules [17, 18]. Eventually, these “naturally 
selected” tumor cells are poorly immunogenic and can only be hardly detected by cytotoxic T 
lymphocytes.  
 
Figure 1.1: The cancer immunoediting concept. 
The process of cancer immunoediting consists of three consecutive phases: elimination, equilibrium 
and escape. If transformed cells escape intrinsic tumor suppression mechanisms like induction of 
senescence or apoptosis, they enter the elimination phase in which innate and adaptive immunity 
destroy the developing tumor before it becomes clinically apparent. If the destruction fails, the tumor 
cells enter into the equilibrium phase in which further tumor development is controlled exclusively by 
the adaptive immune system. The equilibrium phase might persist for the entire lifetime of the host 
and thus represents an end stage of the immunoediting process. However, as a result of the constant 
immune selection pressure within the equilibrium phase, some tumor cell variants which are not 
recognized anymore by the adaptive immune system might emerge and enter the escape phase. As 
these tumor cells are not eliminated any longer by the immune system, they most likely cause 
clinically apparent tumors. Figure was taken from [19]. 
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Alternatively to the aforementioned escape mechanism, tumor cells can promote the 
establishment of an immunosuppressive microenvironment in which adaptive immune cells 
are impaired in fulfilling their function. Mechanisms by which tumor cells establish such a 
microenvironment include the production of immunosuppressive cytokines like transforming 
growth factor-β (TGF- β), vascular endothelial growth factor (VEGF) [20] or indoleamine 2,3-
dioxygenase (IDO) [21]. Additionally, tumor cells can recruit immunosuppressive immune 
cells such as Tregs and myeloid-derived suppressor cells (MDSCs). Immunosuppressive M2 
macrophage recruitment and polarization is mediated by IL-13 and IL-4 secretion [19, 22]. A 
more comprehensive description of the tumor microenvironment composition and its role in 
promoting tumor growth is given in section 1.1.4. 
1.1.3 T cell responses against tumors 
In 1863, Rudolf Virchow noted for the first time that tumors contain lymphocytes, which 
nowadays are referred to as tumor infiltrating lymphocytes (TILs) [23]. A first link between 
prognosis and the extend of TIL infiltration was observed 1949 in breast cancer patients [24]. 
Twenty years later, infiltration of melanomas by lymphocytes was described for the first time 
[25] and was subsequently found to be of prognostic significance [26]. The 5 year survival 
rate of patients with highly infiltrated primary melanoma was 3 times higher compared to 
patients with low numbers of immune cells in the tumor [27]. Clemente et al. further 
demonstrated a negative correlation between the probability to get lymph node metastases 
and TIL infiltration [28]. More comprehensive analysis of the tumor microenvironment in 
melanoma revealed that the T cell composition of infiltrated TILs in individual patients ranged 
from 90 % CD4+ T cells to 90 % CD8+ T cells [29-31]. Several studies demonstrated that the 
infiltrated CD8+ T cells show an anergic or exhausted phenotype as they often lack the 
expression of perforin and only produce low amounts of IFNү upon stimulation with peptide-
pulsed target cells [32, 33]. Nevertheless, the presence of CD8+ T cells in the tumor 
microenvironment was shown to positively correlate with patients’ outcome [34]. While a lot 
is known about CTLs and their function in the tumor microenvironment, the role of CD4+ T 
cells is not well understood yet. Several studies demonstrated that melanoma specific CD4+ 
T cells possess the ability to lyse tumor cells through cognate interaction [35, 36]. Moreover, 
the adoptive transfer of autologous New York esophageal squamous cell carcinoma 
(NY-ESO) 1 antigen specific CD4+ T cells induced durable responses in some patients with 
metastatic melanoma [37]. Additional work revealed that regressing melanoma lesions are 
mainly infiltrated by Th1 CD4+ T cells secreting immunostimulatory cytokines (e.g. IFNү, IL-2 
and IL-15). In contrast, the presence of CD4+ regulatory T cells or Th2 T cells is 
predominantly associated with non-regressing lesions [38, 39]. Furthermore, the 
accumulation of Tregs, which was shown to be associated with a higher risk of melanoma 
recurrence [40], might at least in part, explain the high frequency of anergic and exhausted 
CD8+ T cells in these tumors. These results reveal the important roles of the different CD4+ T 
cell subsets present in the tumor microenvironment and should serve as a basis for more 
comprehensive analyses of these cell populations. 
The above mentioned prognostic value of TILs emphasizes the importance of the immune 
system in controlling tumor development. However, it was uncertain for decades what kinds 
of antigens were recognized by tumor-reactive T cells. The development of new techniques, 
including mass spectrometry analysis of peptides eluted from purified MHC molecules [41, 
42] and screenings of tumor-reactive T cells against cDNA expression libraries [43, 44], 
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facilitated the identification of tumor-associated antigens (TAAs) and their respective 
epitopes. Use of these techniques resulted in the identification of a vast amount of TAAs as 
well as their T cell epitopes. TAAs can be grouped into several categories which are listed 
below in decreasing order of tumor specificity: 
1. Neoantigens 
Nonsynonymous mutations in the genome of tumor cells are a frequent source of tumor-
specific antigenic peptides. Examples of proteins of which mutated epitopes derived 
from include neuroblastoma rat sarcoma (NRAS) [45], cyclin-dependent kinase (CDK) 4 
[46], v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) [47] and a fusion 
protein composed of breakpoint cluster region protein (BCR) and abelson murine 
leukemia viral oncogene homolog (ABL) 1 [48]. 
2. Viral antigens 
Proteins from oncogenic viruses are another source of antigenic peptides which can be 
considered as tumor-specific. Two of the best studied viral oncoproteins that give rise to 
tumor-specific T cell epitopes are E6 and E7 of human papillomavirus (HPV) [49]. 
3. Cancer-testis antigens 
Cancer-testis antigens are exclusively expressed in male germ cells and trophoblastic 
cells [50], which are not recognized by T cells as they have no detectable MHC I or II 
surface expression. In many cancers, cancer-testis genes are expressed as a result of 
genome-wide hypomethylation [51, 52] and can therefore give rise to tumor associated 
epitopes. Examples of cancer-testis antigens include NY-ESO-1 [53] and proteins 
belonging to the melanoma-associated antigen (MAGE) family (MAGE-A, MAGE-B, 
MAGE-C) [54]. 
4. Differentiation antigens 
These are proteins which are only expressed in a certain healthy tissue or cell type and 
in tumor cells arising from them. For instance, CTLs recognizing epitopes derived from 
melanocyte-specific proteins, such as tyrosinase, premelanosome protein (PMEL) 17 
and melanoma antigen recognized by T cells (MART) 1 were detected in melanoma 
patients [55, 56]. 
5. Overexpressed antigens 
These antigens are overexpressed on tumor cells but also present on normal cells. One 
example is the telomerase reverse transcriptase (TERT) which was shown to be highly 
expressed in more than 85 % of all human cancers [57]. Immunogenic TERT epitopes 
facilitating efficient CTL activation were identified in preclinical studies and make TERT 
an attractive target for cancer immunotherapy [58].   
1.1.4 The tumor microenvironment  
For a long time, cancer was considered as a disease that mainly results from genetic 
mutations and genomic instability. However, the strong influence of stromal cells on tumor 
progression is nowadays widely accepted. Tumors are highly complex tissues not only 
consisting of malignant tumor cells, but also stromal cells including cancer-associated 
fibroblasts (CAFs), various immune cell types as well as endothelial cells and pericytes 
which form the tumor vasculature [59]. All these different cell types together with the 
extracellular matrix are referred to as tumor microenvironment (TME). The different 
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components of the TME interact with the tumor cells, thus playing a pivotal role in tumor 
development and disease progression as described in more detail in the following 
paragraphs. 
Fibroblasts are a component of the connective tissue in which they are embedded in fibrillar 
matrix. These cells are specialized in producing components of the extracellular matrix and 
are especially important in the process of wound healing [60]. Tumor resident fibroblasts that 
became activated, for instance by reactive oxygen species, growth factors or cell-cell contact 
are known as CAFs [61]. Activated CAFs were shown to promote tumor growth by inducing 
angiogenesis, cell invasion and proliferation [61, 62]. Moreover, CAFs can mediate epithelial 
to mesenchymal cell transition and produce matrix metalloproteinases (MMPs) [63, 64], 
thereby facilitating metastatic spread of tumor cells. These cells do also have the capacity to 
mediate immunosuppression as they express programmed death-ligand (PD-L) 1 and PD-L2 
[65]. Besides CAFs, all types of immune cells are part of the TME and can have tumor 
promoting or repressing properties depending on the particular cell type and their activation 
state. 
Immune cells originated from a common lymphoid progenitor 
CD8+ T cells infiltrating into the tumor are often impaired in their effector function due to the 
immunosuppressive TME and terminally differentiate into a so called exhausted phenotype. 
Such exhausted T cells express elevated levels of inhibitory receptors (including 
programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein-4 
(CTLA-4) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) [66, 67] and 
secrete less IL-2, tumor necrosis factor (TNF) alpha, IFNү and granzyme B [68, 69]. 
Restoring anti-tumor reactivity of exhausted T cells is an attractive strategy to treat cancer 
and is discussed more in detail in section 1.3. 
Regulatory T cells (Tregs), traditionally defined as CD4+ T cells expressing forkhead 
box P3 (FoxP3) and CD25 [70, 71] contribute to the establishment of an immunosuppressive 
microenvironment, thereby promoting tumor progression. Tregs can be either recruited in 
response to chemokines secreted by the tumor or generated from conventional T cells 
mediated by tumor derived adenosine and TGF-β [72]. The mechanisms by which Tregs 
exert their immunosuppressive function include the secretion of IL-10 [73], TGF-β [74] and 
adenosine [75]. In addition, these cells constitutively express the high affinity IL-2 receptor 
(CD25) and are dependent on exogenous IL-2 which limits the amount of available IL-2 for 
surrounding cells [76]. By constitutive expression of CTLA-4 Tregs mediate downregulation 
of co-stimulatory molecules (CD80 and CD86) on dendritic cells and deprive all other T cell 
subsets of co-stimulatory signals [77]. 
Natural killer (NK) cells were originally discovered as a subset of cells that kill cancer cells 
of certain tumor entities in vitro [78]. Tumor cells which have downregulated MHC 
expression or overexpress ligands (e.g. MHC class I chain-related protein (MIC) A and 
MICB) for activating receptors on NK cells (e.g. natural killer group 2D (NKG2D)) serve as 
ideal NK cell targets [79]. In a NK cell deficient mouse model Kim and colleagues 
demonstrated the importance of NK cells in controlling tumor outgrowth and suppressing 
tumor metastases [80]. The infiltration of NK cells positively correlated with increased overall 
survival in patients with squamous cell lung carcinoma [81] and colorectal carcinoma [82]. 
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Patients with gastric carcinoma and a high rate of NK cell infiltration showed less metastases 
and have a better prognosis compared to patients with low level of NK cell infiltration [83]. 
B cells infiltrating into the tumor microenvironment were associated with good prognosis and 
positively correlated with patient survival in ovarian, breast, non-small cell lung and cervical 
cancer. The tumor infiltrating B cell populations were demonstrated to comprise oligoclonal, 
antigen-experienced cells producing autoantibodies against TAAs [84]. In theory, these 
autoantibodies could induce an anti-tumor response by direct inhibition of the target protein 
or by mediating complement-dependent cytotoxicity (CDC) and antibody-dependent cellular 
cytotoxicity (ADCC). However, the exact contribution of B cells in mediating an anti-tumor 
response is not fully understood. 
B cells also exert several tumor promoting functions, including the secretion of cytokines to 
inhibit T cell activity. Further, B cells have been shown to promote angiogenesis and secrete 
factors which directly mediate enhanced tumor cell survival [85]. 
Immune cells originated from a common myeloid progenitor 
Neutrophils are the most abundant circulating leukocytes and are known to be part of the 
TME in many tumor entities, including melanoma [86], colorectal cancer [87] and renal cell 
carcinoma [88]. In 2009, Fridlender and colleagues demonstrated that neutrophils show a 
certain plasticity and can have a pro- or anti-tumor phenotype (N1 or N2, respectively) which 
is dependent on the environmental factors [89]. However, most studies reported that the 
presence of neutrophils per se correlates with a poor prognosis of cancer patients [90-92]. 
Several mechanisms of how neutrophils contribute to tumor progression have been 
described. By the release of matrix metalloproteinases (MMP8 and MMP9) neutrophils can 
remodel the extracellular matrix which was shown to modulate tumor cell invasion in skin 
cancer models [93]. Moreover, neutrophils can release reactive oxygen species (ROS; 
induces DNA damage) [94], Oncostatin M (increases angiogenesis) [95] and prostaglandin 
E2 (supports proliferation) [96]. 
Mast cells, eosinophils and basophils play an important role in defending the human body 
against parasites by exerting different effector functions [97]. The role of these three cell 
types in promoting or inhibiting tumor growth is still controversial. Several studies have 
shown a poor prognosis for patients with high numbers of mast cells in the TME (e.g. in 
colorectal cancer [98], melanoma [99] and pancreatic cancer [100]), while others found mast 
cell infiltration to be correlated with a good prognosis (e.g. in breast cancer [101] and 
hepatocellular carcinoma [102]). The mechanisms by which mast cells act within the TME 
are diverse and include the release of soluble mediators through degranulation. For 
instance, Histamine classically released by mast cells can have pleiotropic effects within the 
TME and modulate both innate and adaptive immunity [103]. By binding to the histamine 
receptor type 2 (H2R) it inhibits T cell reponses [104] and induces IL-10 secretion by 
peripheral monocytes [105]. Moreover, the release of histamine was shown to recruit Tregs 
to the site of inflammation thereby contributing to the establishment of an 
immunosuppressive TME [106]. Similar to mast cells, the infiltration of eosinophils into the 
TME has been shown to be associated with a good or poor prognosis depending on the 
tumor entity. An improved prognosis was shown for instance in colon tumors [107] and 
prostate cancer [108], whereas eosinophil infiltration was associated with poor prognosis in 
Hodgkin lymphoma [109]. By secretion of proteins like eosinophil peroxidase and eosinophil 
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cationic protein stored in the secondary granules, eosinophils can disrupt lipid bilayer 
integrity and were shown to have cytotoxic effects on tumor cells [110, 111]. While there is 
evidence for direct anti-tumor activity of eosinophils in vitro, data showing similar effects in 
vivo are in large part missing [112]. Carretero et al. demonstrated that eosinophils secrete 
chemokines (e.g. CXCL9, CXCL10) which facilitated recruitment of adoptively transferred 
CD8+ T cells. Moreover, eosinophils induced normalization of the tumor vasculature and 
polarized TAMs into a M1-like phenotype [113]. In contrast to their anti-tumorigenic activities, 
eosinophils may also support tumorigenesis by promoting tissue remodeling, angiogenesis 
and activation of fibroblasts mediated through the release of growth factors (e.g. VEGF, 
FGF) and cytokines (e.g. TGF-β, IL-8) [112]. Basophils are the least abundant granulocytes 
in the peripheral blood and are rapidly recruited to inflamed tissue. They are important in 
promoting a protective immune response against multicellular parasites. However, the role of 
basophiles in the TME of solid tumors is largely unknown.  
Myeloid-derived suppressor cells (MDSCs) are another subset of myeloid cells present in 
the TME. The population of MDSCs comprises immature mononuclear cells (M-MDSCs), 
immature polymorphonuclear (PMN) cells (PMN-MDSCs) as well as a third, small population 
of other myeloid precursors and cells with colony-forming activity [114]. M-MDSCs and PMN-
MDSCs are morphologically and phenotypically similar to monocytes and neutrophils, 
respectively [115]. MDSCs possess strong immunosuppressive capacities and have been 
shown to directly support tumorigenesis (reviewed in [116]). Some of the main features of 
MDSCs include secretion of IL-10 [117] and TGF-β [118] as well as expression of inducible 
nitric oxide synthase (iNOS) and arginase 1 [119]. Furthermore, the expression of 
angiogenesis mediators such as VEGF and MMP9 by MDSCs promote angiogenesis and 
tumor cell invasion [120, 121]. In general, increased numbers of MDSCs in the circulation of 
cancer patients was shown to be associated with poor outcomes [122]. A positive correlation 
between tumor burden and the frequency of circulating MDSCs was demonstrated in 
colorectal [123], non-small-cell lung [124], bladder [125] and breast cancer [126] as well as 
in melanoma [114, 127]. 
Macrophages constitute another major population of tumor infiltrating leukocytes. Due to 
their importance within this study, their role in the tumor microenvironment will be described 
in detail in section 1.2.4.   
1.2 Polarization of macrophages 
Macrophages are a subset of myeloid cells that show phenotypic and functional plasticity. 
Depending on the environmental signals, they are involved in a variety of processes such as 
tissue remodeling, tumor growth promotion/inhibition, clearance of pathogens and 
immunoregulation [128]. In the early 1990s, two macrophage phenotypes were established 
based on studies comparing gene expression upon treatment of macrophages with IL-4 
compared to IFNү and/or lipopolysaccharide (LPS) [129]. Activation of macrophages with 
IFNү and/or LPS resulted in the classically activated phenotype with increased expression of 
proinflammatory cytokines (e.g. TNF-α, IL-1β, IL-6, C-X-C motif chemokine (CXCL) 9, 
CXCL10) and an elevated microbicidal as well as tumoricidal activity. In contrast, treatment 
with IL-4 polarized macrophages to the alternatively activated state in which the cells secrete 
immunosuppressive cytokines (e.g. IL-10, TGF-β) and are involved in tissue repair, matrix 
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remodeling, angiogenesis and parasite clearance. A few years later, Mills and colleagues 
demonstrated that macrophages derived from Th1 mouse strains (e.g. C57BL/6) show 
substantial differences in their arginine metabolism compared to macrophages derived from 
Th2 mouse strains (e.g. BALB/c) [130]. In response to IFNү or LPS, macrophages derived 
from Th1 strains metabolized arginine to nitric oxide, whereas those from Th2 strains 
metabolized arginine to ornithine. In addition, they showed that C57BL/6 and BALB/c 
macrophages, both stimulated with IFNү or LPS induced differential cytokine secretion of 
CB6F1 (hybrid mice: C57BL/6 X BALB/c) lymphocytes. While macrophages from C57BL/6 
mice induced Th1 cytokine secretion, BALB/c derived macrophages mediated a Th2 
cytokine response. Based on their results, the authors proposed to term these different 
macrophage responses “M1” and “M2”, respectively.  
These observations were combined with the aforementioned concept of classically and 
alternatively activated macrophages to propose a general scheme of macrophage 
polarization [131]. Within this widely accepted scheme, classical activation represents M1, 
whereas alternatively activated macrophages represent the M2 state. However, due to the 
plasticity of macrophages the M1 and M2 state should only be considered as the two 
extremes within a spectrum of functional phenotypes. Within the next sections, the signaling 
pathways (section 1.2.1), miRNAs (section 1.2.2) and metabolic changes (section 1.2.3) 
involved in macrophage polarization will be described. Moreover, the contribution of 
macrophages to the establishment of an immunosuppressive tumor microenvironment will 
be discussed in section 1.2.4. Some key characteristics of classically and alternatively 
activated macrophages are summarized and illustrated in Figure 1.2. 
 
Figure 1.2: Classical versus alternative macrophage activation. 
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1.2.1 Transcription factors 
Extensive research has led to a detailed understanding of the signaling pathways that 
underlie macrophage polarization. Some of these pathways are described in the following 
paragraphs and are illustrated in Figure 1.3.  
Alternative activation: 
Besides IL-4, several other cytokines have been shown to induce alternative macrophage 
polarization, including IL-13, IL-10, IL-33 and TGF-β [132]. IL-4 and IL-13 are closely related 
cytokines which share the same receptors. IL-4 utilizes both, type I (IL-4Rα or IL-4Rүc) and 
type II (IL-4Rα or IL-13Rα1) IL-4 receptors, whereas IL-13 signals only through the type II 
receptor [133]. Junttila and colleagues demonstrated that PECs, bone marrow-derived 
macrophages (BMMs) as well as mouse and human monocytes express both receptors and 
have a greater sensitivity to IL-4 than to IL-13 [133]. The cytoplasmic domains of the 
receptor subunits are associated with janus kinase (JAK) tyrosine kinases. Upon binding of a 
ligand, two receptor subunits dimerize and bring two JAKs in close proximity, facilitating 
trans-phosphorylation. Phosphorylated JAKs have an increased kinase activity and therefore 
the capacity to phosphorylate additional targets including the receptor, thereby generating 
docking sites for STATs. Subsequently, recruited STATs are phosphorylated by JAKs which 
permits STAT dimerization and their subsequent entry into the nucleus. In the nucleus, 
STAT dimers bind to regulatory sequences in order to activate or repress target gene 
expression [134]. IL-4 and IL-13 binding to either type I or type II IL-4 receptors eventually 
results in activation of STAT6, which is known to be one of the master regulators for M2- 
associated gene expression [135]. Moreover, IL-4 induces STAT6 mediated expression of 
the demethylase Jmjd3, which demethylates histone H3 lysine-27 and histone H3 lysine-4 in 
the promoter regions of M2-associated genes thereby additionally promoting their 
expression [136]. These results demonstrate the importance of epigenetic regulation and 
chromatin remodeling in the context of macrophage polarization. Additional key transcription 
factors involved in M2 polarization are interferon regulatory factor (IRF) 4 [137] and 
peroxisome proliferator-activated receptor gamma (PPARү) [138]. Bouhlel and colleagues 
reported a positive correlation between PPARү and M2 marker expression [138]. Further, 
they demonstrated that treatment of primary human monocytes with PPARү agonists 
enhanced the activation of M2-associated gene expression. 
IL-10 acts through binding to its receptor IL-10R followed by activation of JAKs. The 
immunosuppressive effects of IL-10 are mainly mediated through the activation of STAT3. A 
consequence of IL-10 signaling is the upregulation of suppressor of cytokine signaling 
(SOCS) 3 which inhibits proinflammatory cytokine signaling pathways. Accordingly, SOCS3 
deficient macrophages (isolated from LysM Cre-SOCS3fl/fl mice) express elevated levels of 
M1-associated cytokines, such as IL-6, IL-12 and IL-1β [139].  
IL-33 is a cytokine belonging to the IL-1 family and acts through binding to its receptor 
interleukin 1 receptor-like 1 (IL1RL1 also known as ST2). IL-33 was reported to induce 
expression of Th2-associated cytokines by activating nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and mitogen-activated protein (MAP) kinases [140]. A 
study of Kurowska-Stolarska and colleagues showed that treatment of BMMs with IL-33 had 
no significant effect on macrophage polarization [141]. However, macrophages treated with 
IL-33 in combination with IL-13 or IL-4 expressed significantly higher levels of typical M2 
Introduction 
11 
 
markers (Mrc1, Arg1 and Ym1) compared to macrophages treated with IL-13 or IL-4 alone. 
These results indicate that IL-33 synergizes with IL-13 and IL-4 to induce alternative 
macrophage polarization. 
The spleen tyrosine kinase (Syk) is activated through phosphorylation upon binding of 
immune complexes to Fc-gamma receptor (FcүR) on macrophages. The signaling pathways 
induced by activated Syk induce expression of IL-10, SOCS3 and other negative regulators 
which results in the inhibition of both, type I IFN signaling as well as TLR4 signaling [142]. 
Ligation of immune complexes to the FcүRIIb on macrophages inhibits secretion of 
proinflammatory cytokines by inducing the production of prostaglandin E2 [143]. These data 
suggest that immune complexes can participate in the modulation of macrophage 
polarization by inhibiting pathways involved in classical activation. 
Classical activation: 
Classical activation of macrophages is induced by binding of LPS or type I IFNs or IFNү to 
TLR4 or IFN-α/β (IFNAR) receptor or IFN-ү (IFNGR) receptor, respectively. After binding to 
its ligand, TLR4 dimerizes and undergoes conformational changes. These changes facilitate 
subsequent recruitment of toll/interleukin-1 receptor (TIR) domain containing adaptor 
molecules including myeloid differentiation primary response 88 (MyD88), TRIF-related 
adaptor molecule (TRAM), TIR-domain containing adapter inducing interferon-β (TRIF) and 
MyD88-adapter like (Mal). Mal functions as bridging molecule between TLR4 and MyD88. 
Upon stimulation, MyD88 recruits IL-1 receptor associated kinase (IRAK) 4 and IRAK1. After 
the recruitment of several other IRAKs, they dissociate from MyD88 to interact with TNF-
receptor associated factor (TRAF) 6. TRAF6 builds up a complex with the transforming 
growth factor beta-activated kinase 1 (TAK1) and several proteins belonging to the family of 
TAK1 binding proteins (TABs). This complex in turn activates the IκB kinase (IKK) complex 
(composed of IKK-α, IKK-β and NF-kappa-B essential modulator (NEMO)) which 
subsequently phosphorylates the NF-κB inhibitory molecule IκB. As a consequence, IκB is 
degraded by the proteasome and NF-κB (heterodimer of p50 and p65) is released. After 
translocation into the nucleus, NF-κB induces expression of proinflammatory genes [144]. 
Besides recruiting MyD88, TLR4 additionally recruits TRAM, serving as bridging molecule 
between TLR4 and TRIF. The recruited TRIF binds to TRAF3, which is important for the 
activation of IKK-related kinases (including TRAF family member-associated NF-kappa-B 
activator (TANK) binding kinase 1 (TBK1) and IKK-i). These kinases eventually 
phosphorylate IRF3 and IRF7 which subsequently translocate into the nucleus and induce 
the expression of additional proinflammatory genes [144, 145]. 
Binding of IFNs to their corresponding receptors induce the JAK/STAT signaling pathway as 
described above. This results in the activation of several transcription factors such as 
STAT1, STAT2 and IRF-1 which subsequently induce M1-associated gene expression [146]. 
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Figure 1.3: Molecular pathways of classical and alternative macrophage activation. 
M1- and M2-associated genes transcribed upon macrophage activation are indicated by red and 
green lettering, respectively. Figure was taken from [147]. 
1.2.2 MicroRNA-mediated control of macrophage polarization 
MicroRNAs (miRNAs) are small non-coding RNA molecules approximately 20 - 24 
nucleotides in length. They play an important role in post-transcriptional gene regulation by 
binding to the 3’-untranslated region (UTR) of target mRNA sequences, mediating their 
translational repression or cleavage. Regulation of gene expression by miRNAs is a highly 
conserved mechanism present in most eukaryotic cells and involved in virtually all biological 
processes. Deregulated miRNA expression can result in pathological conditions such as 
cancer and normalization of miRNA expression might be a valuable therapeutic approach in 
the near future [132]. The following paragraph describes several miRNAs which have been 
identified to play a major role in macrophage polarization by regulating the expression of 
some key transcription factors. The expression and clinical relevance of miRNAs in TAMs 
has been described elsewhere [148]. 
MiR-125a and miR-125b were shown to be highly expressed in human monocyte-derived 
macrophages [149]. However, LPS treatment was accompanied by a downregulation of 
miR-125b in the murine macrophage cell line Raw264.7 cells [150] and an upregulation of 
miR-125a in murine monocyte-derived macrophages [149]. Interestingly, transfection of 
THP-1 cells with miR-125a-5p mimics increased the expression of several M1-associated 
genes [149]. In a cohort of diffuse large B-cell lymphoma biopsies, miR-125a and miR-125b 
have been shown to constitutively stimulate the NF-κB pathway by targeting one of its 
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negative regulators tumor necrosis factor alpha-induced protein 3 (TNFAIP3) [151]. In 
accordance with these findings, macrophages (BMMs or RAW264.7 cells) transfected with 
miR-125b show an increased responsiveness to IFNү, upregulate CD80 expression and 
have the capacity to activate T cells more efficiently compared to untransfected 
macrophages [152]. Further, the transcription factor IRF4 which plays an important role in 
the alternative activation of macrophages was identified to be a direct target of miR-125b 
[152]. Thus, miR-125a and miR-125b seem to be important regulators of macrophage 
polarization, driving macrophages preferentially into the M1 state. 
Expression of miR-155 was shown to be induced upon activation of macrophages by TLR 
ligands and IFNs [153]. In PECs and RAW264.7 cells miR-155 downregulates suppressor of 
cytokine signaling-1 (SOCS1) and B-cell lymphoma-6 protein (BCL6), both of which are 
inhibitors of the classical macrophage activation [154, 155]. SOCS1 is a direct inhibitor of 
type I IFN signaling, whereas BCL6 is a transcription factor known to repress NF-κB 
signaling. Downregulation of these proteins mediated by miR-155 induces the expression of 
proinflammatory cytokines and drives M1 polarization. Further, miR-155 was shown to 
directly target the IL-13 receptor, thereby reducing phosphorylation and activation of STAT6, 
which is one of the key transcription factors promoting M2 polarization [156]. Cai and 
colleagues demonstrated that transfection of M2 polarized (IL-4) BMMs as well as M2 TAMs 
with miR-155 resulted in repolarization into M1 macrophages [157]. However, miR-155 was 
also shown to downregulate SHIP1, a negative regulator of the phosphatidylinositol-4,5-
bisphosphate 3-kinase/RAC-alpha serine/threonine-protein kinase (PI3K/AKT1) pathway. 
The resulting increased activation of AKT1 signaling is associated with alternative BMM 
polarization [158]. Further, miR-155 expression correlates with poor survival of lung 
adenocarcinoma patients [159] as well as higher tumor grade and lymph node metastases in 
breast cancer patients [160] and was shown to be overexpressed in several other tumor 
entities [161]. These results indicate that miR-155 can have both, tumor suppressive as well 
as tumor promoting potential depending on the cell type in which it is expressed.  
Another miRNA which was reported to have substantial effects on macrophage polarization 
is miR-146a. Treatment of THP-1 cells with LPS results in a strong NF-κB dependent 
upregulation of miR-146a as demonstrated by Taganov and colleagues [162]. Of note, 
miR-146a has been demonstrated to target TRAF6 and IRAK1 mRNA, both of which are 
adapter molecules downstream of cytokine and TLR signaling pathways. Thus, miR-146a 
expression is induced in classically activated macrophages to control cytokine and TLR 
signaling in a negative feedback loop and reduce the release of proinflammatory cytokines 
[162]. In accordance with these results, inhibition of miR-146a in polarized PECs promoted 
the expression of M1-associated genes (Il6 and Il1b) and decreased expression of M2-
associated genes (Pdgf and Arg1). Furthermore, miR-146a transfected RAW264.7 cells 
mixed with 4T1 cells and injected subcutaneously (s.c.) into BALB/c mice significantly 
promoted tumor growth [163]. 
Similar regulatory feedback loops as described above were reported for miR-21, miR-9, 
miR-187 and miR-147 [132, 164]. The expression of these miRNAs is induced upon TLR 
stimulation and all of them target different molecules involved in promoting classical 
macrophage activation. While miR-21 is regulating the tumor suppressor programmed cell 
death protein-4 (PDCD4) [165], miR-9 and miR-187 are regulating different components 
involved in NF-κB signaling (NF-κB subunit p50 (NFKB1) [166] and NF-κB inhibitor zeta 
(NFKBIZ) [167], respectively). 
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miR-124 expression was shown to be induced in PECs, BMMs and RAW264.7 cells upon 
stimulation with IL-4 and IL-13 [168]. Inhibition of miR-124 and subsequent polarization of 
macrophages with IL-4 was accompanied by decreased expression levels of M2-associated 
genes (Mrc1, Ym1) and increased expression of several M1 markers (CD86, TNF, iNOS) 
when compared to a scrambled antagomir control. These results indicate that miR-124 has 
an important role in driving and maintaining a M2 phenotype.  
The two miRNAs miR-511-3p and miR378-3p are upregulated upon stimulation of 
macrophages with IL-4 and act in a negative feedback loop by downregulating signaling 
molecules involved in alternative macrophage activation. miR378-3p directly targets the 
protein kinase AKT1 which is a component of the PI3K/AKT1 signaling pathway [169]. 
Interestingly, miR-511 is located within an intron of the Mrc1 gene and its expression is co-
regulated with Mrc1 expression. Mrc1 encodes for the mannose receptor CD206 and is 
typically associated with alternatively activated macrophages. As demonstrated by Zhou and 
colleagues, transfection of a miR-511-3p mimic into LPS treated BMMs resulted in reduced 
expression of proinflammatory cytokines such as IL-1β and IL-6 [170]. Conversely, 
expression of typical M2-associated genes (Ym1, Arg1 and Fizz1) were elevated in IL-4 
treated and miR-511-3p transfected BMMs compared to mock transfected cells. Moreover, 
they showed that macrophages of Mrc1-/- mice express significantly lower amounts of 
miR-511-3p and have a more pronounced M1 phenotype when compared to wild type mice. 
The Rho-dependent kinase-2 (ROCK2), which phosphorylates the transcription factor IRF4 
was identified to be a direct target of miR-155 [171].   
All examples mentioned above illustrate the importance of miRNAs in the context of 
macrophage polarization. However, most of the studies focused only on single miRNAs, 
thereby neglecting that the interplay between multiple miRNAs is essential to orchestrate the 
complex process of alternative and classic activation of macrophages. Thus, experimental 
set ups should additionally include a variety of miRNA combinations to eventually define 
clusters of miRNAs which modulate macrophage phenotypes. 
 
Figure 1.4: Regulation of macrophage polarization by miRNAs. 
The figure illustrates receptor ligand interactions which are known to drive M2 (left, blue) or M1 (right, 
red) polarization of macrophages. miRNAs which primarily maintain the M1 phenotype are shaded in 
red, whereas blue shaded miRNAs are necessary to sustain alternative activation. Figure was taken 
from [132]. 
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1.2.3 Metabolic changes during macrophage polarization 
The polarization of macrophages is accompanied by metabolic changes, including a shift 
towards the anaerobic glycolytic pathway in M1 macrophages [172]. An increase in 
glycolysis is required to rapidly trigger anti-microbial activity and to survive in hypoxic 
microenvironments. In contrast, M2 macrophages predominantly use fatty acid oxidation 
which guarantees permanent energy supply required for processes like tissue repair or 
remodeling [173].  
As already briefly mentioned, polarization of macrophages is also associated with changes 
in the arginine metabolism. While M1 macrophages use iNOS to metabolize arginine to nitric 
oxide, M2 macrophages metabolize arginine to ornithine and urea using arginase. Nitric 
oxide has antimicrobial activities and is an important effector molecule of M1 macrophages, 
whereas ornithine is the starting point for polyamine synthesis required for collagen 
synthesis and tissue remodeling [174].  
Macrophages are constantly phagocytosing red blood cells, thereby recycling iron and 
making it available for erythropoiesis and other processes. Polarization of macrophages is 
associated with changes in their iron metabolism, with M1 macrophages showing low levels 
of CD163 (heme uptake) and ferroportin (iron export) and high levels of ferritin (iron storage) 
[174]. Thus, M1 polarized macrophages are in an iron-retention mode and efficiently keep 
away the iron from invading pathogens. Moreover, they secrete lipocalin-2 which was shown 
to inhibit siderophore-mediated iron uptake by pathogens [175]. As iron is an essential 
growth factor for many bacteria, the iron-retention mode together with the secretion of 
lipocalin-2 support bacteriostatic activity of M1 polarized macrophages. In contrast, M2 
polarized macrophages are in an iron-export mode, with high expression level of CD163 and 
ferroportin, but low expression of ferritin [174]. The high heme concentrations within the cells 
facilitate expression of heme oxygenase by inhibiting the transcription repressor Bach1 
[176]. Heme oxygenase catalyzes the degradation of heme into Fe2+, biliverdin and carbon 
monoxide [177]. Biliverdin is subsequently converted into bilirubin which has anti-
inflammatory properties and acts as antioxidant. Carbon monoxide inhibits the expression of 
TNF-α and IL-1β and increases expression of IL-10 [178], thus contributing to the 
immunosuppressive phenotype of M2-like macrophages. 
1.2.4 Tumor-associated macrophages 
Macrophages express the C-C chemokine receptor (CCR) 2 and can be recruited into the 
tumor microenvironment by C-C chemokine ligand (CCL) 2 expressing tumor cells [179]. The 
phenotype of infiltrated tumor associated macrophages (TAMs) is strongly dependent on the 
microenvironment of the developing tumor and the tumor progression stage. In an early 
stage of tumor development, TAMs resemble the M1 phenotype and have the capacity to 
induce anti-tumor immunity and to elicit tumor eradication. However, in later stages of tumor 
development TAMs receive signals from the tumor cells (e.g. IL-10 and TGF-β) and from 
surrounding stroma cells directing M1-like macrophages to the immunosuppressive M2 state 
[180-182]. TAMs with a M2 phenotype show low surface expression levels of MHC 
molecules and suppress anti-tumor immune responses by various mechanisms: 
1. Release of immunosuppressive cytokines such as IL-10 and TGF-β, thereby impairing 
effector T cell activity. 
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2. Secretion of IL-10 and TNF-α induces PD-L1 expression on TAMs in an autocrine 
manner and suppresses tumor-specific T cell immunity [183]. 
3. Attraction of regulatory T cells by secretion of CCL22 [184]. 
4. Overexpression of the tryptophan degrading enzyme indoleamine 2,3-dioxygenase-1 
(IDO1), thereby depriving T cells of tryptophan and suppressing their activation and 
proliferation [185]. 
5. Expression of B7-H4, a negative regulator of T cell activity that binds to an unknown 
receptor on activated T cells resulting in impaired T cell effector functions [186, 187].  
6. Expression of arginase 1 inhibits antigen-specific T cell responses by depriving the cells 
of the semi-essential amino acid L-arginine [188]. 
However, M2 polarized TAMs do not only promote tumor growth by modulating the immune 
system, but also by inducing and controlling additional processes like angiogenesis, tumor 
cell proliferation and invasion. TAMs secrete high amounts of angiogenesis promoting 
factors such as VEGF and thymidine phosphorylase, thereby contributing to metastases 
formation [189, 190]. Moreover, they express a number of matrix metalloproteinases (e.g. 
MMP-2, MMP-9, MMP-12) which were shown to be important mediators of angiogenesis in a 
mouse model of human cervical carcinogenesis [191]. In accordance with this, high 
frequencies of TAMs were reported to be associated with an increased tumor vascularization 
in many tumor entities including breast [192], bladder [193] and prostate carcinoma [194]. 
Besides promoting tumor growth by inducing angiogenesis, TAMs can also directly affect 
tumor cell survival by secreting factors that are important for tumor cell proliferation, 
including epidermal growth factor (EGF) [195]. Further details about the clinical significance 
of TAMs in different tumor entities and the development of TAM targeting immunotherapeutic 
approaches are given in section 1.3.1.  
1.3 Immunotherapy approaches to treat cancer 
Tumor immunotherapy approaches comprise treatments which improve or restore functions 
of the immune system or involve the administration of immunological compounds, thereby 
facilitating tumor cell killing. In the following paragraphs, the modes of action and preclinical 
as well as clinical data of different immunotherapeutic strategies are described. 
1.3.1 Targeting tumor associated macrophages 
As already described in section 1.2.4, the majority of TAMs are in a M2 state and contribute 
to the establishment of an immunosuppressive microenvironment by various mechanisms. A 
high density of CD68+ TAMs was shown to be associated with negative effects on overall 
survival (OS) in patients with gastric, breast, bladder, ovarian, oral and thyroid cancer [196]. 
In contrast, accumulation of TAMs had beneficial effects on overall survival in patients with 
colorectal cancer. However, not only the density of TAMs within the tumor, but also their 
localization and polarization are of clinical relevance. As demonstrated by Medrek and 
colleagues, the presence of CD163+CD68+ M2 macrophages in the tumor stroma positively 
correlated with increased tumor size and higher tumor grade [197]. Infiltration of TAMs into 
the tumor nest did not correlate with any clinicopathological features. Similar results were 
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obtained in melanomas where high densities of CD163+ macrophages in the tumor stroma 
and CD68+ cells at the invasive front were associated with poor overall survival [198]. In a 
retrospective study using paraffin-embedded non-small cell lung cancer (NSCLC) 
specimens, a high density of M1 macrophages (CD68+HLA-DR+) positively correlated with 
patients survival, whereas M2 densities did not correlate with overall survival [199]. 
As TAMs are generally associated with poor prognosis in most tumor entities they are 
considered as a promising new target for cancer therapy. As illustrated in Figure 1.5, TAM 
targeting approaches are either based on inhibiting TAM recruitment, suppressing TAM 
survival, enhancing tumoricidal activity of TAMs or inhibiting their tumor promoting activity. 
Recruitment of TAMs into the tumor microenvironment is mediated in great part by CCL2. 
High expression levels of CCL2 were shown to be associated with elevated numbers of 
TAMs and poor prognosis in breast [200] and prostate [201] cancer patients. Treatment with 
Bindarit, an inhibitor of CCL2 expression was shown to reduce tumor growth and 
macrophage recruitment in a human melanoma xenograft model [202]. Trabectedin 
(Yondelis) is a DNA binding chemotherapeutic drug which is approved for the treatment of 
patients with advanced soft-tissue sarcoma and relapsed ovarian cancer [203]. The mode of 
action of this compound seems to be different from other DNA intercalating agents used in 
cancer therapy and is not completely understood. Allavena and colleagues reported that 
Trabectedin inhibits macrophage differentiation and reduces CCL2 expression in freshly 
isolated ovarian tumor cells. The authors concluded that these immunomodulatory properties 
probably contribute to the antitumor activity of this drug [204]. Other chemoattractants such 
as macrophage colony-stimulating factor (M-CSF), CCL5 and CXCL12 might additionally 
serve as therapeutic targets to inhibit macrophage recruitment. 
Another approach to reduce the number of TAMs is to kill them locally. This has been 
achieved by chemical drugs, immunotoxin-conjugated antibodies, attenuated bacteria or 
agents that trigger immune cells to recognize TAMs. Legumain, a stress protein 
overexpressed by TAMs was demonstrated to be an ideal target molecule for a legumain-
based DNA vaccine [205]. Vaccination of tumor bearing mice induced a robust CD8+ T cell 
response against TAMs and decreased the release of proangiogenic factors such as VEGF 
and MMP9. Decreasing the number of TAMs in the tumor microenvironment by legumain 
targeting CD8+ T cells suppressed tumor growth and metastases formation in murine breast, 
colon and non-small cell lung cancer models. 
Besides inhibiting macrophage recruitment or inducing their depletion, repolarization of 
TAMs into M1-like macrophages with tumoricidal activity is an attractive approach. 
Successful repolarization of TAMs was already achieved by the use of different compounds. 
Administration of CpG in combination with an anti-interleukin-10 receptor antibody was 
shown to repolarize tumor infiltrating macrophages from M2 to M1 in mammary 
adenocarcinoma bearing BALB/c mice [206]. Banerjee and colleagues achieved TAM 
repolarization in advanced stage B16F10 tumors by using a combination of heat-killed 
Mycobacterium indicus pranii and an agonistic glucocorticoid-induced TNFR-related protein 
(GITR) antibody [207]. A multidrug chemotherapy (vincristine, cyclophosphamide and 
doxorubicin) combined with an anti-CD40 antibody and CpG induced expression of M1-
associated genes in TAMs from B16 tumors, delayed tumor growth and significantly 
increased survival of the mice [208]. Overexpression of histidine-rich glycoprotein (HRG) in 
T241 fibrosarcoma cells, PancO2 cells and 4T1 cells was demonstrated to inhibit tumor 
growth and metastases. HRG promoted repolarization of TAMs to a M1 phenotype which 
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was accompanied by vessel normalization and an effective anti-tumor immune response 
[209]. In Id-specific T cell receptor transgenic mice, CD4+ T cells were reported to induce 
macrophage repolarization in s.c. MOPC315 myeloma tumors by secretion of IFNү [210, 
211]. Klug and colleagues showed that neoadjuvant local low-dose gamma irradiation 
induced accumulation of iNOS expressing M1 macrophages [212]. Moreover, iNOS was 
reported to mediate CTL recruitment into the tumors by inducing vascular normalization, 
endothelial activation and suppressing the production of immunosuppressive factors. 
In addition to enhancing M1 mediated tumoricidal activity as described above, the inhibition 
of M2 tumor promoting features is another promising strategy. This might be achieved by 
inhibition of transcription factors known to be involved in maintaining a M2 phenotype, such 
as STAT3 [213], MYC [214], STAT6 and KLF4 [215].  
 
Figure 1.5: Strategies to target tumor-associated macrophages. 
The strategies to target TAMs are either aiming for a reduction of TAM numbers in the tumor 
microenvironment (two upper rectangles) or a repolarization of TAMs from a tumor promoting to a 
tumoricidal state (two lower rectangles). Figure was taken from [216]. 
1.3.2 Adoptive cell therapy 
Adoptive cell therapy (ACT) is a personalized cancer therapy approach that involves the 
administration of T cells with direct anti-tumor activity to the patient [217]. In 1987 Rosenberg 
and colleagues demonstrated for the first time that tumor-infiltrating lymphocytes (TILs) 
expanded from patients with metastatic melanoma were cytotoxic against autologous 
melanoma cells but not against normal cells [218]. Only one year later, patients with 
metastatic melanoma were treated by ACT using TILs and IL-2. An objective regression of 
the metastases in the lungs, liver, bone and skin was observed in 55 % of the patients and 
lasted from 2 to more than 13 months [30]. Nowadays, ACT using autologous TILs is 
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considered as an effective immunotherapy to treat patients with metastatic melanoma as it is 
more effective in inducing complete durable responses than any other available 
immunotherapy. As reported by several institutions, the objective response rates of 
melanoma patients treated with autologous TILs and IL-2 following lymphodepletion ranged 
from 38 % – 55 % [219-221]. In a study of Rosenberg and colleagues, 22 % of the patients 
with metastatic melanoma achieved a complete tumor regression beyond five to ten years 
after ACT demonstrating that the adoptive transfer of autologous TILs can induce durable 
complete responses [222]. Even though TILs can be expanded from almost all types of 
cancer, a consistent expansion of TILs with anti-tumor reactivity was so far only applicable 
for melanomas. Moreover, ACT using TILs is a very complex, expensive and time 
consuming approach making it unsuitable for general application until now. Another major 
limitation of this approach is the requirement of pre-existing tumor-reactive T cells within the 
tumors of the patients that can be expanded ex vivo.  
Genetically engineered T cells, transduced with either high affinity T cell receptors against 
TAAs or chimeric antigen receptors (CARs) were developed to overcome these limitations. 
The first TCR engineered T cells used in the clinic were transduced with a TCR recognizing 
a human leukocyte antigen (HLA) A2 restricted peptide of the melanocytic differentiation 
antigen MART-1 [223]. In all 15 patients treated, the adoptively transferred T cells were 
detectable in the peripheral blood for at least 2 months. Moreover, in 2 patients who both 
showed regression of metastatic melanoma lesions TCR transduced cells were still detected 
in the circulation 1 year after T cell transfer. In another study, T cells were engineered to 
express a high affinity TCR recognizing a peptide derived from the cancer-testis antigen NY-
ESO-1 [224]. In 16 out of 20 patients with advanced multiple myeloma promising clinical 
responses were observed upon adoptive T cell transfer.  
CAR T cells overcome some limitations associated with TCR engineered T cells as they are 
independent of costimulatory signals (starting from the second generation CARs) and 
expression of MHC molecules on the surface of tumor cells. CARs are fusion proteins 
consisting of an extracellular protein binding domain and intracellular signaling domains. The 
extracellular binding domain is most commonly derived from an antibody single chain 
variable fragment directed against a tumor-associated antigen. The intracellular signaling 
domains derive from proteins involved in TCR signaling. First generation CARs contain only 
a single intracellular signaling module composed of CD3ζ. Second and third generation 
CARs possess one or more costimulatory domains (e.g. CD28 or 4-1BB) fused to CD3ζ, 
respectively. In August 2017, autologous T cells expressing a CAR specific for CD19 were 
approved by the Food and Drug Administration (FDA) for treatment of diffuse large B cell 
lymphoma and refractory pre-B cell acute lymphoblastic leukemia (Kymriah; Novartis). 
Complete remission was achieved in 83 % of treated patients [225]. Only 2 months later, a 
second CD19 CAR T cell therapy was approved for treatment of adults with 
relapsed/refractory large B cell lymphoma (Yescarta; Kite Pharma). The FDA approval was 
based on a study showing an overall response rate (ORR) of 82 %, including a complete 
response in 58 % of the patients [225]. Using CAR T cells to target tumor-associated 
antigens also in solid tumors is more difficult and has achieved only limited success so far, 
due to the immunosuppressive tumor microenvironment and antigen heterogeneity.  
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1.3.3 Vaccination strategies 
Vaccination of cancer patients with recombinant TAAs, whole tumor cell lysates, TAA 
encoding RNAs or synthetic peptides encompassing T cell epitopes are strategies to induce 
an anti-tumor immune response. However, most clinical trials based on one of these 
vaccination approaches demonstrated limited therapeutic efficiencies [226]. 
Several studies demonstrated that vaccinations with peptides derived from TAAs can induce 
T cell responses and even result in durable clinical responses [227, 228]. However, the 
overall clinical response rates were low revealing the need for improved peptide vaccination 
strategies. The outcome of peptide vaccinations might be improved by including long 
peptides, modifying the adjuvants, including new antigens and combining peptide 
vaccination with other immunotherapies. Short peptides might directly bind to MHC 
molecules on the surface of non-professional antigen presenting cells and thereby induce T 
cell anergy. In contrast, long peptides (30-mer) need to be internalized and processed by 
APCs and might harbor both, CD4 and CD8 T cell epitopes which was demonstrated to be 
essential to establish a long-term T cell memory [229, 230]. 
During the last years, several clinical studies testing the efficiency of RNA-based vaccination 
strategies have been set up. mRNAs encoding TAAs have been used to elicit anti-tumor 
immune responses primarily in two ways. The first approach is based on loading of 
autologous dendritic cells ex vivo with mRNA and subsequent transfer of these cells into the 
patient where the encoded protein is expressed and TAA derived epitopes are presented. A 
second approach relies on the presentation of epitopes by APCs upon direct injection of 
mRNA into the patient (either systemically or locally). A study by Fotin-Mleczek and 
colleagues reported a robust TAA specific CD4+ and CD8+ T cell response upon intradermal 
administration of an ovalbumin (OVA) encoding self-adjuvanted mRNA vaccine [231]. After 
two intradermal vaccinations, C57BL/6 mice s.c. injected with E.G7 cells were completely 
protected against tumor outgrowth. A self-adjuvanted mRNA vaccine encoding for various 
prostate cancer associated antigens was safe and well tolerated as demonstrated in a phase 
I/IIa study [232]. Further, tumor antigen specific T cells could be detected in 79 % of the 
patients, with 58 % showing an immunological response against multiple antigens. Even 
though other studies could also demonstrate the induction of antigen specific T cell 
responses upon vaccination with mRNA formulations, the anti-tumor activity remains low 
[233]. Recently, the intravenous (i.v.) administration of OVA encoding RNA-lipoplexes with 
optimal net charge has been shown to protect RNA from degradation and mediate its 
uptake, translation and epitope presentation by dendritic cells [234]. Further, the authors 
showed an induction of strong effector and memory T cell responses resulting in B16-OVA 
tumor rejection. The systemic delivery was more effective in T cell priming compared to local 
vaccine administration and thus appears to have greater therapeutic potential. In a phase I 
dose-escalation trial RNA-lipoplexes encoding four tumor antigens (Tyrosinase, 
Transmembrane phosphatase with tensin homology (TPTE), NY-ESO-1 and MAGE-A3) are 
currently tested in patients with malignant melanoma. 
The use of whole tumor cell lysates represents an attractive alternative to synthetic peptide 
or RNA based immunotherapies. In contrast to TAA derived peptides or TAA encoding 
mRNA, tumor lysates comprise a huge amount of potential T cell epitopes which have the 
capacity to activate CD4+ and CD8+ T cells. The activation of a variety of anti-tumor reactive 
T cell clones increases the likelihood of durable tumor control. Further, vaccination with 
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whole tumor lysates is suitable for treatment of virtually all cancer patients due to the broad 
polyclonal immune response. Treatment of melanoma patients with Canvaxin, an allogenic 
whole cell vaccine composed of three irradiated melanoma cell lines resulted in improved 
overall survival rates [235]. However, two phase 3 clinical trials in patients with stage III and 
IV melanoma were discontinued due to low efficiency [236]. Another example is GVAX 
vaccine which was developed for the treatment of prostate cancer. GVAX is composed of 
two allogenic prostate tumor cell lines which were transduced with an adenoviral vector 
encoding for granulocyte macrophage colony-stimulating factor (GM-CSF) to increase DC 
recruitment to the site of vaccination [237]. The cell lines were irradiated and subsequently 
injected intradermally in prostate cancer patients. Safety and clinical activity of GVAX were 
confirmed in phase I and II studies [238]. However, a phase III trial comparing GVAX with 
the standard of care treatment (docetaxel and prednisone) was terminated due to increased 
number of deaths in the GVAX arm compared to the control arm. Another phase III trial, 
comparing a combination of GVAX and docetaxel with a combination of docetaxel and 
prednisone was terminated in the same year. This decision was based on a study of the 
Independent Data Monitoring Committee which stated that the trial has only a low chance 
(< 30 %) of meeting the predefined end point [238]. 
1.3.4 Monoclonal antibodies  
Within the last 20 years, a variety of monoclonal antibodies for the treatment of solid and 
haematological cancers have been established. Antibodies can mediate tumor cell killing in 
various ways as explained by the following examples. Trastuzumab (anti-HER2/neu) is a 
humanized IgG1 antibody approved for the treatment of human epidermal growth factor 
receptor 2 (HER2/neu) positive breast cancer patients [239]. The monoclonal antibodies 
Cetuximab [240] and Panitumumab [241] target epidermal Growth Factor Receptor (EGFR) 
and are approved for the treatment of EGFR-positive metastatic colorectal cancer. These 
three antibodies act by inhibiting the downstream signaling pathways required for rapid 
tumor cell proliferation. Moreover, Trastuzumab and Cetuximab can induce antibody-
dependent cellular cytotoxicity (ADCC) by recruiting NK cells. 
Rituximab (anti-CD20) is a chimeric human-murine IgG1 antibody approved for treating 
patients with B cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia [242]. This 
antibody facilitates tumor cell killing by directly inducing apoptosis and ADCC as well as 
complement-dependent cytotoxicity (CDC). Other antibodies conjugated to radioisotopes or 
to toxic drugs, such as Yttrium-90 ibritumomab-tiuxetan (anti-CD20) and Iodine-131 
tositumomab (anti-CD20) or Brentuximab vedotin (anti-CD30), respectively have been 
applied to induce tumor cell killing [243].  
Besides targeting tumor-associated antigens to induce direct tumor cell killing, some 
antibodies function by either activating or antagonizing immunological pathways which are 
involved in cancer immune surveillance. For instance, an agonistic CD40 antibody was 
shown to induce tumor regressions in pancreatic ductal adenocarcinoma patients. This effect 
was mediated through the activation of macrophages, which rapidly infiltrated into the tumors 
and became tumoricidal [244]. Moreover, several antibodies blocking negative regulators of 
immune activation such as CTLA-4 and PD-1 resulted in durable responses and have been 
approved by the FDA for the treatment of melanoma. A detailed description of these immune 
checkpoint inhibitors is given in section 1.4.3.3. 
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1.3.5 Oncolytic viruses 
Oncolytic viruses act by selective tumor cell killing as well as by establishing anti-tumor 
immunity. Selective targeting of tumor cells is driven by at least three factors. First, tumor 
cells often overexpress viral entry receptors. Second, viral replication benefits from the high 
metabolic activity of tumor cells compared to normal cells. Third, many tumor cells have 
deficiencies in antiviral type I IFN signaling. The release of viral antigens and cell debris by 
dying tumor cells promotes the development of the aforementioned anti-tumor immunity 
[245]. 
Most of the oncolytic viruses which are tested in clinical trials are engineered to improve 
selective targeting of tumor cells. For instance, many variants of the Herpes simplex virus 
type 1 with deletion of the infected cell protein (ICP) genes ICP34.5 and ICP6 have been 
constructed and showed increased anti-tumor and immune stimulating activity [246, 247]. 
The viral ribonucleotide reductase ICP6 is substantial for the generation of a nucleotide pool 
which is required for viral replication in quiescent cells. Deletion of ICP6 results in selective 
viral replication in tumor cells with inactivated p16INK4A tumor suppressor. PROSTVAC is a 
prime-boost regimen using vaccinia virus as primary vaccination followed by booster 
injections with fowlpox virus. Both virus types are engineered to express costimulatory 
molecules (lymphocyte function-associated antigen (LFA) 3, B7.1 and intercellular adhesion 
molecule (ICAM) 1) and prostate-specific antigen (PSA). Subcutaneous injection of vaccinia 
viruses induces a strong immune response against the tumor-associated antigen PSA, 
resulting in PSA specific CTLs that can kill prostate cancer cells. As neutralizing antibodies 
against the vaccinia virus are produced rapidly, booster vaccinations with fowlpox viruses 
are required to enhance the anti-tumor T cell immunity. Treatment with PROSTVAC and 
GM-CSF in a Phase II trial was well tolerated and significantly improved median overall 
survival of prostate cancer patients [248].  
In 2015, the first oncolytic virus (talimogene laherparepvec) was approved by the FDA for 
treatment of unresectable melanoma lesions. Talimogene laherparepvec is a herpes simplex 
virus type I engineered to express GM-CSF and deleted for ICP34.5 and ICP47. ICP47 
inhibits the TAP mediated transfer of viral derived peptides across the endoplasmic reticulum 
(ER) membrane, thereby preventing MHC restricted presentation of viral peptides on the 
infected cell surface which eventually results in immune evasion [249]. Melanoma patients 
that received intralesional injections of talimogene laherparepvec showed a significantly 
higher durable response rate compared to GM-CSF injections (16.3 % vs. 2.1 %) [250]. 
Moreover, the overall response rate as well as the median overall survival was higher and 
the therapy was well tolerated.  
Many other viruses, including adenoviruses, vaccinia viruses, measles viruses and 
coxsackieviruses are now tested in clinical trials with some of them showing encouraging 
data [251]. 
1.3.6 Toll-like receptor agonists and cytokines 
The two immunostimulatory cytokines IL-2 and IFN-α2b have been shown to improve an 
anti-tumor immune response and were approved by the FDA as standalone therapy for the 
treatment of advanced melanoma (described more in detail in section 1.4.3.3). However, 
most of the times administration of cytokines is combined with other immunotherapies to 
enhance their immunogenic potential. GM-CSF is a cytokine which promotes recruitment, 
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proliferation and maturation of antigen presenting cells, such as DCs and macrophages. As 
described in previous sections, the immunomodulatory properties of GM-CSF were already 
utilized in combination with several immunotherapeutic approaches such as vaccination with 
oncolytic viruses [248, 250], whole tumor cells [237] or with synthetic peptides [252].   
Until today, only three TLR agonists have been approved by the FDA for the treatment of 
cancer patients. Bacillus Calmette-Guérin (BCG) is a weakened strain of the bovine 
tuberculosis bacterium Mycobacterium bovis which was initially used as a vaccine against 
tuberculosis. Currently, the TLR2/TLR4 agonist BCG is approved for the treatment of 
bladder cancer [253]. Monophophoryl lipid A (a derivative of LPS) is another TLR2/TLR4 
agonist which is used as an adjuvant in prophylactic vaccination regimens against human 
papillomavirus 16 and 18 [254]. The imidazoquinoline derivative imiquimod exerts its 
proinflammatory functions mainly through binding to TLR7 and is currently approved for the 
treatment of superficial basal cell carcinoma, genital warts and actinic keratosis [255]. 
1.4 Melanoma 
Skin cancers comprise of three main types including basal cell carcinoma, squamous cell 
carcinoma as well as melanoma. Basal cell carcinoma and squamous cell carcinoma 
together are called non-melanoma skin cancers. These two types are the most common 
forms of skin cancer, are rarely lethal and are both from epithelial origin (basal cell 
keratinocytes or squamous epithelial keratinocytes, respectively) [256]. In contrast, 
melanoma is a deadly skin cancer arising from melanocytes which are the melanin 
producing cells found in the basal layer of the epidermis [257]. Even though melanoma only 
accounts for approximately 5 % of the skin cancer cases, it is responsible for the majority of 
skin cancer related deaths due to its aggressiveness and resistance to various forms of 
therapy [258, 259]. In 2012, 232,000 new cases of melanoma were reported which 
accounted for 1.6 % of all diagnosed cancers worldwide. This makes melanoma the 16th and 
15th most common malignancy in females and males, respectively, and accounts for 0.7 % 
(55,000 total deaths) of all cancer related deaths worldwide [260]. 
1.4.1 Pathophysiology 
Melanomas are often associated with so called precursor lesions. These are melanocytic 
neoplasms of the skin ranging from benign naevi and dysplastic naevi to melanoma in situ 
which bear an increased risk of progressing into melanoma. Simplified melanoma 
progression models often suggest a single path of evolution from benign naevi, to dysplastic 
naevi, to melanoma in situ and eventually to metastatic melanoma. However, different 
evolutionary paths have been described which are dependent on the melanoma type and 
the precursor lesion the melanoma originated from. The molecular events taking place in 
several of these paths were reviewed in detail by Shain and Bastian and will not be 
discussed within this thesis [261].  
Large-scale analyses revealed that melanomas have a relatively high mutational load when 
compared to other tumor entities, with a frequency that exceeds 100 somatic mutations per 
mega base [262]. The first mutations in melanoma commonly occur in genes belonging to 
the MAP kinase signaling pathway, with BRAF and NRAS being the most frequently mutated 
genes [263]. Besides these mutations in genes controlling cell proliferation, invasive and 
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metastatic melanomas additionally harbor mutations in genes involved in growth and 
metabolism (phosphatase and tensin homolog (PTEN) and KIT), apoptosis and genetic 
integrity (TP53), chromatin remodeling (AT-rich interactive domain-containing protein 1A 
(ARID1A)), cell cycle control (cyclin-dependent kinase Inhibitor 2A (CDKN2A)) and telomere 
length (TERT) [261, 263-266]. 
1.4.2 Staging systems 
Stratification of patients into clinically relevant stage groups is essential for therapeutic 
decision making and eventually to improve patients’ course of disease and overall survival. 
Three classification systems to determine the progress of melanoma are applied in clinics. 
The Clark scale can be used to evaluate how deep the neoplastic cells have grown into the 
skin and which skin layers are affected. In contrast, the Breslow scale considers the overall 
melanoma depth within the skin without taking the different skin layers into account. Third, 
the tumor-node-metastasis (TNM) staging, which determines the thickness of the melanoma 
(T), the presence of tumor cells in the nearby lymph nodes (N) and the formation of 
metastases (M). Based on the TNM classification system tumors are divided into clinical 
stages I to IV. Melanomas that have not spread to lymph nodes or other organs are 
designated as stage I or II depending on the thickness of the primary lesion as well as on the 
absence or presence of ulceration. In stage III melanomas, tumor cells have spread to 
regional lymph nodes and/or so called satellite (within 2 cm of the primary lesion) and/or in-
transit metastases (more than 2 cm distance to primary lesion but before the first draining 
lymph node) have developed. Stage IV melanomas are defined by metastatic spread to 
distant organs such as lung, liver, brain or areas of the skin [259, 267-269]. 
1.4.3 Current therapeutic options  
While traditional therapies against melanoma including surgery, chemotherapy and 
radiotherapy are often curative in an early stage of disease (Stage I and II), they are not 
effective in combating advanced metastatic melanoma (Stage III and IV). However, the 
development of new targeted therapy and immunotherapy approaches during the last years 
has dramatically improved clinical outcome of melanoma patients. The following paragraphs 
describe chemo-, targeted-, and immunotherapies currently approved by the FDA for the 
treatment of patients with stage III or IV metastatic melanoma.  
1.4.3.1 Chemotherapy 
The only FDA approved chemotherapeutic drug for the treatment of advanced melanoma is 
dacarbazine, an alkylating agent which executes its cytotoxic function by methylation of 
O6-guanine. The presence of methylguanine containing DNA causes mismatches with 
thymine and cytosine which eventually leads to cell death [270]. Tumor cells are more 
susceptible to alkylating agents compared to healthy cells as they divide faster and their 
DNA repair mechanisms are often defective. The determined response rate of patients with 
advanced melanoma is about 20 % with complete responses in only 5 % of the patients 
(OS: 6.5 month). Common side effects include nausea and vomiting [271, 272]. 
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1.4.3.2 Targeted therapy 
The second class of therapeutic agents to treat stage III and IV melanoma are so called 
targeted therapies composed of small molecules which are designed to selectively target 
one of the kinases (either BRAF or MEK) involved in the MAP kinase signaling pathway. The 
inhibition of molecules within this pathway demonstrated improved clinical outcome 
compared to chemotherapy, as approximately 50 % of all melanoma patients harbor a 
mutation within the BRAF kinase (BRAFV600) resulting in a constitutively active MAP kinase 
signaling [273]. Vemurafenib, which selectively targets V600 mutated BRAF was the first 
small molecule approved by the FDA for the treatment of advanced melanoma in 2011 
(ORR: 50 - 51 %; OS: 17.8 - 18 month) [274-276]. Treatment with dabrafenib, another 
BRAFV600 targeting small molecule approved by the FDA two years later showed similar 
response rates (53 %) and overall survival (18.7 month) compared to vemurafenib [277, 
278]. The most common resistance mechanism in patients treated with BRAF inhibitors is 
the reactivation of the MAP kinase signaling pathway, thus treatment regimens in which 
BRAF and MEK inhibitors are used in combination were tested in clinical trials. In 2014, the 
first dual treatment approach using the BRAF inhibitor dabrafenib and the MEK inhibitor 
trametinib in combination was approved by the FDA and demonstrated an increase in the 
overall response rates (64 - 69 %) and overall survival (25.1 - 26.1 month) compared to the 
monotherapies [274, 276-278]. One year later, a second combination therapy including 
vemurafenib and the MEK inhibitor cobimetinib was approved showing comparable response 
rates (70 %) and overall survival (22.3 month) compared to dabrafenib and trametinib [275, 
279]. Even though the rates of treatment associated adverse events were similar for both 
combination regimens, the toxicity profiles differed substantially. The most common side 
effects observed for the combination of dabrefenib and trametinib included fever, headache 
and vomiting [280], whereas treatment with vemurafenib and cobimetinib resulted in 
photosensitivity reactions, rash and increased liver enzymes [275]. 
The advantages of targeted therapy include the high response rates, the fast and deep 
tumor response as well as the fact that the treatment is not impaired by continuous 
administration of immunosuppressive agents like corticosteroids. However, tumor cells 
develop resistance mechanisms in a majority of the patients [264]. 
1.4.3.3 Immunotherapy 
As described above (see section 1.4.1), melanomas have a high mutational load which 
increases the likelihood for the generation of neoepitopes that might induce anti-tumor T cell 
responses [281]. Thus, melanomas are an attractive target for immunotherapeutic 
approaches that involve the activation and expansion of T cells. Immunotherapy approaches 
that have been approved by the FDA for the treatment of advanced melanoma include 
IFNα-2b, IL-2 and monoclonal antibodies against CTLA-4 and PD-1 [282]. IFNα-2b activates 
the JAK/STAT signaling pathway by binding to the interferon α/β receptor. The binding 
triggers dimerization of the receptor subunits (IFNARI and IFNAR2) and subsequent 
activation and phosphorylation of JAKs and STATs. The phosphorylated STATs then bind to 
IRF9 to form the interferon-stimulated gene factor-3 (ISGF-3). ISGF-3 translocates into the 
nucleus to induce transcription of INF-inducible genes. The induced changes in gene 
expression are responsible for the pleiotropic, immunomodulatory functions of IFNs and 
include the upregulation of MHC I molecules on tumor cells thereby facilitating anti-tumor 
attack by CTLs [282-284]. Treatment of melanoma patients with IFNα-2b has been shown to 
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increase relapse-free survival but not overall survival. Common side effects include flu-like 
symptoms, vomiting, neutropenia, leukopenia and elevated transaminase levels [285]. 
A second cytokine approved by the FDA for the treatment of stage IV melanoma is IL-2. This 
cytokine induces a variety of effects on cells of the immune system. Most importantly, it 
induces the expansion of antigen-specific CD4+ and CD8+ T cells [286], enhances antibody 
secretion by B cells [287] and promotes proliferation and enhances cytolytic activity of 
natural killer (NK) cells [288, 289]. Treatment with IL-2 showed an overall response rate of 
16 % with a complete response in 6 % of the patients [290]. However, IL-2 related 
cytotoxicity is high and none of the conducted clinical trials could show an overall survival 
benefit [291]. Common side effects include flu-like symptoms, hypotension, arrhythmias and 
vomiting. 
Ipilimumab, a monoclonal antibody targeting CTLA-4 was approved by the FDA in 2011 for 
treatment of stage IV melanoma. CTLA-4 is upregulated in conventional T cells upon 
activation and constitutively expressed on the surface of Tregs. It serves as a negative 
regulator of T cell activation by binding to its ligands CD80 and CD86 which are expressed 
on the surface of antigen-presenting cells. Monoclonal antibodies targeting CTLA-4 were 
shown to increase T cell activation and expansion by blocking the inhibitory signals. At the 
same time these antibodies mediate Treg depletion which eventually results in an increased 
T effector/Treg ratio [292]. While the response rates of ipilimumab alone are relatively low 
(11 - 19 %), the treatment improved overall survival of advanced melanoma patients as 
demonstrated in a clinical phase III study (28 % decreased mortality rate compared to 
dacarbazine) [293-297]. Common side effects including rash, nausea, and fatigue might be 
accompanied by more severe autoimmune side effects like enterocolitis, hypophysitis and 
pancreatits which can be life threatening [298]. 
Two monoclonal antibodies (nivolumab and pembrolizumab), targeting PD-1, were approved 
by the FDA in 2014 for the treatment of stage IV melanoma. Similar to CTLA-4, PD-1 is 
involved in maintaining peripheral tolerance and is thus referred to as immune checkpoint 
molecule. The PD-1 receptor is expressed on the surface of lymphocytes and binds to its 
ligand PD-L1 which is frequently expressed on tumor cells (40 - 50 % of melanomas). The 
interaction between PD-1 and its ligand eventually leads to T cell exhaustion. The use of 
pembrolizumab and nivolumab improved the overall response rates up to 40 % and 
increased the median overall survival of melanoma patients to 32.3 and 37.6 months, 
respectively [294-297, 299, 300]. Only 10 - 16 % of the patients developed grade 3 or 4 
toxicities when treated with a monoclonal antibody against PD-1 [294, 295, 299]. In contrast, 
such toxicities were induced in approximately 30 % of the patients when treated with 
ipilimumab, showing that anti-PD-1 treatment is tolerated better [293, 301].  
The combination of ipilimumab and nivolumab improved the overall response rates further 
(57 - 58 %) and was approved by the FDA in 2015 for the treatment of stage IV melanoma 
[294, 297, 302]. However, the combinatorial therapy is accompanied by grade 3 or 4 side 
effects in up to 59 % of the patients [297]. 
In summary, immunotherapies have the highest chance to induce a durable response 
against tumors compared to other treatment options. In addition, this reponse can be 
ongoing even after stopping the therapy. However, lower response rates and the prolonged 
period of time it takes to induce a potent anti-tumor response are the current major 
disadvantages of immunotherapies [264]. 
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1.5 Aims of the study 
The immunosuppressive TME established by inhibitory immune cells such as myeloid 
derived suppressor cells (MDSC), regulatory T cells (Treg) and tumor associated 
macrophages (TAM) forms a major obstacle for successful immunotherapy. Combining 
available tumor immunotherapies with approaches to repolarize immunosuppressive M2-like 
macrophages might overcome this hurdle. The aim of this study is to investigate three 
strategies to repolarize M2-like macrophages (illustrated in Figure 1.6). 
Strategy I: Repolarization of macrophages through cognate interaction with CD4+ T cells. 
The goal of this part of the project is to answer the question whether tumor antigen specific 
CD4+ T cells are able to polarize M2-like macrophages into immunostimulatory M1 in vitro. 
Another goal was to clarify whether adoptively transferred CD4+ T cells have the capacity to 
reprogram M2-like TAMs in vivo, thereby neutralizing the immunosuppressive tumor 
microenvironment and facilitating anti-tumor attack by tumor antigen specific CD8+ CTLs.  
Strategy II: Repolarization of M2-like PECs by transcription factor knock down. 
This part of the study focuses on the identification of key transcription factors (TFs) 
mediating macrophage polarization. Identification of such TFs should reveal new insights 
into the metabolic and transcriptional reprogramming of macrophages and might be useful 
for the identification of therapeutic targets to reprogram M2-like macrophages 
Strategy III: Repolarization of M2-like PECs by miRNA transfection. 
This strategy aims at repolarizing M2-like PECs by miRNA transfection, thereby further 
elucidating the regulation of miRNA-mediated macrophage polarization. 
 
Figure 1.6: Investigated strategies to induce macrophage repolarization. 
Strategy I: Repolarization of macrophages through cognate interaction with CD4
+
 T cells. IFNγ 
secretion by activated CD4
+
 T cells (orange) induces M2-like macrophages (blue) to polarize to 
proinflammatory M1 (red). Strategy II: Repolarization of M2-like macrophages by knocking down 
transcription factors involved in maintaining the M2 state using transcription factor targeting siRNA 
pools. Strategy III: Repolarization of M2-like macrophages by transfecting miRNAs that mediate M1 
polarization.
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2 Materials & Methods 
2.1 Materials 
2.1.1 General instrumentation 
Table 2.1: General instrumentation 
Instrument Manufacturer 
7300 Real time PCR system Applied Biosystems, Foster City, USA 
accu-jet pro Pipette Controller VWR International, Radnor, USA 
Biological Safety Cabinet Heraeus, Hanau, Germany 
CASY Cell counter OMNI Life Science, Bremen, Germany 
CB 150 incubator BINDER, Tuttlingen, Germany 
Centrifuge 5415 D Eppendorf, Hamburg, Germany 
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Centrifuge 5424 R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Dynal (MPC-L) Thermo Fischer Scientific, Waltham, USA 
Dynal (MPC-S) Thermo Fischer Scientific, Waltham, USA 
ELISpot Reader System 
Cellular Technology Limited, Sharker 
Heights, USA 
FACS Aria I Cell Sorter Becton Dickinson, Franklin Lakes, USA 
FACS Aria II Cell Sorter Becton Dickinson, Franklin Lakes, USA 
FACS Calibur1 Flow Cytometer Becton Dickinson, Franklin Lakes, USA 
FACS Canto II Flow Cytometer Becton Dickinson, Franklin Lakes, USA 
Gammacell 1000 Elite MDS, Ottawa, Canada 
Gel Documentation System Bio-Rad Laboratories, Hercules, USA 
Gel iX Imager system  
Intas Science Imaging Instruments, 
Göttingen, Germany 
Innova 4230 Refrigerated Benchtop Incubator New Brunswick Scientific, Edison, USA 
IVIS Lumina Series III  PerkinElmer, Waltham, USA 
LSR II Flow Cytometer Becton Dickinson, Franklin Lakes, USA 
Megafuge 2.0R Heraeus, Hanau, Germany 
Micro-centrigue 2 CMG-060 neoLab Migge, Heidelberg, Germany 
Microscope Olympus CK40 Leica Camera, Wetzlar, Germany 
Microwave intellowave LG, Seoul, South Korea 
Mini Laboratory Centrifuge neoLab Migge, Heidelberg, Germany 
Mithras LB940 
Berthold Technologies, Bad Wildbad, 
Germany 
Mixer Mill MM301 Retsch, Haan, Germany 
MR 3002 S Magnetic stirring hot plate 
Heidolph Instruments, Schwabach, 
Germany 
Multipipette E3x Eppendorf, Hamburg, Germany 
Neubauer counting chamber Brand, Wertheim, Germany 
pH Meter 766 Calimatic Knick, Berlin, Germany 
PIPETBOY acu 2 INTEGRA Biosciences, Biebertal, Germany 
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Pipette (P2, P10, P20, P100, P200, P1000) Gilson, Middleton, USA 
PowerPac™ Basic Power Supply  Bio-Rad Laboratories, Hercules, USA 
Spectrophotometer NanoDrop 2000 Thermo Fischer Scientific, Waltham, USA 
Sterilgard class II Type A/B3 The Baker Company, Sanford, USA 
Syro II  MultiSynTech, Witten, Germany 
Tecan Infinite 200 PRO Tecan Group, Männedorf, Switzerland 
Thermo Finnigan LCQ Deca XP LCMS System Thermo Fischer Scientific, Waltham, USA 
thermomixer comfort Eppendorf, Hamburg, Germany 
Trans-Blot Turbo Transfer System Bio-Rad Laboratories, Hercules, USA 
Veriti 96-Well Thermal Cycler Applied Biosystems, Foster City, USA 
Vortex-Genie 2 Scientific Industries, New York, USA 
Water bath GFL, Burgwedel, Germany 
Wet Blotting System Mini Trans-Blot Cell Bio-Rad Laboratories, Hercules, USA 
xCELLigence® RTCA SP System  ACEA Biosciences, San Diego, USA 
2.1.2 General consumables 
Table 2.2: General consumables 
Material Manufacturer 
14mL Round Bottom High Clarity PP Test Tube Corning, New York, USA 
3MM CHR Blotting Paper neoLab Migge, Heidelberg, Germany 
5 ml Polystyrene round bottom tube with cell strainer 
cap 
Corning, New York, USA 
BD Discardit II disposable syringe (5, 10 ml) Becton Dickinson, Franklin Lakes, USA 
BD Mircolance 3 (21G, 27G) Becton Dickinson, Franklin Lakes, USA 
Bepanthen Bayer, Leverkusen, Germany 
Cap for PCR microcentrifuge tubes nerbe plus, Winsen, Germany 
CASY ton OMNI Life Science, Bremen, Germany 
CASYcups OMNI Life Science, Bremen, Germany 
Cell culture flask 50 ml Greiner Bio-One, Kremsmünster, Austria 
cell scraper Corning, New York, USA 
Centrifuge tube pp with screw cap PE (15, 50 ml) nerbe plus, Winsen, Germany 
Corning® 96 Well Solid Polystyrene Microplate Sigma-Aldrich, St. Louis, USA 
Cover glasses Thermo Fischer Scientific, Waltham, USA 
Cryogenic vials Thermo Fischer Scientific, Waltham, USA 
Disposable scalpel Feather, Osaka, Japan 
Disposable serological pipette (5, 10, 25, 50 ml) Corning, New York, USA 
easystrainer  (40, 70 µm) Greiner Bio-One, Kremsmünster, Austria 
Einmal-Drigalskispatel Dreiecksform neoLab Migge, Heidelberg, Germany 
Enthaarungscreme dm-drogerie markt, Karlsruhe, Germany 
E-Plate 96 ACEA Biosciences, San Diego, USA 
Eppendorf Combitips advanced (0.1, 1, 5, 25 ml) Eppendorf, Hamburg, Germany 
Eppendorf Micro test tube 3810X 1.5 ml Eppendorf, Hamburg, Germany 
Eppendorf Safe-Lock microtubes, PCR clean 2.0 ml Eppendorf, Hamburg, Germany 
Eppendorf Tubes 3810X 1.5 ml Eppendorf, Hamburg, Germany 
Eppendorf tubes 5.0 ml Eppendorf, Hamburg, Germany 
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LS columns 
Miltenyi Biotech, Bergisch Gladbach, 
Germany 
LumaPlate 96 PerkinElmer, Waltham, USA 
Messpipetten BRAND, Wertheim, Germany 
MicroAmp Optical 96-Well Reaction plate Applied Biosystems, Foster City, USA 
Mini-PROTEAN® Combs, 15-Well, 1.5 mm, 40 μl Bio-Rad Laboratories, Hercules, USA 
Mini-PROTEAN® Short Plates (1.5 mm integrated 
spacers) 
Bio-Rad Laboratories, Hercules, USA 
Mini-PROTEAN® Tetra Handcast Systems, 1.5 mm Bio-Rad Laboratories, Hercules, USA 
Mouse restrainer Braintree Scientific, Braintree, USA 
MS columns 
Miltenyi Biotech, Bergisch Gladbach, 
Germany 
MultiScreenHTS-IP, 0,45 µm, transparent, nicht steril Merck KGaD, Darmstadt, Germany 
Neubauer Zählkammer BRAND, Wertheim, Germany 
Nunc™ MaxiSorp™ ELISA Plates, uncoated BioLegend, San Diego, USA 
Parafilm M Pechiney Plastic Packaging, Chicago, USA 
PCR microcentrifuge tube PP, 0.2 ml, without cap nerbe plus, Winsen, Germany 
Pipette filter tips (10, 20, 100, 200, 1250 µl) nerbe plus, Winsen, Germany 
Pipette tips PP refill system (10, 200, 1000 µl) nerbe plus, Winsen, Germany 
Plastic serum pipette Greiner Bio-One, Kremsmünster, Austria 
Premium Aluminum Foil VWR International, Radnor, USA 
Protran BA 85 GE Healthcare, Little Chalfont, UK 
Reagent Reservoir Corning, New York, USA 
Safe-lock microcentrifuge tubes (1.5, 2 ml) Eppendorf, Hamburg, Germany 
Sealing Tape Thermo Fischer Scientific, Waltham, USA 
Soft-Ject single use syringes Henke-Sass, Wolf, Tuttlingen, Germany 
Tissue culture dish 100 TPP, Trasadingen, Switzerland 
Tissue culture flask (75, 150 cm
2
) TPP, Trasadingen, Switzerland 
Tissue culture test plate (96F, 96U) TPP, Trasadingen, Switzerland 
Tissue culture test plates (6, 12, 24, 96 Wells) TPP, Trasadingen, Switzerland 
2.1.3 Chemicals and Reagents 
2.1.3.1 Cell culture 
Table 2.3: Cell culture 
Component Cat. No. Manufacturer 
2-Mercaptoethanol M6250 Sigma-Aldrich, St. Louis, USA 
Accutase cell detachment solution SCR005 Merck KGaA, Darmstadt, Germany 
ACK Lysing Buffer A10492-01 Thermo Fisher Scientific, Waltham, USA 
Biocoll L6115 Merck KGaA, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Cell culture 
grade 
A3672 AppliChem , Darmstadt, Germany 
DMEM, high glucose, GlutaMAX™ 
Supplement 
61965-026  Thermo Fisher Scientific, Waltham, USA 
DPBS, no calcium, no magnesium 14190-094 Thermo Fisher Scientific, Waltham, USA 
Dynabeads® Mouse T-Activator 
CD3/CD28 
11452D Gibco, Waltham, USA 
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Fetal calf serum S 0115 Biochrom , Darmstadt, Germany 
Fluorescein isothiocyanate–dextran 
FD40-
100MG 
Sigma-Aldrich, St. Louis, USA 
FluoSpheres™ Carboxylate-Modified 
Microspheres, 2.0 µm 
F8827 Thermo Fisher Scientific, Waltham, USA 
HEPES solution  H0887 Sigma-Aldrich, St. Louis, USA 
Iscove's Modified Dulbecco's Medium 
(IMDM) 
12440053 Thermo Fisher Scientific, Waltham, USA 
Lactacystin L6785 Sigma-Aldrich, St. Louis, USA 
L-Glutamine (200 mM) 25030-081 Thermo Fisher Scientific, Waltham, USA 
Lympholyte®-M Cell Separation Media CL5035 
Cedarlane Laboratories, Burlington, 
Canada 
Methyl α-D-mannopyranoside M6882  Sigma-Aldrich, St. Louis, USA 
Minimum Essential Medium Eagle M4526 Sigma-Aldrich, St. Louis, USA 
Opti-MEM™ I Reduced Serum Medium 31985070 Thermo Fisher Scientific, Waltham, USA 
Penicillin-Streptomycin P0781 Sigma-Aldrich, St. Louis, USA 
RPMI 1640 Medium, GlutaMAX™ 
Supplement   
61870-010 Thermo Fisher Scientific, Waltham, USA 
Sodium Pyruvate S8636 Sigma-Aldrich, St. Louis, USA 
Trypsin-EDTA (0.25%), phenol red 25200-056 Thermo Fisher Scientific, Waltham, USA 
X-VIVO™ 20 Chemically Defined, 
Serum-free Hematopoietic Cell Medium 
BE04-448Q Lonza Group, Basel, Switzerland 
2.1.3.2 Transfection reagents 
All transfection reagents used within this thesis to transfect miRNAs or plasmids into tumor 
cell lines and PECs are listed in Table 2.4. The reagents were used according to 
manufacturer’s instructions, unless otherwise stated. 
Table 2.4: Transfection reagents 
Transfection Reagent Cat. No. Manufacturer 
DharmaFECT 4 Transfection Reagent T-2004-01 Dharmacon, Lafayette, USA 
DharmaFECT Duo Transfection Reagent T-2010-01 Dharmacon, Lafayette, USA 
Effectene Transfection Reagent Kit 301425 Qiagen, Venlo, Netherlands 
Lipofectamine 3000 Transfection 
Reagent 
L3000001 Thermo Fisher Scientific, Waltham, USA 
Lipofectamine LTX Reagent 15338030 Thermo Fisher Scientific, Waltham, USA 
Lipofectamine RNAiMAX Transfection 
Reagent 
13778-100 Thermo Fisher Scientific, Waltham, USA 
METAFECTENE® PRO T040-1.0  Biontex Laboratories , München, Germany 
METAFECTENE® SI⁺ T100-1.0 Biontex Laboratories , München, Germany 
PromoFectin-Macrophage 
PK-CT-
2000-MAC-
10 
Promokine, Heidelberg, Germany 
siLentFect Lipid Reagent for RNAi 1703361 Bio-Rad Laboratories, Hercules, USA 
TransIT Dynamic Delivery System MIR-6003 Mirus Bio LLC, Madison, USA 
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TransIT-2020 Transfection Reagent MIR-5404 Mirus Bio LLC, Madison, USA 
TurboFect Transfection Reagent R0533 Thermo Fisher Scientific, Waltham, USA 
Viromer Red 230151 
Biozym Scientific, Hessisch Oldendorf, 
Germany 
2.1.3.3 Reagents for flow cytometry 
Table 2.5: Reagents for flow cytometry 
Component Cat. No. Manufacturer 
7-AAD Viability Staining Solution 420403 BioLegend, San Diego, USA 
BD Perm/Wash™ - Perm/Wash Buffer  51-2091KZ Becton Dickinson , Franklin Lakes, USA 
CountBright™ Absolute Counting Beads C36950 Thermo Fisher Scientific, Waltham, USA 
Cytofix/Cytoperm™ - 
Fixation/Permeabilization Solution  
51-2090KZ Becton Dickinson , Franklin Lakes, USA 
LIVE/DEAD® Fixable Blue Dead Cell 
Stain Kit 
L-23105 Thermo Fisher Scientific, Waltham, USA 
LIVE/DEAD® Fixable Yellow Dead Cell 
Stain Kit 
L-34959 Thermo Fisher Scientific, Waltham, USA 
Normal Syrian Hamster Serum  
007-000-
120 
Jackson Laboratory, Bar Harbor, USA 
OneComp eBeads 01-1111-42 eBioscience, Waltham, USA 
Purified Rat Anti-Mouse CD16/CD32  553142 Becton Dickinson , Franklin Lakes, USA 
Rat serum GTX73216 GeneTex, Irvine, USA 
2.1.3.4 Reagents for protein biochemistry 
Table 2.6: Reagents for protein biochemistry 
Component Cat. No. Manufacturer 
10% SDS 51206 Lonza Group, Basel, Switzerland 
30% Acrylamide/Bis Solution, 37.5:1 161-0158 Bio-Rad Laboratories, Hercules, USA 
Acetic acid 9526 Avantor, Center Valley, USA 
Albumin from chicken egg white A5503 Sigma-Aldrich, St. Louis, USA 
Albumin from chicken egg white A2512 Sigma-Aldrich, St. Louis, USA 
Albumin, from bovine serum A7030 Sigma-Aldrich, St. Louis, USA 
Amersham ECL Prime Western Blotting 
Detection Reagent  
RPN2232 
GE Healthcare Life Sciences, Chalfont St 
Giles, UK 
Ammonium Persulfate 1610700 Bio-Rad Laboratories, Hercules, USA 
Bromophenol blue B0126  Sigma-Aldrich, St. Louis, USA 
Cell Lysis Buffer (10X) 9803 Cell Signaling Technology, Cambridge, UK 
Glycerol A3561 AppliChem , Darmstadt, Germany 
Glycine  33226 Sigma-Aldrich, St. Louis, USA 
Isopropanol 33539 Sigma-Aldrich, St. Louis, USA 
Methanol 32213 Sigma-Aldrich, St. Louis, USA 
Milk powder T145.2 Carl Roth, Karlsruhe, Germany 
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N,N,N',N'-Tetramethylethylendiamin, 1,2-
Bis(dimethylamino)-ethan 
2367.3 Carl Roth, Karlsruhe, Germany 
Phenylmethanesulfonyl fluoride P7626 Sigma-Aldrich, St. Louis, USA 
Precision Plus Protein™ Dual Color 
Standards 
161-0374 Bio-Rad Laboratories, Hercules, USA 
Protein-Marker IV ('Prestained') 27-2110 VWR International, Radnor, USA 
Sodium chloride 31434 Sigma-Aldrich, St. Louis, USA 
Substrate Reagent A 51-2606KC Becton Dickinson , Franklin Lakes, USA 
Substrate Reagent B 51-2607KC Becton Dickinson , Franklin Lakes, USA 
Trizma base T1503 Sigma-Aldrich, St. Louis, USA 
Tween 20 A4974 AppliChem , Darmstadt, Germany 
2.1.3.5 Restriction enzymes 
The type II restriction endonucleases listed in Table 2.7 were used as advised by the 
manufacturer. 
Table 2.7: Restriction enzymes 
Enzyme Cat. No. Manufacturer 
EcoRI (10 U/µL) ER0271 Thermo Fisher Scientific, Waltham, USA 
FastDigest ScaI FD0434 Thermo Fisher Scientific, Waltham, USA 
2.1.3.6 Antibiotics 
Table 2.8: Antibiotics 
Antibiotic Cat. No. Manufacturer 
Blasticidine S hydrochloride  15205 Sigma-Aldrich, St. Louis, USA 
Geneticin® Selective Antibiotic 10131035 Thermo Fisher Scientific, Waltham, USA 
Hygromycin B (50 mg/mL) 10687010 Thermo Fisher Scientific, Waltham, USA 
Puromycin Dihydrochloride A1113803 Thermo Fisher Scientific, Waltham, USA 
2.1.3.7 Reagents for polymerase chain reaction 
Table 2.9: Reagents for polymerase chain reaction 
Component Cat. No. Manufacturer 
dNTP-Mix Long Range 20-3111 
PEQLAB Biotechnologie, Erlangen, 
Germany 
MgCl2 (magnesium chloride) R0971 Thermo Fisher Scientific, Waltham, USA 
Nuclease free water W4502 Sigma-Aldrich, St. Louis, USA 
Taq Buffer with (NH4)2SO4 (10X) B33 Thermo Fisher Scientific, Waltham, USA 
Taq DNA Polymerase EP0401 Thermo Fisher Scientific, Waltham, USA 
2.1.3.8 Reagents for tumor digestion 
All reagents used for tumor digestion were resolved/diluted in Hanks’ Balanced Salt solution 
to reach the desired stock concentrations and stored at -80 °C. 
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Table 2.10: Reagents for tumor digestion 
Component Cat. No. Manufacturer 
Collagenase D  1108885800 Hoffmann-La Roche, Basel, Switzerland 
Deoxyribonuclease I from bovine 
pancreas 
D5025 Sigma-Aldrich, St. Louis, USA 
Nα-Tosyl-L-lysine chloromethyl ketone 
hydrochloride (TLCK) 
90182 Sigma-Aldrich, St. Louis, USA 
Hanks’ Balanced Salt solution  H9269 Sigma-Aldrich, St. Louis, USA 
2.1.3.9 Reagents for gel electrophoresis 
Table 2.11: Reagents for gel electrophoresis 
Component Cat. No. Manufacturer 
Agarose Basic A8963 AppliChem , Darmstadt, Germany 
EcoRI Buffer (10X) B12 Thermo Fisher Scientific, Waltham, USA 
Ethidiumbromidlösung 0,025 % HP47.1 Carl Roth, Karlsruhe, Germany 
FastDigest Green Buffer (10X) B72 Thermo Fisher Scientific, Waltham, USA 
O’GeneRuler 1 kb DNA Ladder SM1163 Thermo Fisher Scientific, Waltham, USA 
Quick-Load® 100 bp DNA Ladder N0467G New England Biolabs, Ipswich, USA 
6X Orange DNA Loading Dye R0631 Thermo Fisher Scientific, Waltham, USA 
2.1.3.10 Bacteria 
Table 2.12: Bacteria 
Bacteria Cat. No. Manufacturer 
One Shot® TOP10 Chemically 
Competent E. coli 
C4040-06 Thermo Fisher Scientific, Waltham, USA 
2.1.3.11 Reagents for transformation of bacteria 
Table 2.13: Reagents for transformation of bacteria 
Component Cat. No. Manufacturer 
S.O.C. Medium 15544-034 Thermo Fisher Scientific, Waltham, USA 
Tryptone T7293  Sigma-Aldrich, St. Louis, USA 
Yeast extract 70161 Sigma-Aldrich, St. Louis, USA 
Ampicillin sodium salt A9518 Sigma-Aldrich, St. Louis, USA 
Agar-Agar 5210.3 Carl Roth, Karlsruhe, Germany 
2.1.3.12 Cytokines and TLR ligands 
Table 2.14: Cytokines and TLR ligands 
Component Cat. No. Manufacturer 
Lipopolysaccharides from Salmonella 
typhosa 
L2387 Sigma-Aldrich, St. Louis, USA 
Mouse IFN gamma Recombinant Protein 
Carrier-Free 
34-8311-82 eBioscience, Waltham, USA 
ODN 1826 (CpG) tlrl-1826-1 InvivoGen, San Diego, USA 
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Recombinant Mouse IL-2 (carrier-free) 575402 Biolegend, San Diego, USA 
Recombinant Mouse IL-4 (carrier-free) 574302 Biolegend, San Diego, USA 
2.1.4 Cell lines and culture medium 
All cell lines used and generated within this thesis are listed in Table 2.15. The “Medium 
Index” column shows the index of the cell line specific culture medium (listed in Table 2.16). 
2.1.4.1 Cell lines 
Table 2.15: Cell lines 
Cell line 
Cell 
type 
Modification Provider 
Medium 
Index 
Antibiotic 
771 B cell lymphoma BL - 
Offringa, 
Rienk 
5 - 
B16F10 ATCC M - ATCC 2 - 
B16F10 ATCC/Acceptor 10 M 
FRT site in Rosa26 
locus 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 10/Ctrl. M 
Fluorophore in Rosa26 
locus (isogenic) 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 10/OVA-F M 
OVA in Rosa26 locus 
(isogenic) 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 10/OVA-T M 
OVA in Rosa26 locus 
(isogenic) 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 35 M 
FRT site in Rosa26 
locus 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 35/Ctrl. M 
Fluorophore in Rosa26 
locus (isogenic) 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 35/M2KO M 
FRT site in Rosa26 
locus/MHC-class II KO 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 35/OVA-F M 
OVA in Rosa26 locus 
(isogenic) 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/Acceptor 35/OVA-T M 
OVA in Rosa26 locus 
(isogenic) 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/M1KO M MHC-class I KO 
generated in 
this thesis 
2 - 
B16F10 ATCC/M2KO M MHC-class II KO 
generated in 
this thesis 
2 - 
B16F10 ATCC/M2KO/OVA-F M MHC-class II KO/OVA 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/M2KO/OVA-F/Luci M 
MHC-class II 
KO/OVA/Luciferase 
generated in 
this thesis 
2 
1 mg/ml G418,  
1 µg/ml Puromycin 
B16F10 ATCC/M2KO/OVA-T M MHC-class II KO/OVA 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/M2KO/OVA-T/Luci M 
MHC-class II 
KO/OVA/Luciferase 
generated in 
this thesis 
2 
1 mg/ml G418,  
1 µg/ml Puromycin 
B16F10 ATCC/OVA-F M OVA 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/OVA-F/Luci M OVA/Luciferase 
generated in 
this thesis 
2 
1 mg/ml G418,  
1 µg/ml Puromycin 
B16F10 ATCC/OVA-T M OVA 
generated in 
this thesis 
2 1 mg/ml G418 
B16F10 ATCC/OVA-T/Luci M OVA/Luciferase 
generated in 
this thesis 
2 
1 mg/ml G418,  
1 µg/ml Puromycin 
B16F10/M1KO M MHC-class I KO 
generated in 
this thesis 
2 - 
CD4
+
 T cell line (OVA323-339; IA
b
) T - 
generated in 
this thesis 
7 - 
Materials & Methods 
36 
 
CTL (OVA257-264; K
b
) T - 
Osen, 
Wolfram 
7 - 
E.G7 TL OVA unknown 2 0.8 mg/ml G418 
EL-4 TL - unknown 2 - 
EO771 BC - unknown 1 - 
EO771/Luci BC Luciferase 
generated in 
this thesis 
1 1 µg/ml Puromycin 
EO771/Luci/OVA-F BC Luciferase/OVA 
generated in 
this thesis 
1 
1 µg/ml Puromycin 
0.2 mg/ml G418 
EO771/Luci/OVA-T BC Luciferase/OVA 
generated in 
this thesis 
1 
1 µg/ml Puromycin 
0.2 mg/ml G418 
EO771/OVA-F BC OVA 
generated in 
this thesis 
1 0.2 mg/ml G418 
EO771/OVA-T BC OVA 
generated in 
this thesis 
1 0.2 mg/ml G418 
MC-38 CC - unknown 6 - 
MC-38/OVA-T CC OVA 
Offringa, 
Rienk 
6 25 µg/ml G418 
Panc02 PC - 
Offringa, 
Rienk 
2 - 
PDAC (30364) PC - 
Offringa, 
Rienk 
3 - 
PDAC/OVA-F (30364 Klon #7 
m14865) 
PC OVA 
Offringa, 
Rienk 
3 10 µg/ml Blasticidin 
      
All cell lines are of mouse origin. BL: B lymphoma; M: melanoma; T: T cell line; TL: T lymphoma; BC: breast cancer; 
CC: colon carcinoma; PC: pancreatic cancer 
2.1.4.2 Culture medium 
Table 2.16: Culture medium 
Index Name Medium Supplements 
1 
RPMI Complete 
Medium with HEPES 
RPMI 1640 Medium, 
GlutaMAX™ Supplement   
10 % FCS 
10 mM HEPES 
100 U/ml Penicillin 
100 µg/ml Streptomycin  
2 
RPMI Complete 
Medium 
RPMI 1640 Medium, 
GlutaMAX™ Supplement   
10 % FCS 
100 U/ml Penicillin 
100 µg/ml Streptomycin  
3 
DMEM Complete 
Medium with sodium 
pyruvate 
DMEM, high glucose, 
GlutaMAX™ Supplement 
10 % FCS 
1 mM sodium pyruvate 
100 U/ml Penicillin 
100 µg/ml Streptomycin  
4 
DMEM Complete 
Medium for PECs 
DMEM, high glucose, 
GlutaMAX™ Supplement 
10 % FCS 
100 U/ml Penicillin 
100 µg/ml Streptomycin  
5 
IMDM Complete 
Medium with 
Glutamine 
Iscove's Modified 
Dulbecco's Medium 
(IMDM) 
10 % FCS 
2 mM L-Glutamine   
100 U/ml Penicillin 
100 µg/ml Streptomycin  
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6 
IMDM Complete 
Medium with 2-
Mercaptoethanol 
Iscove's Modified 
Dulbecco's Medium 
(IMDM) 
10 % FCS 
50 µM 2-Mercaptoethanol 
100 U/ml Penicillin 
100 µg/ml Streptomycin  
7 
Complete T cell 
Medium 
Minimum Essential 
Medium Eagle 
10 % FCS 
2 mM L-Glutamine  
50 µM 2-Mercaptoethanol 
12.5 mM Methyl α-D-mannopyranoside  
12.5 ml ConA culture supernatant 
100 U/ml Penicillin 
100 µg/ml Streptomycin  
2.1.5 Plasmids 
All plasmids used in this thesis are listed in Table 2.17. Plasmids were stored in double-
distilled water (ddH2O) at -20 °C. 
Table 2.17: Plasmids 
Designation Insert Promotor Backbone Resistance Source 
pDEST26_pHIS_6_N_
OVAK1_Klon1 
OVA-F CMV pDEST26 Neomycin 
Rainer Will (German 
Cancer Research Center, 
Heidelberg, Germany) 
pDEST26_pHIS_6_N_
OVA Trunc_Klon1 
OVA-T CMV pDEST26 Neomycin 
Rainer Will (German 
Cancer Research Center, 
Heidelberg, Germany) 
2.1.6 Guide RNA sequences 
All nucleotide sequences used for the generation of target specific guide RNAs were 
purchased from Sigma-Aldrich (St. Louis, USA) and are shown in Table 2.18. On-target 
scores obtained from the CRISPR Design Tool (https://crisper.mit.edu/) are shown in the 
right column. 
Table 2.18: H2-IAb targeting guide RNA sequences 
exon 1 
guide #1 
sense 5'-CACCGACTCCGAAAGTAAGTGCCG-3' 
95 
antisense 5'-AAACCGGCACTTACTTTCGGAGTC-3' 
exon 1 
guide #4 
sense 5'-CACCGAGACTCCGAAAGTAAGTGC-3' 
80 
antisense 5'-AAACGCACTTACTTTCGGAGTCTC-3' 
exon 1 
guide #5 
sense 5'-CACCGAGCCATCTCTAAGGCAC-3' 
61 
antisense 5'-AAACGTGCCTTAGAGATGGCTC-3' 
exon 2 
guide #3 
sense 5'-CACCGAAATGCCCTGCGGACGGACG-3' 
94 
antisense 5'-AAACCGTCCGTCCGCAGGGCATTTC-3' 
exon 2 
guide #12 
sense 5'-CACCGCGAGTGCTACTTCACCAAC-3' 
87 
antisense 5'-AAACGTTGGTGAAGTAGCACTCGC-3' 
exon 1 up 
guide #1 
sense 5'-CACCGGCTCTCTATGCGCGGCA-3' 
96 
antisense 5'-AAACTGCCGCGCATAGAGAGCC-3' 
exon 1 up 
guide #2 
sense 5'-CACCGTTACAAAGGCTCTCTATGCG-3' 
88 
antisense 5'-AAACCGCATAGAGAGCCTTTGTAAC-3' 
exon 6 down sense 5'-CACCGCCCGCCCTTACATGGAGTTC-3' 82 
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guide #1 antisense 5'-AAACGAACTCCATGTAAGGGCGGGC-3' 
exon 6 down 
guide #2 
sense 5'-CACCGAACCTCCACAACTGAGC-3' 
81 
antisense 5'-AAACGCTCAGTTGTGGAGGTTC-3' 
2.1.7 siRNA pools 
siRNA pools purchased from siTools Biotech contain 30 siRNAs targeting the same gene of 
interest. Each siRNA is only present in picomolar working concentrations which dilutes the 
off-target effect of each individual siRNA, increases on-target specificity and ensures a co-
operative knock-down of the target gene. The lyophilized siRNA pools were resolved in 
nuclease free water to reach a stock concentration of 10 µM. The ON-TARGET plus siRNA 
pools obtained from Dharmacon contain 4 individual siRNAs with a dual-strand modification 
to reduce off-target effects. The lyophilized siRNA pool targeting MYC was resolved in 
nuclease free water to reach a stock concentration of 50 µM. 
Table 2.19: siRNA pools 
siPool target NCBI Gene ID Description Manufacturer 
Myc 17869 myelocytomatosis oncogene Dharmacon, Lafayette, USA 
E2f1 13555 E2F transcription factor 1 siTools Biotech, Planegg, Germany 
Ctcf 13018 CCCTC-binding factor siTools Biotech, Planegg, Germany 
Stat6 20852 
signal transducer and 
activator of transcription 6 
siTools Biotech, Planegg, Germany 
Pparg 19016 
peroxisome proliferator 
activated receptor gamma 
siTools Biotech, Planegg, Germany 
2.1.8 miRNA sequences 
The miRIDIAN miRNA Mimics were purchased from Dharmacon (Lafayette, USA) and 
resolved in nuclease free water to reach a stock concentration of 10 µM. 
Table 2.20: miRNA sequences 
miRNA Cat. No. Sequence 
mmu-let-7e-5p C-310507-07-0005 5'-UGAGGUAGGAGGUUGUAUAGUU-3' 
mmu-let-7i-5p C-310375-07-0005 5'-UGAGGUAGUAGUUUGUGCUGUU-3' 
mmu-miR-1198-5p C-311047-00-0005 5'-UAUGUGUUCCUGGCUGGCUUGG-3' 
mmu-miR-210-3p C-310570-05-0005 5'-CUGUGCGUGUGACAGCGGCUGA-3' 
mmu-miR-221-5p C-311234-00-0005 5'-ACCUGGCAUACAAUGUAGAUUUCUGU-3' 
mmu-miR-222-3p C-310584-07-0005 5'-AGCUACAUCUGGCUACUGGGU-3' 
mmu-miR-27b-3p C-310380-05-0005 5'-UUCACAGUGGCUAAGUUCUGC-3' 
mmu-miR-30e-3p C-310467-07-0005 5'-CUUUCAGUCGGAUGUUUACAGC-3' 
mmu-miR-674-5p C-310694-01-0005 5'-GCACUGAGAUGGGAGUGGUGUA-3' 
mmu-miR-744-5p C-310776-03-0005 5'-UGCGGGGCUAGGGCUAACAGCA-3' 
mmu-miR-99b-5p C-310387-05-0005 5'-CACCCGUAGAACCGACCUUGCG-3' 
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2.1.9 Primers 
All primers used within this thesis were obtained from Sigma-Aldrich (St. Louis, USA) and 
are listed in Table 2.21 and Table 2.22. The lyophilized primers were resolved in ddH2O to a 
stock concentration of 100 µM and stored at -20 °C. 
2.1.9.1 Primers for quantitative real-time polymerase chain reaction (qPCR) 
All primers used for qPCR were tested for their amplification efficiency using a standard 
curve that is based on four 10 fold dilutions of a cDNA sample. The efficiency was calculated 
using the slope of the standard curve and the following formula: 
Efficiency = (10(-1/slope)-1)*100 
Table 2.21: Primers for quantitative real-time PCR 
Target Primer Sequence (5'-3') 
Product 
size 
[bp] 
Efficiency Source 
Ym1 
Ym1_qPCR_FP1 CACCATGGCCAAGCTCATTCTTGT 
114 97.23 
Tatano et al. 
2014 [303] 
Ym1_qPCR_RP2 TATTGGCCTGTCCTTAGCCCAACT 
Fizz1 
Fizz1_qPCR_FP3 ACTGCCTGTGCTTACTCGTTGACT 
82 100.08 
Fizz1_qPCR_RP4 AAAGCTGGGTTCTCCACCTCTTCA 
Cd163 
CD163_fw35 TCCACACGTCCAGAACAGTC 
107 83.98 
CD163_rev36 CCTTGGAAACAGAGACAGGC 
Il6 
IL-6_qPCR_FP5 GTCTTCTGGAGTACCATAGC 
368 81.02 
Movahedi et 
al. 
2010 [181] 
IL-6_qPCR_RP6 GTCAGATACCTGACAACAGG 
Cxcl10 
CXCL10_qPCR_FP7 TCTGAGTCCTCGCTCAAGTG 
228 92.34 
CXCL10_qPCR_RP8 CCTTGGGAAGATGGTGGTTA 
Cxcl9 
CXCL9_qPCR_FP9 TCAACAAAAGAGCTGCCAAA 
263 85.72 
CXCL9_qPCR_RP10 GCAGAGGCCAGAAGAGAGAA 
Il12b 
IL12b_qPCR_FP11 GAAAGACCCTGACCATCACT 
314 81.3 
IL12b_qPCR_RP12 CCTTCTCTGCAGACAGAGAC 
Il1b 
IL1b_qPCR_FP13 GTGTGGATCCAAAGCAATAC 
282 80.19 
IL1b_qPCR_RP14 GTCTGCTCATTCATGACAAG 
Nos2 
NOS2_qPCR_FP15 GCTTCTGGTCGATGTCATGAG 
506 60.92 
NOS2_qPCR_RP16 TCCACCAGGAGATGTTGAAC 
Vegfa 
VEGFA_qPCR_FP17 CAGGCTGCTGTAACGATGAA 
187 97.23 
VEGFA_qPCR_RP18 AATGCTTTCTCCGCTCTGAA 
Arg1 
ARG1_qPCR_FP19 TCACCTGAGCTTTGATGTCG 
257 83.29 
ARG1_qPCR_RP20 TTATGGTTACCCTCCCGTTG 
Mrc1 
Mrc1_qPCR_FP21 GCAAATGGAGCCGTCTGTGC 
299 83.29 
Mrc1_qPCR_RP22 CTCGTGGATCTCCGTGACAC 
Mrc1 
CD206_qPCR_FP23 TTGGACGGATAGATGGAGGG 
182 96.84 
Zhu et al. 
2014 [304] 
CD206_qPCR_RP24 CCAGGCAGTTGAGGAGGTTC 
Hprt 
HPRT_qPCR_FP25 AGTACAGCCCCAAAATGGTTAAG 
203 95.29 
HPRT_qPCR_RP26 CTTAGGCTTTGTATTTGGCTTTTC 
Actb 
bACTIN_qPCR_FP27 TGGAATCCTGTGGCATCCATGAAAC 
348 79.39 
Davis et al. 
2013 [305] bACTIN_qPCR_RP28 TAAAACGCAGCTCAGTAACAGTCCG 
Itgax 
CD11c_fw29 CTGGATAGCCTTTCTTCTGCTG 
113 94.91 
Shaul et al. 
2010 [306] CD11c_rev30 GCACACTGTGTCCGAACTC 
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Il10 
IL10_fw31 GCTCTTACTGACTGGCATGAG 
105 111.66 
Shaul et al. 
2010 [306] 
IL10_rev32 CGCAGCTCTAGGAGCATGTG 
Il13 
IL13_fw33 CCAGGTCCACACTCCATACC 
117 
not 
tested IL13_rev34 TGCCAAGATCTGTGTCTCTCC 
Stat6 
STAT6_fw37 CTGGGGTGGTTTCCTCTTG 
94 112.03 
STAT6_rev38 TGCCCGGTCTCACCTAACTA 
Il1b 
IL1β_fw39 CTGGTGTGTGACGTTCCCATTA 
76 90.25 
IL1β_rev40 CCGACAGCACGAGGCTTT 
Stat1 
STAT1_fw41 CTGAATATTTCCCTCCTGGG 
103 96.06 
STAT1_rev42 TCCCGTACAGATGTCCATGAT 
Vegfa 
VEGF_fw43 CCTTCGTCCTCTCCTTACCC 
117 94.17 
VEGF_rev44 AAGCCACTCACACACACAGC 
Cd86 
CD86_fw45 TCTCCACGGAAACAGCATCT 
100 95.29 
CD86_rev46 CTTACGGAAGCACCCATGAT 
Cd80 
CD80_fw47 GGCAAGGCAGCAATACCTTA 
94 104.43 
CD80_rev48 CTCTTTGTGCTGCTGATTCG 
Tgfb1 
TGFβ1_fw49 AAGTTGGCATGGTAGCCCTT 
128 93.8 
TGFβ1_rev50 GCCCTGGATACCAACTATTGC 
Nos2 
iNOS_fw51 CAGAGGACCCAGAGACAAGC 
300 80.47 
designed by 
David Eisel 
iNOS_rev52 TGCTGAAACATTTCCTGTGC 
Arg2 
ARG_fw53 AGGAACTGGCTGAAGTGGTTA 
215 100.9 
ARG_rev54 GATGAGAAAGGAAAGTGGCTGT 
Cxcl9 
CXCL9_fw55 CGAGGCACGATCCACTACAA 
265 80.47 
CXCL9_rev56 TCTTCCTTGAACGACGACGAC 
Il12b 
IL12b_fw57 AGTGACATGTGGAATGGCGT 
285 105.35 
IL12b_rev58 CAGGAGTCAGGGTACTCCCA 
Il1b 
IL1b_fw59 GGACAGAATATCAACCAACAAGACT 
190 134.6 
IL1b_rev60 TTGCTTGGGATCCACACTCTC 
Actb 
bactin_fw61 ACCCTAAGGCCAACCGTGA 
193 91.28 
bactin_rev62 ATGGCGTGAGGGAGAGCATA 
Rpl19 
Rpl19_fw69 TACCGGGAATCCAAGAAGATTGA 
89 98.13 
PrimerBank 
ID  
226958656c3 Rpl19_rev70 AGGATGCGCTTGTTTTTGAAC 
Ldha 
Ldha_fw71 TGTCTCCAGCAAAGACTACTGT 
155 98.11 
PrimerBank 
ID  
6754524a1 Ldha_rev72 GACTGTACTTGACAATGTTGGGA 
Ppat 
Ppat_fw75 TTCAGGGTGCATAAGGGAATGG 
104 98.73 
PrimerBank 
ID  
247301190c1 Ppat_rev76 GCGTACCTCGTATGTCCGA 
Ppia 
Ppia_fw79 GAGCTGTTTGCAGACAAAGTTC 
125 95.62 
PrimerBank 
ID  
6679438c1 Ppia_rev80 CCCTGGCACATGAATCCTGG 
Nos2 
Nos2_fw81 GTTCTCAGCCCAACAATACAAGA 
127 90.33 
PrimerBank 
ID  
6754872a1 Nos2_rev82 GTGGACGGGTCGATGTCAC 
Cxcl9 
CXCL9_fw83 GGAGTTCGAGGAACCCTAGTG 
82 99.68 
PrimerBank 
ID  
162287427c1 CXCL9_rev84 GGGATTTGTAGTGGATCGTGC 
Myc 
Myc_fw89 ATGCCCCTCAACGTGAACTTC 
78 100.47 
PrimerBank 
ID  
293629266c1 Myc_rev90 GTCGCAGATGAAATAGGGCTG 
Pparg 
Pparg_fw99 TTTTCCGAAGAACCATCCGATT 
139 91.86 
PrimerBank  
187960104c3 Pparg_rev100 ATGGCATTGTGAGACATCCCC 
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Stat6 
Stat6_fw103 TGGAGAGCATCTATCAGAGGGA 
95 95.3 
PrimerBank 
ID  
128485773c3 Stat6_rev104 GCGGAACTCTTCTATAACAGCTT 
Ctcf 
Ctcf_fw125 GATCCTACCCTTCTCCAGATGAA 
175 91.41 
PrimerBank 
ID  
31044459a1 Ctcf_rev126 GTACCGTCACAGGAACAGGT 
E2f1 
E2f1_fw127 TGCAGAAACGGCGCATCTAT 
122 95.45 
PrimerBank 
ID  
158517881c2 E2f1_rev128 CCGCTTACCAATCCCCACC 
   
  
 
  M1-like 
 
  
 
  M2-like 
 
  
 
  TF 
 
  
 
  Housekeeping gene 
 
  
 
2.1.9.2 Primers for PCR 
Table 2.22: Primers for PCR 
Target Primer Sequence (5'-3') 
Length 
[bp] 
Product 
size [bp] 
OVA-F 
forward CGCAGCAAGCATGGAATTTTG 21 
229 bp 
reverse GTGAACGTTTACAGATGTGCCA 22 
OVA-F and OVA-T 
forward TCAAAGTGTACTTACCTCGCATGA 24 
323 bp 
reverse AGGGGAAACACATCTGCCAA 20 
Actb 
forward ACCCTAAGGCCAACCGTGA 19 
193 bp 
reverse ATGGCGTGAGGGAGAGCATA 20 
H2-Ab1 
forward TTTGCTTTCTGAAGGGGGCA 20 
309 bp 
reverse AGAATGGAGTCTCACTCTCTCTT 23 
2.1.10 Antibodies 
All antibodies used in this study are listed in Table 2.23, Table 2.24 and Table 2.25. If not 
stated otherwise, the listed antibodies react against mouse antigens and were stored 
according to manufacturer’s recommendations. 
2.1.10.1 Antibodies used for flow cytometry 
Table 2.23: Flow cytometry antibodies 
Index Antigen Coupled Cat. No. Manufacturer Clone 
Isotype 
Index 
101 CD11b PerCP-Cy 5.5 101228 BioLegend M1/70 100 
109 CD11c V450 560521 Becton Dickinson  HL3 108 
125 CD19 PE 115508 BioLegend 6D5 126 
175 CD2 APC 100111 BioLegend RM2-5 - 
112 CD206 Brilliant Violet 605 141721 BioLegend C068C2 111 
201 CD206 PE-Cy7 141719 BioLegend C068C2 87 
165 CD25 PE 102008 BioLegend PC61 167 
44 CD3 PerCP-Cy 5.5 100217 BioLegend 17A2 100 
110 CD4 V450 560468 Becton Dickinson  RM4-5 148 
117 CD44 Brilliant Violet 421 103039 BioLegend IM7 164 
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53 CD45 PE 553081 Becton Dickinson  30-F11 158 
154 CD45.1 APC 110714 BioLegend A20 155 
99 CD45.2 Alexa Fluor 488 109816 BioLegend 104 98 
116 CD49b Alexa Fluor 647 108912 BioLegend  DX5  - 
174 CD49d PE 103705 BioLegend 9C10 (MFR4.B) 126 
166 CD69 PerCP-Cy 5.5 104522 BioLegend H1.2F3 168 
89 CD8 PE-Cy7 100722 BioLegend 53-6.7 87 
145 Egr2 APC 17-6691-80 ebioscience erongr2 146 
97 F4/80 APC-Cy7 123118 BioLegend BM8 119 
107 F4/80 Alexa Fluor 647 123122 BioLegend BM8 106 
156 F4/80 PE-Cy7 123114 BioLegend BM8 87 
159 F4/80 Brilliant Violet 421 123137 BioLegend BM8 160 
94 Gr-1 Alexa Fluor 700 108422 BioLegend RB6-8C5 93 
202 Gr-1 Alexa Fluor 488 108417 BioLegend RB8-8C5 203 
144 H2-Db PerCP-Cy 5.5 111517 BioLegend KH95 150 
143 H2-Kb FITC 116505 BioLegend AF6-88.5 151 
152 
H-2Kb 
SIINFEKL 
PE-Cy7 141607 BioLegend 25-D1.16 153 
10 I-A[b] PE 553552 Becton Dickinson  AF6-120.1 122 
104 I-A[b] Alexa Fluor 647 116412 BioLegend AF6-120.1 103 
176 LFA-1 PerCP-Cy 5.5 141007 BioLegend H155-78 177 
88 NOS2 PE-Cy7 25-5920-82 eBioscience CXNFT 87 
42 TCR Vα2 FITC 127805 BioLegend B20.1 - 
43 TCR Vβ5.1 APC 139505 BioLegend MR9-4 198 
            
 
Index Antigen Coupled Cat. No. Company Clone 
 
87 Isotype Ctrl. PE-Cy7 400522 BioLegend RTK2758 
 
93 Isotype Ctrl. Alexa Fluor 700 400628 BioLegend RTK4530 
 
98 Isotype Ctrl. Alexa Fluor 488 400233 BioLegend  MOPC-173  
 
100 Isotype Ctrl. PerCP-Cy 5.5 400632 BioLegend RTK4530 
 
103 Isotype Ctrl. Alexa Fluor 647 400234 BioLegend  MOPC-173  
 
106 Isotype Ctrl. Alexa Fluor 647 400526 BioLegend  RTK2758  
 
108 Isotype Ctrl. V450 560552 Becton Dickinson  G235-2356   
 
100 Isotype Ctrl. PerCP-Cy 5.5 400632 BioLegend RTK4530 
 
111 Isotype Ctrl. Brilliant Violet 605 400539 BioLegend  RTK2758  
 
119 Isotype Ctrl. APC-Cy7 400523 BioLegend RTK2758 
 
122 Isotype Ctrl. PE 553457 Becton Dickinson  G155-178 
 
126 Isotype Ctrl. PE 400507 BioLegend RTK2758 
 
146 Isotype Ctrl. APC 17-4321-41 ebioscience eBR2a 
 
148 Isotype Ctrl. V450 560377 Becton Dickinson  R35-95 
 
150 Isotype Ctrl. PerCP-Cy 5.5 400337 BioLegend MPC-11 
 
151 Isotype Ctrl. FITC 400209 BioLegend MOPC-173 
 
153 Isotype Ctrl. PE-Cy7 400125 BioLegend MOPC-21 
 
155 Isotype Ctrl. APC 400219 BioLegend MOPC-173 
 
158 Isotype Ctrl. PE 553989 Becton Dickinson  A95-1 
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160 Isotype Ctrl. Brilliant Violet 421 400535 BioLegend RTK2758 
 
164 Isotype Ctrl. Brilliant Violet 421 400639 BioLegend RTK4530 
 
167 Isotype Ctrl. PE 401905 BioLegend G0114F7 
 
168 Isotype Ctrl. PerCP-Cy 5.5 400931 BioLegend HTK888 
 
177 Isotype Ctrl. PerCP-Cy 5.5 400425 BioLegend RTK2071 
 
198 Isotype Ctrl APC 17-4714-81 ebioscience P3.6.2.8.1  
203 Isotype Ctrl. Alexa Fluor 488 400625 BioLegend RTK4530 
 
2.1.10.2 Antibodies used for Western blot 
Table 2.24: Western blot antibodies 
Antigen Reactivity Coupled Dilution 
Cat. 
No. 
Manufacturer Clone Isotype Organism 
Actin mouse - 10000 691001 
MP 
Biomedicals 
C4 IgG1 mouse 
IgG mouse HRP 5000 
sc-
2005 
Santa Cruz 
Biotechnology 
polyclonal ns goat 
Ovalbumin chicken - 1000 
sc-
65984 
Santa Cruz 
Biotechnology 
3G2E1D9 IgG1 mouse 
ns: not specified 
       
2.1.10.3 Antibodies used for ELISpot assay 
Table 2.25: ELISpot antibodies 
Antigen Coupled Dilution Cat. No. Manufacturer Clone Isotype Organism 
IFN-γ - 200 551216 
Becton 
Dickinson  
R4-6A2 IgG1, κ Rat 
IFN-γ Biotin 500 554410 
Becton 
Dickinson  
XMG1.2 IgG1, κ Rat 
2.1.11 Peptides 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself. Peptides were synthesized by Fmoc chemistry using the fully automated 
multiple synthesizer Syro II, followed by HPLC purification on a Kromasil 100–10C 10 μm 
120 A reverse phase column (20 x 150 mm). Eluted peptides were analyzed by HPLC and 
MS using the Thermo Finnigan LCQ Deca XP LCMS System. The lyophilized peptides were 
dissolved in DMSO to a stock concentration of 20 mg/ml and subsequently diluted in culture 
medium to the desired working concentration. 
Table 2.26: Peptides 
Sequence Position Length 
MHC 
Restriction 
Protein 
AAHAEINEA 329-337 9 H2-IA
b
 Ovalbumin 
ISQAVHAAHAEINEAGR 323-339 17 H2-IA
b
 Ovalbumin 
SIINFEKL 257-264 8 H2-K
b
 Ovalbumin 
SVYDFFVWL 180-188 9 H2-K
b
 Tyrosinase-related protein 2 
TPPAYRPPNAPIL 128-140 13 H2-IA
b
 HBV core antigen 
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2.1.12 Kits 
Commercially available kits used within this study are listed in Table 2.27. All kits were used 
according to the manufacturer’s protocols, unless otherwise stated. 
Table 2.27: Kits 
Kit Cat. No. Manufacturer 
Anti-Mouse/Rat Foxp3 Staining Set APC 77-5775-40 eBioscience, Waltham, USA 
CD4 (L3T4) MicroBeads, mouse 130-049-201 
Miltenyi Biotec , Bergisch Gladbach, 
Germany 
CD4+ T Cell Isolation Kit, mouse 130-104-454 
Miltenyi Biotec , Bergisch Gladbach, 
Germany 
CD8a (Ly-2) MicroBeads, mouse 130-049-401 
Miltenyi Biotec , Bergisch Gladbach, 
Germany 
ELISA Kit for Ovalbumin (OVA) MBS2000240 MyBioSource, San Diego, USA 
iScript cDNA Synthesis Kit 1708890 Bio-Rad Laboratories, Hercules, USA 
Luciferase Assay System E1500 Promega, Madison, USA 
miRNeasy Mini Kit 217004 Qiagen, Venlo, Netherlands 
Mouse IFN gamma ELISA Ready-SET-
Go! 
88-7314-88 eBioscience, Waltham, USA 
Mouse IFN-γ Secretion Assay – 
Detection Kit (PE) 
130-090-516 
Miltenyi Biotec , Bergisch Gladbach, 
Germany 
Pierce™ BCA Protein Assay Kit 23225 Thermo Fisher Scientific, Waltham, USA 
QIAamp DNA Blood Mini Kit 51104 Qiagen, Venlo, Netherlands 
QIAprep Spin Miniprep Kit 27104 Qiagen, Venlo, Netherlands 
QIAquick Gel Extraction Kit 28704 Qiagen, Venlo, Netherlands 
QIAquick PCR Purification Kit 28106 Qiagen, Venlo, Netherlands 
RNase-Free DNase Set 79254 Qiagen, Venlo, Netherlands 
RNeasy Plus Mini Kit 74134 Qiagen, Venlo, Netherlands 
TaqMan™ MicroRNA Reverse 
Transcription Kit 
4366596 Thermo Fisher Scientific, Waltham, USA 
TaqMan™ Universal PCR Master Mix 4304437 Thermo Fisher Scientific, Waltham, USA 
TOPO® TA Cloning® Kit for Sequencing 450030 Thermo Fisher Scientific, Waltham, USA 
Transcriptor First Strand cDNA 
Synthesis Kit 
04379012001 Hoffmann-La Roche, Basel, Switzerland 
2.1.13 Software 
Table 2.28: Software 
Software Provider 
ApE - A plasmid Editor v2.0.47 M. Wayne David 
EndNote X7.0.1 Thomson Reuters, Toronto, Canada 
FlowJo V10 Becton Dickinson , Franklin Lakes, USA 
GraphPad Prism 5 GraphPad Software, Inc., San Diego, USA 
Living Image Software 4.4  PerkinElmer, Waltham, USA 
Microsoft Office 2010 Microsoft, Redmont, USA 
RTCA Software 2.0 ACEA Biosciences, San Diego, USA 
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2.2 Methods 
2.2.1 Cell culture 
Working with cell lines or primary cells was performed under sterile conditions in a tissue 
culture hood. Cells were maintained by incubation at 37 °C in a CO2 incubator (5 % CO2). A 
commercially available hemocytometer was used for cell number adjustments. Reagents 
used for cell culture work are listed in Table 2.3. All cell lines used or generated within this 
thesis and their corresponding culture medium are listed in Table 2.15 and Table 2.16, 
respectively. 
2.2.2 Generation of single guide RNA encoding plasmids 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself. Single guide (sg)RNAs targeting exon 1 of the murine IAb beta chain gene 
were designed by Ashish Goyal (German Cancer Research Center, Heidelberg, Germany) 
using the online sgRNA design tool available at https://crispr.mit.edu/. In order to maximize 
specificity, guide sequences with high scores for on-target activity and at least 3 base pair 
mismatches to any predicted off-targets in the genome were selected. The corresponding 
sense and antisense DNA oligomers are shown in Table 2.18. Annealed oligomers were 
cloned downstream of the U6 promoter of PX458 (Addgene, Plasmid 48138, Middlesex, UK) 
as described earlier [308]. A plasmid map of PX458 is depicted in supplementary Figure 6.1 
[307]. 
2.2.3 Transfection of B16F10 cells with single guide RNA encoding plasmids 
B16F10 cells were transfected using the Effectene Transfection Reagent Kit (Table 2.4). The 
transfection protocol was optimized to achieve the highest possible transfection efficiency. 
Briefly, 2 x 105 B16F10 cells were seeded in a 6-Well plate in a total volume of 2.5 ml culture 
medium and incubated overnight at 37 °C and 5 % CO2. The following day, 0.8 µg DNA were 
diluted in DNA-condensation buffer (Buffer EC) to reach a total volume of 100 µl. In case of 
double transfection with two guide RNA constructs, 0.5 µg of each plasmid was used. After 
adding 6.5 µl Enhancer the solution was vortexed for 1 second and incubated at room 
temperature (RT) for 4 minutes. Subsequently, 8 µl of Effectene Transfection Reagent were 
added to the DNA-Enhancer mixture and the solution was mixed by pipetting up and down 
5 times. The mixture was incubated at RT for 10 min to allow transfection-complex 
formation. While complex formation took place, the culture medium of B16F10 cells was 
aspirated and the adherent cells were washed once with PBS. Fresh culture medium 
(1600 µl per well) containing serum and antibiotics was added. After adding 600 µl of culture 
medium to the transfection-complex tube, the solution was mixed by pipetting up and down 
twice and immediately dispensed in the 6-Well plates dropwise (714.4 µl/well). The cells 
were incubated at 37 °C and 5 % CO2 and analyzed 24, 48 or 72 h post transfection without 
changing the transfection-complex containing culture medium. 
2.2.4 IFNγ treatment of tumor cells 
Tumor cells were seeded at a density of 2 x 105 cells per well in a 6-Well plate in 2 ml of 
culture medium. After overnight incubation at 37 °C and 5 % CO2, Mouse IFNү (Table 2.14) 
Materials & Methods 
46 
 
was added to the culture medium at a final concentration of 20 U/ml. The cells were 
incubated for 24, 48 or 72 h and subsequently analyzed by flow cytometry as described in 
detail in the corresponding figure legends. 
2.2.5 Genomic DNA isolation and PCR 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself. Genomic DNA of various cell lines, including the generated IAb knockout 
(KO) B16F10 cells, was isolated using the QIAamp DNA Blood Mini Kit according to 
manufacturer’s instructions. The sequences of interest were amplified by PCR using 0.5 µM 
of forward and reverse primer (Table 2.22), 0.2 mM dNTP-Mix Long Range, 2.5 mM MgCl2, 
1.25 U Taq DNA Polymerase, and 160 ng genomic DNA resolved in Taq Buffer (compare 
Table 2.29). The desired genomic loci were amplified with the Veriti 96-Well Thermal Cycler 
using the cycler protocol shown below (Table 2.30). All reagents required to perform PCRs 
are listed in Table 2.9. 
Table 2.29: Pipetting scheme for PCR 
Component Volume per reaction 
Forward primer (10 μM) 2.5 µl 
Reverse primer (10 μM) 2.5 µl 
Taq Buffer with (NH4)2SO4 (10X) 5 µl 
dNTP-Mix Long Range (10 mM) 1 µl 
MgCl2 (25 mM) 5 µl 
Taq DNA Polymerase (5 U/µl) 0.25 µl 
DNA template (160 ng) x µl 
Nuclease free water 50 - (16.25 + x) µl 
Total volume 50 µl 
Table 2.30: Cycler protocol for PCR 
Step Temp. Time 
Initial 95 °C 1 min 
Amplification (40 cycles) 
95 °C 30 s 
60 °C 30 s 
72 °C 1 min 
Final 72 °C 5 min 
2.2.6 TOPO TA cloning 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself. The CRISPR/Cas9 (clustered regularly interspaced short palindromic 
repeats/CRISPR-associated 9) induced mutations in the generated IAb knockout clones 
were analyzed on genomic DNA level. Therefore, genomic DNA was isolated and the 
sequences of interest containing the predicted cutting sites of the Cas9 nuclease were 
amplified by PCR using IAb specific primers (Table 2.22) as described in section 2.2.5. The 
PCR products were purified using the QIAquick PCR Purification Kit according to 
manufacturer’s instructions. Subsequently, the purified PCR products were cloned into the 
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TOPO vector using the TOPO® TA Cloning® Kit for Sequencing. In order to set up the 
TOPO cloning reaction, 2.5 µl of purified PCR product were mixed with 1 µl of the supplied 
salt solution and filled up with water to a total volume of 5 µl. After the addition of 1 µl TOPO 
vector, the reaction was gently mixed, incubated for 10 min at RT and either used 
immediately for subsequent transformation (section 2.2.7) or stored at -20 °C. 
2.2.7 Transformation, plasmid isolation and sequencing 
LB Medium (pH 7.5): 1 % Tryptone 
 
0.5 % Yeast extract 
 
170 mM NaCl 
  LB-Amp Medium: LB Medium 
 
50 µg/ml Ampicilin 
  LB-Amp Plates: LB-Amp Medium 
 
1.5 % Agar 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself. In order to amplify the TOPO vectors with the integrated PCR products 
(refer to section 2.2.6), 2 µl of the plasmids were added to one vial of One Shot competent 
TOP10 bacteria (Table 2.12). After incubating the vial for 10 min on ice, the cells were heat-
shocked for 30 seconds at 42 °C without shaking. The cells were immediately transferred to 
ice and 250 µl of room temperature S.O.C medium were added. Next, the vial was shaken 
horizontally at 37 °C and 200 revolutions per minute (rpm) for 1 h. The bacteria were 
subsequently dispensed (10, 30 or 50 µl) on pre-warmed LB-Amp Plates and incubated 
overnight. To verify that the PCR product was successfully integrated into the TOPO vector 
of growing colonies, several clones were picked to perform a colony PCR. For this, the 
picked colonies were transferred into 10 µl ddH2O and incubated at 95 °C for 10 minutes. 
The lysate (4 µl per reaction) was used as DNA template for amplifying the insert by PCR 
(protocol as described in section 2.2.5) using IAb specific primers (Table 2.22) or M13 
primers which are part of the TOPO® TA Cloning® Kit for Sequencing. After verifying that all 
picked colonies carried the insert, several additional clones were picked and expanded for 
24 h in LB-Amp Medium at 37 °C and 200 rpm. Plasmids were isolated using the QIAprep 
Spin Miniprep Kit according to manufacturer’s instructions and sent to GATC Biotech 
(Konstanz, Germany) for sequencing. The sequences were analyzed using the ApE-A 
plasmid Editor Version 2.0.47. All reagents used for transformation of bacteria are listed in 
Table 2.13. 
2.2.8 Titration of Geneticin and Puromycin on tumor cells 
EO771 or B16F10 cells were seeded into a 12-Well plate (105 cells per well) and incubated 
overnight at 37 °C and 5 % CO2. On the following day, the culture medium was replaced by 
medium supplemented with different concentrations of the corresponding selection antibiotic 
(Table 2.8). Puromycin concentrations ranged from 0.5 µg/ml to 5 µg/ml with increments of 
0.25 µg/ml. Geneticin concentrations ranged from 3 mg/ml to 0.4 mg/ml with 0.2 mg/ml 
increments. Cell viability was assessed every day using an optical microscope. The minimal 
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concentration of each antibiotic that was lethal to 100 % of the cells was used for selection 
and subsequent culturing of transduced clones.  
2.2.9 Generation of stable transduced clones 
The transduction of tumor cell lines using retroviral particles was done by the Genomics and 
Proteomics Core Facility of the German Cancer Research Center in Heidelberg, Germany. 
The wild type OVA encoding sequence (RefSeq NM_205152.2.) as well as a truncated 
sequence of OVA lacking the first 150 base pairs flanked by attL recombination sites were 
synthesized and cloned into a pMX plasmid (Thermo Fisher Scientific, Waltham, USA). The 
sequences were shuttled in lentiviral expression vectors adding a C-terminal IRES sequence 
coupled to a neomycin resistance gene by gateway recombination. For generation of 
lentiviral particles, HEK293FT cells (Thermo Fisher Scientific, Waltham, USA; Cat. No. 
R70007) were co-transduced with the lentiviral OVA expression constructs and 2nd 
generation viral packaging plasmids VSV.G (Addgene #14888) and psPAX2 (Addgene 
#12260). Transduction of B16F10, B16F10 IAb knockout and EO771 cells with luciferase 
was performed using a retroviral construct expressing red Firefly luciferase and a puromycin 
selection marker under control of a SV40 promoter. Retroviral particles were produced by 
co-transduction of HEK293FT cells with pBabe-Puro red Firely luciferase expression vector 
and the packaging plasmids pHIT60 and pMD2G (Addgene #12259). Two days after 
transduction, the virus containing supernatants were collected and cleared by centrifugation 
at 500 g (gravitational force) for 5 minutes. After the supernatants were passed through a 
0.45 μm filter to remove remaining cellular debris, B16F10, B16F10 IAb knockout and EO771 
cells were transduced with viral particles at 70 % confluency in the presence of 10 μg/ml 
polybrene (Merck KGaA, Darmstadt, Germany; Cat. No. TR-1003-G). The virus containing 
medium was replaced by the corresponding selection medium one day post transduction. 
After two weeks, clones were picked and expanded. 
2.2.10 Lactacystin treatment 
In order to block the proteasome, transduced cell clones and their respective parental cell 
lines were seeded in a 6 well plate (105 cells per well) one day prior lactacystin treatment 
(Table 2.3). The cells were incubated in the presence of 10 µM or 25 µM lactacystin for 6 or 
13 h. Finally, the culture supernatants were collected and whole cell protein samples were 
prepared (see section 2.2.25) for subsequent Western blot analysis. 
2.2.11 Magnetic activated cell sorting (MACS) for positive and negative 
selection 
MACS buffer (pH 7.2): PBS 
 
0.5 % BSA 
 
2 mM EDTA 
OVA specific CD4+ T cells were isolated from either OT-II splenocytes or restimulated T cell 
cultures using either CD4 (L3T4) MicroBeads (positive selection) or the CD4+ T Cell Isolation 
Kit (negative selection) according to manufacturer’s instructions. If purification of CD8+ T 
cells was required, CD8a (Ly-2) MicroBeads were used according to manufacturer’s 
instructions. 
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2.2.12 Generation of OVA specific CD4+ T cell lines 
In order to generate an OVA specific CD4+ T cell line that can be kept in culture through 
recurring restimulations, three different strategies were implemented as described in the 
following sections. 
2.2.12.1 Peptide immunization of C57BL/6 mice 
C57BL/6 mice were immunized subcutaneously (s.c.) with 100 µg of IAb restricted OVA 
peptide ISQAVHAAHAEINEAGR (aa 323–339; compare Table 2.26) diluted in complete 
Freund’s Adjuvant (Sigma-Aldrich, St. Louis, USA). After 7 or 13 days, mice were sacrificed 
and 6 x 106 splenocytes were cultured in Minimum Essential Medium Eagle Alpha 
Modification supplemented with 2 µg/ml peptide, 2 mM L-Glutamine, 10 % FCS, 50 µM beta-
Mercaptoethanol, 100 U/ml Penicillin and 100 µg/ml Streptomycin. Every 7 days, half of the 
supernatant was exchanged with the above mentioned supplemented medium, additionally 
containing 12.5 mM Methyl α-D-mannopyranoside and 2.5 % (v/v) culture supernatant from 
ConA stimulated rat-spleen cells, as a source of interleukin-2 (Complete T cell Medium). 
Spleen cell cultures were restimulated every 4 weeks by the addition of 6 x 106 irradiated 
(33 Gray (Gy)) syngeneic feeder cells together with antigenic peptide (2 μg/ml). All reagents 
needed for culturing OVA specific CD4+ T cells are listed in Table 2.3. 
2.2.12.2 OT-II CD4+ T cell expansion using peptide 
In the homozygous T cell receptor transgenic OT-II mice, all T cells express the mouse 
alpha- and beta-chain T cell receptor specifically recognizing the IAb restricted OVA peptide 
(aa 323-339). Therefore, an OVA specific CD4+ T cell line can be generated without the 
need to perform in vivo immunizations. The strategy described in this section included the 
isolation of splenocytes from naïve OT-II mice which were cultured in 24-Well plates in 2 ml 
Complete T cell Medium containing 2 µg/ml IAb restricted OVA peptide (aa 323-339). Spleen 
cell cultures were restimulated every 4 weeks by the addition of 6 x 106 irradiated (33 Gy) 
syngeneic feeder cells together with antigenic peptide (2 μg/ml). 
2.2.12.3 OT-II CD4+ T cell expansion using CD3/CD28 Dynabeads 
As all CD4+ T cells in OT-II mice bear the same T cell receptor, it is possible to expand those 
cells using CD3/CD28 Dynabeads without the risk of unwanted T cell clones expanding. To 
avoid co-expansion of CD8+ T cells, the isolated OT-II splenocytes were negatively selected 
using the CD4+ T Cell Isolation Kit (compare section 2.2.11), adjusted to the desired cell 
concentration in Complete T cell Medium and dispensed in 24-Well plates (1 x 106 cells in 
2 ml). Next, 25 µl of CD3/CD28 Dynabeads were added to each well. Three days later, the 
proliferated T cells were harvested, counted and 8 x 105 T cells per well were seeded in a 
fresh 24-Well plate (without the addition of fresh Dynabeads). After additional 5 days of 
culturing, 1 ml of old medium was aspirated and replaced by 6 x 106 irradiated (33 Gy) 
syngeneic feeder cells together with IAb restricted OVA peptide (2 μg/ml). The T cell culture 
was restimulated every 4 weeks using the aforementioned amounts of irradiated syngeneic 
feeder cells and antigenic peptide. 
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2.2.13 In vitro propagation of ovalbumin specific CD8+ T cells 
OVA specific CTLs (CTL (OVA257-264; K
b)) were cultured in 24-Well plates using 2 ml 
Complete T cell Medium. Every 7 days, half of the supernatant was aspirated and replaced 
by 5 x 106 irradiated (33 Gy) syngeneic feeder cells together with 2 x 105 irradiated (200 Gy) 
stimulator cells (E.G7). All reagents needed for culturing OVA specific CD8+ T cells are listed 
in Table 2.3. 
2.2.14 Isolation, purification and polarization of peritoneal exudate cells (PECs) 
C57BL/6 mice were injected intraperitoneally (i.p.) with 1 ml of 3 % (w/v) Thioglycolate 
medium (Applichem, Darmstadt, Germany; Cat. No. A3869) using a 27 G needle. Four days 
later, mice were sacrificed by gradual CO2 exposition and 8 ml of ice cold PBS were injected 
into the peritoneal cavity using a 21 G needle. PECs containing fluid was aspirated and 
centrifuged at 300 g for 10 minutes. PECs were resuspended in DMEM containing 
10 % FCS and 2 x 106 or 0.5 x 106 cells were seeded to each well of a 6 well or 24 well 
plate. After two hours (h), the medium was removed and adherent cells were washed three 
times with PBS. To induce M2 or M1 polarization, cells were cultured in DMEM 
supplemented with either 10 ng/ml IL-4 or a combination of 100 ng/ml LPS and 50 ng/ml 
IFNγ, respectively for 4, 24, 48 or 72 h. For subsequent analysis, cells were detached with 
500 µl Accutase at 37 °C for 5 minutes and harvested using a cell scraper. The reagents and 
cytokines used for PECs isolation and polarization are listed in Table 2.3 and Table 2.14, 
respectively. 
2.2.15 Peptide loading of PECs 
Adherent, polarized PECs were incubated at 37 °C for 45 min in X-VIVO™ 20 serum free 
medium containing 1 µg/ml IAb restricted OVA specific peptide (aa 323–339) or HBV core 
antigen derived peptide (aa 128–140; compare Table 2.26) as control. Cells were washed 3–
5 times with PBS to remove unbound peptides. Tumor cell lines (B16F10 derived or 771 B 
cell lymphoma) were harvested, adjusted to a cell concentration of 2 x 106 cells/ml in X-
VIVO™ 20 serum free medium containing the relevant peptides as mentioned above. After 
45 minutes of incubation at 37 °C, the cells were washed 3-5 times with PBS, resuspended 
in culture medium and used for co-culture experiments. 
2.2.16 Co-culture of PECs and OVA specific CD4+ T cells 
M2 polarized PECs (24 h) were loaded with peptide (5 µg/ml) and co-cultured with OVA 
specific CD4+ T cells for 24 h (ratio 4:1). Supernatants were collected to measure IFNγ 
concentrations and macrophages were washed 3 times to remove the non-adherent T cells. 
The cells were subsequently detached as described above (section 2.2.14) and analyzed by 
flow cytometry or lyzed for the preparation of cell lysates (as described in sections 2.2.21 
and 2.2.27). 
2.2.17 Phagocytosis and pinocytosis assay 
PECs were seeded in a 24-Well plates (5 x 105) and polarized for 72 h as described in 
section 2.2.14. In case of co-culture experiments, PECs were polarized for 24 h into M2-like 
macrophages, loaded with peptide (section 2.2.15) and subsequently cultured for additional 
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24 h with OVA specific CD4+ T cells (section 2.2.16). After washing three times with PBS, 
the cells were maintained in DMEM containing 10 % FCS and either 1 mg/ml FITC-dextran 
(pinocytosis) or 1.25 x 106/ml FluoSpheres™ Carboxylate-Modified Microspheres (2.0 µm; 
phagocytosis) [309, 310]. Thereafter, PECs were detached, harvested, stained with 
LIVE/DEAD® Fixable Yellow dye and analyzed by flow cytometry (section 2.2.27). 
Background values were determined upon incubation of cells with FITC labeled particles at 
4 °C and subtracted from the values measured after culturing at 37 °C. All reagents needed 
to perform phagocytosis and pinocytosis assays are listed in Table 2.3. 
2.2.18 Transfection of PECs with plasmids 
Plasmid transfection of PECs was carried out using Lipofectamine LTX Reagent, 
Lipofectamine 3000 Transfection Reagent, PromoFectin-Macrophage, TransIT Dynamic 
Delivery System, TransIT-2020 Transfection Reagent, TurboFect Transfection Reagent, 
Viromer Red, Effectene Transfection Reagent Kit, DharmaFECT Duo Transfection Reagent 
or METAFECTENE® PRO (Table 2.4). All Reagents were used according to manufacturer’s 
instructions. Detailed information about the exact transfection conditions (cell density, 
amount of DNA and transfection reagent) is specified in the corresponding figure legends. 
2.2.19 Transfection of PECs with siRNAs and miRNAs 
PECs were transfected with a custom-made fluorescently labeled siRNA (Sigma-Aldrich, St. 
Louis, USA) using DharmaFECT 4 Transfection Reagent, Lipofectamine RNAiMAX 
Transfection Reagent, METAFECTENE® SI⁺ or siLentFect Lipid Reagent for RNAi (Table 
2.4). Based on these results DharmaFECT 4 Transfection Reagent was determined to be 
the most suitable Reagent to deliver siRNAs in macrophages (high transfection efficiency 
and low cytotoxicity) and was used for all experiments according to manufacturer’s 
instructions. Briefly, siRNAs or miRNAs were diluted in serum-free DMEM medium to a total 
volume of 200 µl and a concentration that was 10 times higher than the desired final 
concentration. Next, 4 µl of DharmaFECT 4 Transfection Reagent were diluted in 196 µl 
serum-free DMEM medium. Both tubes were gently mixed by pipetting carefully up and 
down and incubated for 5 min at RT. The contents of both tubes were mixed and incubated 
for 20 min at RT. Meanwhile, the old PECs culture medium was aspirated and replaced by 
1600 µl antibiotic-free DMEM medium containing 10 % FCS. Finally, 400 µl of the 
transfection reagent/siRNA or miRNA mixture were added dropwise and the cells were 
incubated at 37 °C and 5 % CO2. Analysis was performed 24, 48 or 72 h post transfection. 
The transfection reagent was not replaced since cytotoxicity could not be observed. The 
protocol was applied to transfect 2 x 106 PECs seeded in 6-Well plates. 
2.2.20 miRNA isolation and quantification of miRNA expression level 
Micro RNA of PECs was isolated using the miRNeasy Mini Kit according to manufacturer’s 
instructions. Reverse transcription was performed using the TaqMan™ MicroRNA Reverse 
Transcription Kit according to the pipetting scheme shown below (Table 2.31). Each miRNA 
was reverse transcribed using its specific RT primer pair by incubating in a thermal cycler at 
16 °C for 30 minutes, then at 42 °C for 30 minutes and finally at 85 °C for 5 minutes. 
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Table 2.31: cDNA synthesis using the TaqMan™ MicroRNA Reverse Transcription Kit 
Component Volume per reaction 
Deoxynucleotide Mix (100 mM) 0.15 µl 
MultiScribe Reverse Transcriptase (50 U/µl) 1 µl 
Reverse Transcription Buffer (10 X) 1.5 µl 
Rnase Inhibitor (20 U/µl) 0.19 µl 
nuclease free water 4.16 µl 
RT primer 3 µl 
RNA template (40 ng) 5 µl 
Total volume 15 µ 
Gene expression was quantified using quantitative real-time PCR. Therefore, 2 µl of the 
undiluted cDNA was mixed with the matching TaqMan Probes, the TaqMan™ Universal 
PCR Master Mix and nuclease free water to reach a total volume of 20 µl as shown in Table 
2.32. The selected miRNAs were amplified using the ABI 7300 Real-time PCR System and 
the cycler protocol shown in Table 2.33. Gene expression was quantified by normalization to 
small nucleolar RNA 202 (snoRNA202). Primer pairs for reverse transcription as well as 
TaqMan Probes were obtained from Thermo Fisher Scientific, Waltham, USA (Cat. No. 
4427975). 
Table 2.32: qPCR pipetting scheme using TaqMan™ Universal PCR Master Mix 
Component Volume per reaction 
cDNA (undiluted) 2 µl 
TaqMan Probe 1 µl 
TaqMan™ Universal PCR Master Mix (2 X) 10 µl 
nuclease free water 7 µl 
Total volume 20 µl 
Table 2.33: Cycler protocol for qPCR using TaqMan™ Universal PCR Master Mix 
Step Temp. Time 
Pre-incubation (1 cycle) 
50 °C 2 min 
95 °C 10 min 
Amplification (45 cycles) 
95 °C 15 s 
60 °C 1 min 
2.2.21 RNA isolation and quantitative real-time PCR 
RNA of tumor cell lines was isolated using the RNeasy Plus Mini Kit according to 
manufacturer’s instructions. RNA of primary macrophages sorted from tumor tissue was 
isolated using the RNeasy Micro Kit according to manufacturer’s instructions. RNA of PECs 
was isolated using phenol-chloroform extraction followed by solid-phase anion-exchange 
chromatography. Briefly, PECs in 6-Well plates were washed twice with PBS, lyzed by the 
addition of 1 ml QIAzol Lysis Reagent (Qiagen, Venlo, Netherlands; Cat. No. 79306) per well 
and transferred into a 1.5 ml Eppendorf tube. After the addition of 200 µl chloroform (VWR 
International, Radnor, USA; Cat. No. 22711.29) and a subsequent centrifugation step at 
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maximum speed and 4 °C for 15 minutes, the aqueous phase was transferred into a fresh 
tube containing 600 µl 75 % Ethanol. The mixture was transferred on RNeasy columns and 
RNA extraction was carried out using the RNeasy Plus Mini Kit according to manufacturer’s 
instructions (including on-column DNA digestion).  
The isolated RNA of tumor cell lines or PECs was quantified using Nanodrop 
Spectrophotometer. In case of low 260/230 ratios, the RNA was purified by ethanol 
precipitation (see section 2.2.22) prior reverse transcription using the Transcriptor First 
Strand cDNA Synthesis Kit according to the pipetting scheme shown in Table 2.34. The 
reaction mix from step 1 was incubated at 65 °C for 10 min to ensure denaturation of RNA 
secondary structures. After the additional components were added, the reaction mix from 
step 2 was incubated at 50 °C for 1 h followed by a 5 min incubation at 85 °C. The cDNA 
was cooled down to 4 °C and stored at -80 °C. 
Table 2.34: cDNA synthesis using the Transcriptor First Strand cDNA Synthesis Kit 
Step 1 
 
Component Volume per reaction 
RNA template (500 ng) x μl 
nuclease free water (12 - x) μl 
Anchored-oligo(dT)18 primer (50 pmol/μl) 1 μl 
Total volume 13 µl 
  Step 2  
Component Volume per reaction 
Reaction mix from Step 1 13 μl 
Reverse Transcriptase Reaction Buffer (5 X) 4 µl 
Protector RNase Inhibitor (40 U/μl) 0.5 μl 
Deoxynucleotide Mix (10 mM each) 2 μl 
Transcriptor Reverse Transcriptase (20 U/μl) 0.5 μl 
Total volume 20 μl 
The yield of RNA isolated from sorted macrophages was too low for accurate quantification. 
Therefore, the whole volume was used for reverse transcription using the iScript cDNA 
Synthesis Kit according to the protocol in Table 2.35. The complete reaction mix was 
incubated at 25 °C for 5 min, at 42 °C for 30 min and at 85 °C for 5 min. The cDNA was 
cooled down to 4 °C and stored at -80 °C until further use. 
Table 2.35: cDNA synthesis using the iScript cDNA Synthesis Kit 
Component Volume per reaction 
RNA template 15 μl 
5x iScript reaction mix 4 μl 
iScript reverse transcriptase 1 μl 
Total volume 20 μl 
Gene expression was measured using quantitative real-time PCR. Therefore, 2 X Power 
SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Waltham, USA; Cat. No. 
4367659), 10 ng cDNA, 400 nM of each primer pair and nuclease free water were mixed to a 
total volume of 20 µl (see also Table 2.36). The selected genes were amplified using the ABI 
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7300 Real-time PCR System and the cycler protocol shown in Table 2.37. Gene expression 
was quantified by normalization to the corresponding housekeeping gene. All primers used 
for quantitative real-time PCR are shown in Table 2.21. 
Table 2.36: qPCR pipetting scheme using Power SYBR® Green PCR Master Mix  
Component Volume per reaction 
cDNA (diluted 1:5 in nuclease free water) 2 μl 
Power SYBR® Green PCR Master Mix (2X) 10 μl 
Forward primer (10 μM) 0.4 μl 
Reverse primer (10 μM) 0.4 μl 
nuclease free water 7.2 μl 
Total volume 20 μl 
Table 2.37: Cycler protocol for qPCR using Power SYBR® Green PCR Master Mix 
Step Temp. Time 
Pre-incubation (1 cycle) 
50 °C 2 min 
95 °C 10 min 
Amplification (40 cycles) 
95 °C 15 s 
60 °C 1 min 
72 °C 30 s 
Melting curve (1 cycle) 
98 °C 15 s 
60 °C 1 min 
95 °C 15 s 
60 °C 15 s 
2.2.22 Ethanol precipitation of RNA samples 
RNA samples with low 260/230 ratios (below 1.8), indicating phenol contamination, were 
purified by ethanol precipitation as described in the following. After adding 0.1 volume of 3 M 
sodium acetate and 2.75 volumes of ice cold 100 % ethanol to the RNA, the samples were 
stored overnight at -80 °C to allow RNA precipitation. The following day, the samples were 
centrifuged at full speed and 4 °C for 30 minutes and the ethanol was carefully aspirated. 
The precipitated RNA pellet was washed by the addition of 500 µl ice cold 75 % ethanol 
followed by a 10 minute centrifugation at full speed and aspirating the ethanol carefully. After 
repeating the washing step once, the RNA pellet was air dried and resolved in an 
appropriate amount of nuclease free water. 
2.2.23 Whole RNA and small RNA sequencing 
Whole RNA sequencing as well as small RNA sequencing of polarized PECs was done by 
the Genomics and Proteomics Core Facility of the German Cancer Research Center in 
Heidelberg, Germany using a HiSeq 2000 Sequencing System from Illumina (San Diego, 
USA). The sequencing data were analyzed by Franziska Hoerhold (Integrated Research and 
Treatment Center, Center for Sepsis Control and Care (CSCC), Jena, Germany). Briefly, 
Reads were mapped against the mouse GRCm38/mm10 reference genome by using 
TopHat [311]. The read counts of whole RNA sequencing data were calculated with 
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featureCounts [312, 313]. The read counts of small RNA sequencing data were calculated 
with customized scripts. Subsequently, DESeq2 [314] was used to determine differentially 
expressed genes. 
2.2.24 SDS-PAGE gel casting 
4 X Lower buffer: 1.5 M Trizma Base 
 
0.4 % SDS 
 
adjust pH to 8.8 
  4 X Upper buffer: 0.5 M Trizma Base 
 
0.4 % SDS 
 
adjust pH to 6.8 
The amounts of required reagents for one gel with dimensions 0.15 x 8 x 8 cm are given in 
Table 2.38. The polymerized separating gel was overlaid by 2 ml of the 5% stacking gel and 
a 1.5 mm x 5 mm gel strip was introduced. All reagents required to cast the gels are listed in 
Table 2.6. 
Table 2.38: SDS-PAGE gel casting 
2.2.25 Protein detection by Western blot 
5 X Protein loading buffer: 0.02% Bromophenol blue 
 
30 % Glycerol 
 
10 % SDS 
 
250 mM Trizma Base (adjusted with HCL to pH 6.8) 
 
10 % β-Mercaptoethanol (just before usage) 
  10 X Running buffer: 0.25 M Trizma Base 
 
1 % SDS 
 
1.9 M Glycine 
  10 X Transfer buffer: 0.25 M Trizma Base 
 
0.4 % SDS 
 
1.9 M Glycine 
  1 X Transfer buffer: 10 X Transfer buffer 
 
20 % Methanol 
  Blocking buffer: 1 X TBS 
 
5 % Milk powder 
 
0.05 % Tween 20 
Component 5 % stacking gel 12 % separating gel 
30% Acrylamide/Bis Solution [µl] 425 4000 
4 X Upper Buffer [µl] 312.5 - 
4 X Lower Buffer [ml] - 2.5 
Ammonium Persulfate [µl] 25 100 
TEMED [µl] 2.5 4 
Add water to final volume [ml] 2.5 10 
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  10 X TBS: 0.2 M Trizma Base 
 
1.37 M NaCl 
 
adjust pH to 7.6 
  Washing buffer (TBS-T): 1 X TBS 
 
0.05 % Tween 20 
In order to detect secreted proteins in the medium of cultured tumor cell lines, the cell culture 
supernatants were collected, mixed with 5 X protein loading buffer and heat denatured at 
95 °C for 10 min. For the preparation of whole cell protein samples, cells were harvested, 
counted and resuspended in an appropriate amount of Cell Lysis Buffer (2.5 x 104 cells per 
µl) supplemented with 1 mM Phenylmethylsulfonylfluorid (PMSF). The samples were stored 
on ice for 10 min and subsequently centrifuged at 4 °C and 14000 g for 20 min. The protein 
containing supernatants were transferred into fresh tubes, mixed with 5 X protein loading 
buffer and heat denatured at 95 °C for 10 minutes. Cell culture supernatants as well as 
whole cell protein samples were separated on a 12 % polyacrylamide gel (20 min at 80 V 
followed by 1.5 h at 120 V) and the proteins were electro-transferred onto nitrocellulose 
membranes using the Trans-Blot Turbo Transfer System. The membranes were blocked 
with 5 % of non-fat milk in Tris-buffered saline containing 0.05 % Tween (Blocking buffer) for 
1 h. Subsequently, the membranes were incubated overnight at 4 °C on a shaking platform 
with an OVA specific antibody diluted 1:1000 in blocking buffer. Next, membranes were 
washed 3 times for 5 min with 10 ml TBS-T and incubated at RT for 1 h with a horseradish 
peroxidase (HRP) conjugated secondary antibody 1:5000 diluted in blocking buffer. After 3 
additional washing steps with TBS-T as described above, protein signals were detected by 
adding ECL Prime Western Blotting Detection Reagent directly on the membrane and 
exposing blots to a charge-coupled device (CCD)-camera. Afterwards the membranes were 
washed 5 times for 5 min using TBS-T and incubated at RT for 1 h with an actin specific 
antibody diluted 1:10000 in blocking buffer. After 3 additional washing steps for 5 min using 
TBS-T, the membranes were incubated a second time at RT for 1 h with a HRP conjugated 
antibody diluted 1:5000 in blocking solution and analyzed using the ChemiDoc™ XRS+ 
System after adding detection reagent. Data were analyzed using the Image Lab Software. 
The material and antibodies used for Western blot analysis are listed in Table 2.6 and Table 
2.24, respectively. 
2.2.26 Gel electrophoresis 
1 X Tris-acetate-EDTA (TAE) buffer (pH 8.6):  40 mM Trizma Base 
 
20 mM Acetate 
 
1 mM EDTA 
For the electrophoretic separation of PCR products according to their size, the samples were 
mixed with DNA Ladder and loaded on a 1 % agarose gel. For gel preparation, appropriate 
amounts of agarose were boiled in Tris-acetate-EDTA (TAE) buffer. After cooling down to 
approximately 50 °C, Ethidiumbromide (5 drops per 100 ml) was added and the agarose 
poured into a gel chamber. An appropriate volume of sample and DNA Ladder were loaded 
as soon as the agarose gel was completely polymerized. After separation at a constant 
voltage of 120 V for 60 minutes in TAE buffer, the nucleic acid intercalating Ethidiumbromide 
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was excited with ultraviolet light and light emission was measured using the Gel iX Imager 
system. 
2.2.27 Immunofluorescence staining for flow cytometry and cell sorting 
FACS buffer: PBS 
 
3 % FCS 
Immunofluorescence staining of cells was performed using monoclonal antibodies listed in 
Table 2.23. The respective isotype matched antibodies against irrelevant epitopes were 
included as controls. All centrifugation steps were carried out for 2 min at 300 g and RT. 
After harvesting the cells and resuspending the cell pellet in an appropriate amount of FACS 
buffer, 200 µl of the cell suspension were dispensed per well in a 96-Well U-bottom plate. 
The plate was centrifuged, the supernatant was discarded and the pellet was incubated at 
4 °C for 20 min in a mixture of rat anti-mouse CD16/CD32 (50 µg/ml), normal Syrian 
Hamster serum (1:100) and Rat serum (1:100) in a total volume of 100 µl to block Fc-
receptors. The Fc-receptor blocking step was not performed if tumor cells or T cells were 
stained. Subsequently, the cells were centrifuged and washed using 180 µl FACS buffer. 
After an additional centrifugation, the cells were incubated at 4 °C for 1 h in FACS buffer 
containing fluorochrome conjugated antibodies and LIVE/DEAD Fixable Yellow Dead Cell 
dye (1:1000). Finally, the cells were washed twice, resuspended in 200 µl FACS buffer and 
analyzed with a FACSCanto II or LSR II cytometer or sorted using a FACS Aria I or II. The 
data were evaluated with FlowJo software (Version 10). If absolute quantification was 
required, 33 µl of CountBright Absolute Counting Beads were added to the cell suspension 
prior measurement.  Absolute quantification was calculated based on the following formula: 
 
No. of cell events
No. of Bead events
 ×
 No. of Beads added per sample
Volume of sample [µl]
 =  concentration of sample as cells/µl 
 
In case of intracellular staining of proteins the cells were fixed and permeabilized using 
FoxP3 staining Kit according to manufacturer’s instructions. Briefly, the cell pellets were 
resuspended in 100 µl Fixation/Permeabilization solution and incubated at 4 °C for 20 min. 
After washing the cells twice with 200 µl Perm/Wash buffer, they were incubated with 100 µl 
fluorochrome conjugated antibodies diluted in Permeabilization Buffer at 4 °C for 1 h. The 
cells were washed twice with 200 µl Perm/Wash buffer and resuspended in 200 µl FACS 
buffer for subsequent analysis. The different buffers, compensation beads and Fc-blocking 
reagents are listed in Table 2.5. 
2.2.28 xCELLigence 
The xCELLigence® RTCA SP System was set up by measuring the background signal of an 
E-Plate 96 filled with 50 µl of RPMI 1640 per well supplemented with Glutamax, 10 % FCS, 
100 U/ml Penicillin and 100 µg/ml Streptomycin. Afterwards, 2 x 103 cells per well were 
dispensed to reach a final volume of 200 µl and the impedance as a measure of cell 
proliferation was recorded for 10 days. Data were analyzed using the RTCA Software 2.0. All 
reagents used to perform the xCELLigence assay are listed in Table 2.3. 
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2.2.29 IFNγ ELISpot assay 
Washing buffer: PBS 
 
0.5 % Tween 20 
IFNγ ELISpot assays were performed in order to investigate IFNγ secretion by activated 
T cells. The Polyvinylidenfluorid (PVDF) membrane of MultiScreenHTS-IP ELISpot plates 
was activated by incubating each well with 50 µl 80 % Ethanol for 2 min. After 2 washing 
steps with 200 µl PBS per well, the membrane was coated with 1 μg/ml goat anti-mouse 
IFNγ capture antibody (100 µl per well) overnight at 4 °C. The ELISpot plate was washed 
once with PBS and blocked with 200 µl serum containing medium. Next, graded numbers of 
antigen-specific T cells were added to 5 x 104  target cells in a total volume of 200 μl per 
well. Alternatively, 1.5 x 106 splenocytes of immunized mice in combination with a relevant 
peptide were dispensed. The plates were incubated for 16–18 h at 37 °C and 5 % CO2 and 
subsequently washed 5 times with washing buffer followed by an additional washing step 
using PBS only. After washing 4 times with PBS, the plates were incubated with 2 μg/ml 
biotinylated rat anti-mouse IFNγ antibody (100 µl per well) for 1 h at 4 °C followed by 
additional 4 washing steps using PBS. Next, 100 µl avidin-conjugated alkaline phosphatase 
(Becton Dickinson, Franklin Lakes, USA; Cat. No. 554065) was added to each well and the 
plate was incubated for 30 min at RT. Finally, IFNγ-specific spots were visualized by adding 
100 µl of BCIP/NBT (Sigma-Aldrich, St. Louis, USA; Cat. No. B1911). The reaction was 
stopped after 3 min of incubation at RT in the dark with distilled water. Spots were counted 
using the CTL ELISpot Reader System as soon as the membranes were dry. All antibodies 
used for the ELISpot Assay are depicted in Table 2.25. 
2.2.30 IFNγ ELISA 
Supernatants of co-cultured PECs were collected and IFNγ secretion of T cells was 
quantified using Mouse IFN gamma ELISA Ready-SET-Go! Kit according to manufacturer’s 
instructions. The IFNү concentrations of the samples were determined based on the 
standard curve generated in GraphPad Prism. 
2.2.31 Luciferase assay 
The luciferase expression of transduced clones was tested using the luciferase Assay 
System (Table 2.27). Tumor cells were dispensed in 96-Well F-bottom plates at a density of 
5 x 104 cells per well and incubated overnight at 37 °C and 5 % CO2. On the next day, the 
culture medium was aspirated and the cells were washed once with 200 µl PBS per well. 
After adding 20 µl 1 X Lysis Reagent to each well and incubating for 10 min at RT, 10 µl of 
the lysates were transferred into a white 96-Well F-bottom plate. Light emission was 
measured immediately after the addition of 100 µl luciferase Substrate using the Mithras 
LB940 system. 
2.2.32 In vivo tumor growth 
In order to measure tumor growth of tumor cells in vivo, cells were harvested, washed 3 
times using PBS and adjusted to the desired concentration in PBS. C57BL/6 or C57BL/6 
Ly5.1 mice were injected s.c. into the right flank with 100 µl of B16F10 (2 x 105) or PDAC 
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(2 x 106) or EO771 cells (3.5 x 105 or 2 x 106) or their corresponding transduced/knock out 
cell lines. Tumor growth was monitored at least twice per week by caliper measurement and 
mice were killed after the tumor had achieved a size of 1.5 cm in diameter. Mice were 
sacrificed by gradual CO2 exposition. 
2.2.33 In vivo imaging 
C57BL/6 Ly5.1 mice were injected s.c. with luciferase expressing B16F10 clones (2 x 105) 
and tumor growth was monitored every 2-4 days using a caliper (as described in section 
2.2.32). In order to determine the individual luciferase expression kinetic for each cell line, 
30 gram heavy mice were shaved, sedated (1.5 vol. % Isofluoran (Zoetis, Parsippany-Troy 
Hills Township, USA)) and injected i.p. with 300 µl StayBrite D-Luciferin (15 mg/ml; BioCat, 
Cat. No. 7903-100-BV), which corresponds to 150 mg/kg body weight, 13 days post tumor 
cell injection. After substrate injection, the total Flux (p/s) was measured using auto 
exposure time, medium binning, F/stop of 1 and subject height of 1.5 cm every two minutes 
for 1 h using the IVIS Lumina Series III. The data were analyzed using the Living Image 
Software 4.4. to determine the percentages of max. Flux. Each total Flux value was divided 
by the highest total Flux value measured within a sequence of pictures. 
2.2.34 Adoptive cellular therapy 
Tumor bearing C57BL/6 Ly5.1 mice received adoptive cellular therapy 8-10 days post tumor 
cell injection. Therefore, splenocytes of OT-II mice were used either in their naïve state or 
after 3 days of expansion using CD3/CD28 Dynabeads or IAb restricted OVA peptide as 
described in the following. 
Naïve OT-II CD4+ T cells: 
OT-II splenocytes were isolated and underwent positive selection using CD4 (L3T4) 
MicroBeads (section 2.2.11). After adjusting the cell concentration to 50 x 106 cells/ml in 
PBS, 100 µl of the cell suspension were administered intravenously (i.v.) into the lateral tail 
vein of tumor bearing C57BL/6 Ly5.1 mice. 
Pre-activation using CD3/CD28 Dynabeads: 
OT-II splenocytes were isolated, positively selected using CD4 (L3T4) MicroBeads (section 
2.2.11) and resuspended in an appropriate amount of Complete T cell Medium. Next, 
1.5 x 106 CD4+ T cells were dispensed into each well of a 24-Well plate and 37.5 µl 
CD3/CD28 Dynabeads were added. After 2 days of incubation, 1 ml of the old culture 
medium was replaced by fresh medium. Three days post CD4+ T cell isolation, the cells 
were harvested and the Dynabeads were removed according to manufacturer’s instructions. 
The cells were washed 3 times using PBS and adjusted to a cell concentration of 50 x 106 
cells/ml in PBS. The cell suspension (100 µl per mouse) was administered i.v. into the lateral 
tail vein of tumor bearing C57BL/6 Ly5.1 mice. 
Pre-activation using peptide: 
OT-II splenocytes were isolated, resuspended in Complete T cell medium and dispensed in 
24-Well plates (6 x 106 cells per well in 2 ml). The cells were cultured in the presence of 
1 µg/ml IAb restricted OVA peptide (aa 323-339) for 3 days. On day 2, 1 ml of old culture 
medium was replaced by fresh medium. After 3 days of incubation, the cells were harvested, 
positively selected using CD4 (L3T4) MicroBeads (section 2.2.11) and were adjusted in PBS 
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to a cell concentration of 50 x 106 cells/ml. A total of 5 x 106 CD4+ T cells were injected i.v. 
into the lateral tail vein of tumor bearing C57BL/6 Ly5.1 mice. 
2.2.35 Spleen and lymphnode preparation 
Spleens and lymphnodes were harvested, transferred into PBS and passed through a 70 µm 
and 40 µm cell strainer, respectively. The single cell suspensions were centrifuged at 300 g 
for 10 min, the supernatants were discarded and the pellets resuspended in either 4 ml ACK 
lysing buffer (spleens) or an appropriate amount of FACS buffer for subsequent 
immunofluorescence staining (lymphnodes). After incubating the splenocytes for 2 min at RT 
in ACK lysing buffer, the 50 ml falcon tubes were filled up to a total volume of 50 ml using 
RPMI 1640 Medium. The cell suspension was centrifuged at 300 g for 10 min and the pellet 
was resuspended in an appropriate amount of RPMI 1640 Medium for subsequent cell 
counting. If necessary, the erythrocyte lysis step was repeated until the splenocyte pellet 
was completely white. 
2.2.36 Tumor digestion and isolation of tumor infiltrating leukocytes 
Tumors were harvested, transferred into hanks' balanced salt solution (HBSS) and cut into 
small pieces using a pair of scissors. Next, the tumors were digested for 1 h at 37 °C by 
shaking at 200 rpm using 0.5 mg/ml collagenase D, 10 µg/ml DNAse I, 0.1 µg/ml TLCK and 
10 mM HEPES buffer diluted in HBSS (components listed in  
Table 2.10). After passing the digested solution through a 70 µm cell strainer and then 
through a 40 µm cell strainer, the single cell suspension was centrifuged at 300 g for 10 
minutes. The cell pellet was resuspended in 4 ml ACK lysing buffer and incubated for 2 min 
at RT. The erythrocyte lysis was stopped by filling up the 50 ml falcon tube to a total volume 
of 50 ml with RPMI 1640 Medium. After another centrifugation step at 300 g for 10 min, the 
cell pellet was resuspended in an appropriate amount of FACS buffer and the cell 
suspension was transferred into 96-Well U-bottom plates for subsequent 
immunofluorescence staining. 
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3 Results 
3.1 Generation of ovalbumin and luciferase expressing, IAb deficient B16F10 
cells 
The project aims for answering the question whether adoptively transferred tumor antigen 
specific CD4+ T cells are able to polarize TAMs into immunostimulatory M1, thereby 
neutralizing the immunosuppressive tumor microenvironment and facilitating efficient tumor 
attack by tumor antigen specific CD8+ CTLs. 
An IAb deficient variant of the murine melanoma cell line B16F10 was established to avoid 
possible interactions between transferred CD4+ T cells and tumor cells and promote cognate 
interaction between CD4+ T cells and TAMs in vivo. The IAb KO B16F10 clone was 
generated using the CRISPR/Cas9 system (section 3.1.1). Therefore, nine guide RNAs 
(Table 2.18) targeting the beta chain of IAb were designed and cloned into PX458 
(supplementary Figure 6.1) downstream of the U6 promotor by Goyal Ashish (German 
Cancer Research Center, Heidelberg, Germany). Five of these guide RNAs target either 
Exon 1 (guide# 1, 4 and 5) or Exon 2 (guide# 3 and 12) creating a double strand break 
within the coding region of the gene. The target sequence of the remaining four guide RNAs 
is either upstream (u) of Exon 1 (guide# 1u and 2u) or downstream (d) of Exon 6 
(guide# 1d and 2d), both in non-coding regions. These guide RNAs need to be combined, 
thus inducing two individual double strand breaks which result in the deletion of the 
intermediate region. The PX458 plasmid additionally encodes for a Cas9-GFP transcript 
which is cleaved by a self-cleaving T2A peptide. As Cas9 is flanked by nuclear localization 
sequences, the enzyme localizes to the nucleus whereas GFP remains in the cytoplasm 
allowing the determination of transfection efficiency. 
In a next step, nucleotide sequences encoding two variants of the model antigen OVA were 
either transduced into the parental B16F10 cell line or into the IAb KO clone (M2KO) (section 
3.1.2). The first variant represents the full length sequence of OVA (OVA-F), whereas the 
second variant lacks the annotated signal peptide (amino acids 22-48 [315]) and is retained 
within the cytosol (OVA-T). The different OVA variants (either secreted or not) allow us to 
clarify whether induced changes in macrophage polarization upon adoptive CD4+ T cell 
transfer are dependent on secretion of the tumor-associated antigen or not. As outlined in 
Figure 3.1, OVA transduced cells were characterized by quantification of OVA 
expression/secretion, MHC surface expression, susceptibility to CD8+ T cell recognition and 
efficient tumor growth in C57BL/6 mice. 
Finally, the OVA expressing clones (B16F10/OVA-F, B16F10/OVA-T, M2KO/OVA-F and 
M2KO/OVA-T) were transduced with retroviral particles encoding Red Firefly Luciferase 
(section 3.1.3). After expansion, luciferase expression levels of individual clones were 
analyzed and used to establish the in vivo bioluminescence imaging protocol. The luciferase 
expressing clones B16F10/OVA-F/Luci, B16F10/OVA-T/Luci, M2KO/OVA-F/Luci and 
M2KO/OVA-T/Luci can be used for subsequent in vivo experiments, in which the effect of 
adoptively transferred CD4+ and/or CD8+ T cells on tumor outgrowth is analyzed. The whole 
process of generating OVA and luciferase expressing B16F10 cells deficient in MHC II 
expression is illustrated in Figure 3.1. The designations of clones finally selected are given in 
brackets. 
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A. MHC I knock out using a β2m-specific single guide RNA 
B. MHC II knock out using a single guide RNA specific for the β-chain encoding locus of the IA
b
 molecule 
C. Transduction using lentiviral particles (rwpLX305-Ovalbumin-IRES-Neo) 
D. Transduction using retroviral particles (rwpBABE-Puro-Red Firefly Luciferase) 
 
Validation legend: 
 
1. Ovalbumin expression level (qPCR and WB; Figure 3.6) 
2. Ovalbumin secretion (WB; Figure 3.10) 
3. MHC expression profile (FC; Figure 3.9) 
4. Recognition by OVA spec. CD8
+
 T cells (ELISpot; Figure 3.7 and Figure 3.12) 
5. In vitro growth curve (xCELLigence; Figure 3.8) 
6. Luciferase expression level (LA; Figure 3.12) 
7. Tumor growth curve (Figure 3.11 and Figure 3.13) 
8. Luciferase expression kinetic in vivo (IVIS; Figure 3.13) 
Figure 3.1: Workflow for the generation of OVA and luciferase expressing B16F10 clones 
deficient in MHC II expression. 
The corresponding clone names are enclosed in brackets. 
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3.1.1 Establishment of B16F10 cells deficient in MHC II expression 
3.1.1.1 Transfection optimization of B16F10 cells 
The first step in generating MHC II KO B16F10 cells was to transfect the tumor cell line with 
a guide RNA and Cas9 encoding plasmid. In order to guarantee optimal plasmid transfection 
efficiency in B16F10 cells, the cells were transfected with guide #1 or PX458 backbone 
using different amounts of DNA as well as different DNA:Enhancer (µg:µl) and 
DNA:Effectene (µg:µl) ratios (Figure 3.2 A). 
 
Figure 3.2: Optimization of the transfection protocol for B16F10 cells using Effectene 
transfection reagent. 
One day after seeding 2 x 10
5
 B16F10 cells into 6-Well plates, the cells were transfected either with 
guide #1 (approach 1-9) or the empty PX458 plasmid (approach 10-12) using different amounts of 
DNA and transfection reagent. (A) Table displaying all tested transfection conditions. (B) Cells were 
harvested 24 h after transfection and analyzed by flow cytometry. The bar graph shows the 
percentage of GFP
+
 cells (left y-axis) as well as the median fluorescence intensity values of GFP
+
 
cells (right y-axis). (C) Representative dot plots of the mock control as well as of Reaction 5 and 9 
24 h after transfection. (D) Analysis of B16F10 cells 48 h after transfection. Gating strategy: FSC-A 
vs. SSC-H → GFP vs. FSC-H. 
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Transfection of the plasmids yielded between 15.4 % and 71.7 % GFP positive cells, as 
determined by flow cytometry 24 h post transfection (Figure 3.2 B and C). The highest 
percentage of transfected cells was detected in reaction 9, in which 0.8 µg of DNA and a 
DNA:Effectene ratio of 1:10 was used. Cell viability was assessed 24 h after transfection 
using the CASY cell counting technology. The overall viability was high (between 72.4 % and 
87.8 %) with the exception of cells transfected using reaction 8 (data not shown). These cells 
showed a viability of only 61.2 % which was probably due to the large volume of transfection 
reagent used (40 µl). Two days after transfection the ranking of the different reactions 
according to the percentage of GFP+ cells changed only slightly (Figure 3.2 D). Based on 
those results, the conditions tested in reaction 9 were used for all subsequent experiments. 
3.1.1.2 Determination of guide RNA knock out efficiencies 
In a next step, the guide RNA knock out efficiencies were determined. Therefore, B16F10 
cells were transfected with the different guide RNA constructs using the optimized 
transfection protocol (see section 3.1.1.1). Two days after transfection, parts of the bulk 
cultures were analyzed by flow cytometry to determine transfection efficiencies. As 
expected, the percentages of GFP+ cells among the different constructs appeared similar 
ranging from 46.8 % to 62.4 % (Figure 3.3 A). However, big differences in the median 
fluorescence intensities were detected, being lowest in cells transfected with PX458 
backbone (MFI: 137) and highest after transfection with a combination of guide #1d and #2u 
(MFI: 373). The remaining cells were expanded for 7 days and treated with IFNγ for 72 h, to 
induce IAb surface expression. As shown in Figure 3.3 B, the percentage of IAb negative 
B16F10 cells increased upon transfection with one of the single guide RNAs compared to 
PX458 backbone transfected cells. In contrast, no differences in IAb expression were 
observed when combinations of guide RNAs were transfected (e.g. 1d + 1u). The analysis 
revealed that transfection of guide #4 resulted in the most prominent subpopulation of IAb 
negative cells (51.4 %) compared to 29.6 % IAb negative cells in PX458 backbone 
transfected cells (Figure 3.3 C). Based on the transfection efficiencies and the percentages 
of IAb negative cells, the knock out efficiencies of the different guide RNA constructs were 
calculated, revealing the guide #4 containing construct as the most effective one (Figure 
3.3 D). 
Results 
65 
 
 
Figure 3.3: Different guide RNA constructs have different knock out efficiencies. 
B16F10 cells (2 x 10
5 
cells/well) were transfected with all available guide RNA constructs using the 
optimized transfection protocol (Reaction 9). In case of double transfection with two guide RNA 
constructs, 0.5 µg of each plasmid was used. (A) Cells were harvested 48 h after transfection with the 
annotated guide RNA and analyzed by flow cytometry. The bar graph shows the percentage of GFP
+
 
cells (left y-axis) as well as the median fluorescence intensity values of GFP
+
 cells (right y-axis). 
Gating strategy: FSC-A vs. SSC-H → GFP
+
 vs. FSC-H. (B) The cells were expanded and 7 days post 
transfection treated with 20 U/ml IFNγ for 72 h. The percentage of IA
b-
 cells was determined after 
staining with IA
b
 specific monoclonal antibody. (C) Density plots of B16F10 cells transfected either 
with guide #4 or empty PX458 plasmid and subsequently treated with IFNү for 72 h. Gating strategy: 
FSC-A vs. SSC-H → living cells → IA
b
 vs. FSC-H. (D) Table displaying calculated guide RNA 
construct knock out efficiencies. The percentage of IA
b-
 cells in PX458 transfected cells was 
considered as background and subtracted from the other values. 
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3.1.1.3 Generation of a stable MHC II negative B16F10 clone 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself.  
For the generation of a stable IAb negative clone, B16F10 cells were transfected with the two 
guide RNA constructs which resulted in the highest percentage of IAb negative cells (guide 
#1 and #4). The GFP expressing transfectants were isolated by FACS and further expanded 
in vitro (Figure 3.4 A). After 9 days, the cells were treated with IFNγ to stimulate IAb surface 
expression, thus creating most stringent conditions for subsequent selection of IAb KO 
clones. Indeed, flow cytometry analysis revealed that transfection of guide #1 resulted in a 
subpopulation of 25.3 % IAb negative cells, whereas the proportion of IAb negative cells 
induced with guide #4 was 32.8 % (Figure 3.4 B). In contrast, no IAb negative population was 
observed within parental B16F10 cells treated with IFNγ. Upon single cell sorting, 24 
individual clones were established from the IAb negative subpopulations of the transfected 
bulk cultures, resulting in 23 clones with stable loss of IAb surface expression 
(supplementary Figure 6.2). Finally, clone #4G10 was selected, from now on termed M2KO, 
and expanded for subsequent experiments. Flow cytometry analysis confirmed lack of IAb 
surface expression on IFNγ treated M2KO cells, in contrast to parental B16F10 cells that 
upregulated IAb expression upon IFNγ treatment (Figure 3.4 C). 
In order to confirm, that the stable IAb KO clone had lost susceptibility to CD4+ T cell 
recognition, IFNγ ELISpot assays with an OT-II derived CD4+ T cell line were performed 
(expanded with CD3/CD28 Dynabeads as explained in section 2.2.12.3). As expected, IFNγ 
treated parental B16F10 cells, but not M2KO cells loaded with the IAb restricted OVA323-339 
peptide were recognized by OVA specific CD4+ T cells (Figure 3.5 A). These results show 
that M2KO cells had lost both, surface expression of IAb and susceptibility to CD4+ T cell 
recognition, even when cell had been treated with IFNγ concentrations that induce MHC II 
expression on parental cells. 
Next, tumorigenic capacity of the established IAb knockout clone was tested in C57BL/6 
mice. After s.c. injection into syngeneic C57BL/6 mice, parental B16F10 cells and M2KO 
transfectants showed almost superimposing tumor growth curves, reaching a tumor size of 
approximately 135 mm2 within 15 days (Figure 3.5 B). As the absence of MHC II on the 
surface of M2KO cells did not alter their tumor growth behavior in vivo, these cells resemble 
a suitable tool for additional modifications (integration of OVA and luciferase) and 
subsequent in vivo experiments.  
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Figure 3.4: Transfection of B16F10 cells with guide #4 encoding constructs results in 
generation of a stable B16F10 IA
b 
KO clone.  
(A) B16F10 cells were transfected with guide #1 or guide #4 encoding constructs. Two days later, 
GFP
+
 cells were sorted and expanded. Gating strategy: FSC-A vs. SSC-H → GFP
+
 vs. FSC-H. (B) 
Sorted bulk cultures were treated with IFNγ (20 U/ml) 9 days post transfection, followed by surface 
staining with IA
b
 specific monoclonal antibody. (C) Immunofluorescence staining confirmed complete 
loss of IA
b
 surface expression on the selected B16F10 KO clone (M2KO), even when treated with 
IFNγ. Gating strategy: FSC-A vs. SSC-H → living cells → IA
b
 vs. FSC-H. 
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Figure 3.5: Stable IA
b
 KO clone loses susceptibility to cognate CD4
+
 T cell recognition and 
gives rise to tumors in C57BL/6 mice. 
(A) Peptide loaded B16F10 cells but not M2KO cells were recognized by OVA-specific CD4
+
 T cells. 
Target cells were treated with IFNγ (20 U/ml) prior to the assay to upregulate IA
b
 expression. Empty 
bars (Ctrl.) represent the recognition of target cells loaded with IA
b
 restricted HBV core antigen control 
peptide 128-140 (TPPAYRPPNAPIL). Error bars represent standard deviation (SD) of technical 
triplicates. (B) C57BL/6 mice (n = 10) were injected s.c. with the parental B16F10 cells or the stable 
IA
b
 KO clone (2 x 10
5
) and tumor growth was monitored every 2-4 days. Error bars represent standard 
error of the mean (SEM) within each animal collective. 
3.1.1.4 Analysis of CRISPR/Cas9 induced mutations in M2KO cells 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself.  
Finally, we analyzed the CRISPR/Cas9 induced mutations within IAb KO clone M2KO. 
Therefore, the Cas9 target region within exon 1 of the IA beta chain gene was amplified by 
PCR and the resulting PCR products were cloned into TOPO vectors. After transformation of 
these vectors into One Shot competent TOP10 bacteria and subsequent plasmid isolation, 
the plasmids were sequenced as described in section 2.2.7. As shown in Table 3.1, all 
plasmids isolated from a total of 26 bacterial colonies showed the same 11 bp deletion, 
occurring at the vicinity of the putative Cas9 cutting site (highlighted in green) which is 
located 3 base pairs upstream of the PAM sequence (highlighted in blue). The deletion 
caused a frameshift in exon 1, thereby generating a stop codon resulting in a truncated 
protein. In contrast, no sequence changes were observed within the exon 1 of the IA beta 
chain gene in the parental B16F10 cell line as compared to the wild type C57BL/6 genome. 
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Table 3.1: guide RNA sequence and sequence analysis of the mutated M2KO clone 
Cell line 
Bacterial 
colony 
Sequence 
B16F10 30 5'-GGAGACTCCGAAAGTAAG|TGCCGGGGGCAGGGC-3' 
M2KO 
1 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
2 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
3 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
6 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
10 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
18 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
23 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
25 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
26 5'-GGAGACTCCGA-------|------GGGGGCAGGGC-3' 
- guide RNA 5'-~GAGACTCCGAAAGTAAGTGC-3' 
3.1.2 Establishment of ovalbumin expressing B16F10 derived clones 
3.1.2.1 Transduced B16F10 clones express OVA on RNA and protein level 
B16F10 and M2KO cells were transduced with either the native, full length version of OVA 
(OVA-F) or a truncated version of OVA (OVA-T), lacking the first 150 bp including the signal 
peptide. The transduced bulk cultures were selected with 1 mg/ml Geneticin, which was 
found to be the minimal concentration lethal to 100 % of untransduced B16F10 cells. After 
7 days of culture, genomic DNA of the bulk cultures was isolated and the stable integration 
of the introduced OVA sequences was confirmed by PCR using two different primer pairs. 
One primer pair includes the amplification of the signal peptide and was therefore specifically 
amplifying OVA-F, whereas the second primer pair binds downstream of the signal peptide, 
thereby amplifying both, OVA-F as well as OVA-T. By using these primer pairs it was 
possible to distinguish between the two different OVA sequences and to prove that in each 
bulk culture the correct OVA version was integrated (supplementary Figure 6.3). After two 
weeks of culture, clones were picked and expanded. The expression of OVA-F on protein 
level in both, B16F10 and M2KO clones, was confirmed by Western blot analysis as shown 
in Figure 3.6 A and B. The full length OVA was detected at the expected molecular weight of 
42.8 kDa in all OVA-F transfectant clones, except for M2KO/OVA-F clone B2. In contrast, no 
such band was detected in parental B16F10 or M2KO cells which served as negative 
controls (-). Quantification of the detected OVA-F signals revealed that B16F10/OVA-F clone 
A1 and C2 as well as M2KO/OVA-F clone A1 and C2 possessed the highest levels of OVA 
protein (Figure 3.6 B) which correlated well with OVA RNA expression results obtained by 
qPCR (Figure 3.6 C). In contrast to full length OVA, OVA-T could not be detected on protein 
level (molecular weight: 37.6 kDa) even though the used antibody is specific for an epitope 
outside the signal sequence (data not shown). However, qPCR analysis showed that in all 
clones, except for B16F10/OVA-T clone A2, the truncated OVA variant was expressed on 
RNA level. Notably, even though B16F10/OVA-T clone C2 possessed a higher OVA 
expression on RNA level than all B16F10/OVA-F clones, the truncated version was still not 
detected on protein level. These results indicate a rapid turnover of the truncated OVA 
protein due to the lacking signal peptide. 
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Figure 3.6: Transduced B16F10 derived clones express OVA on RNA and protein level. 
(A) Expression of OVA in transduced B16F10 and M2KO cells was validated by Western blot. The full 
length version (42.8 kDa), but not the truncated version of OVA (37.6 kDa) is detected. As negative 
controls (-), whole cell protein samples of the parental cell lines were loaded (left: B16F10, right: 
M2KO). (B) Quantification of Western blot results. (C) Quantitative real-time PCR confirmed OVA 
expression on RNA level in all clones tested. 
3.1.2.2 Transduced B16F10 clones are recognized by OVA specific CTLs 
In order to investigate whether the truncated version of OVA is processed resulting in 
epitope presentation by MHC molecules, despite the assumed rapid degradation of the 
protein, an IFNү ELISpot assay was performed. Therefore, the OVA expressing B16F10 
derived clones were co-cultured with OVA specific CTLs for 16 h and the number of IFNү 
spots was determined. As shown in Figure 3.7, all the transduced clones were susceptible to 
OVA specific CTL recognition, regardless of whether these clones expressed OVA-F or 
OVA-T. These results demonstrate that the truncated OVA RNA was not only successfully 
translated into protein, but also that the protein can be processed, thereby generating CTL 
epitopes that can be presented by MHC molecules on the cell surface. Both steps, the 
synthesis of the truncated protein as well as the presentation of OVA derived epitopes on 
MHC molecules, are essential for using these clones in subsequent in vivo experiments.  
Based on the ELISpot results, four clones showing equal susceptibility to OVA specific CTL 
recognition, namely B16F10/OVA-F clone A1, B16F10/OVA-T clone B2, M2KO/OVA-F clone 
A1 and M2KO/OVA-T clone A2 were selected for subsequent experiments. For reasons of 
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clarity, the clone specifications in the clone designations are omitted from now on and can 
be looked up in Figure 3.1. 
 
Figure 3.7: Transduced B16F10 derived clones are susceptible to OVA specific CTL 
recognition. 
OVA transduced B16F10 derived clones (5 x 10
4
) were incubated over night with 10
3
 OVA specific 
CTLs. All transduced clones were susceptible to T cell recognition as measured by IFNγ ELISpot 
assay, whereas the parental B16F10 and M2KO cells were not recognized by CTLs. Error bars 
represent SD of technical triplicates. 
3.1.2.3 In vitro proliferation and MHC expression of OVA expressing clones 
Within the next set of experiments, the proliferative capacity in vitro as well as the MHC 
expression profile of the selected clones was characterized. In order to assess cell 
proliferation, the cells were seeded into a 96-Well plate and monitored over the course of 
eight days using the xCELLigence system. As shown in Figure 3.8 A, OVA transduced 
clones showed slower growth compared to the corresponding parental cell lines. However, 
the four clones that were finally selected showed similar proliferation capacity (Figure 3.8 B). 
Interestingly, the viability of B16F10 derived clones (green lines) drops one day earlier 
compared to the viability of M2KO derived clones (blue lines), suggesting that M2KO might 
be more resistant to nutrient deprivation. 
 
Figure 3.8: In vitro proliferation of B16F10 and M2KO OVA derived clones. 
(A) The OVA transduced clones as well as their parental cell lines were seeded into a 96-Well F-
bottom plate (2 x 10
3
 cells/well) and proliferation was monitored using the xCELLigence system. All 
transduced clones (grey) show a decreased proliferation capacity compared to the corresponding 
parental cell lines (blue and red). (B) Growth curve comparison of clones finally selected. 
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The MHC expression profile of the selected clones was analyzed by immunofluorescence 
staining using H2-Kb, H2-Db, and IAb specific monoclonal antibodies. To make sure that 
M2KO derived clones still lack the MHC II molecule IAb, the cells were treated for 48 h with 
20 U/ml IFNү in order to induce possible MHC expression. As an additional proof of 
successful OVA processing and MHC restricted epitope presentation (besides the ELISpot 
results shown in Figure 3.7), the clones were stained using a H2-Kb SIINFEKL specific 
monoclonal antibody. As shown in Figure 3.9, MHC expression on cells without IFNү pre-
treatment (solid line histograms) is almost absent (percentages of positive cells range 
between 0.2 and 0.5 %). In contrast, cells cultured in the presence of IFNү for two days 
(dashed line histograms) highly upregulate MHC I as well as MHC II expression. Most 
importantly, IAb expression was not detected on the cell surface of M2KO derived, OVA 
expressing clones even after IFNү treatment. As expected, OVA transduced clones 
upregulated H2-Kb SIINFEKL expression to certain extent after IFNү stimulation, whereas 
the parental B16F10 and M2KO cells did not show any H2-Kb SIINFEKL molecules on their 
surface. 
 
Figure 3.9: MHC expression profiles of B16F10 and M2KO OVA transduced clones. 
The OVA expressing clones were treated with 20 U/ml IFNγ for 48 h  (dashed line histograms) or left 
untreated (solid line histograms) and subsequently stained with H2-K
b
, H2-D
b
, IA
b
 and H2-K
b
 
SIINFEKL specific monoclonal antibodies. Analysis was performed on living, single cells. The clones 
show a strong upregulation of H2-K
b
 SIINFEKL expression when treated with IFNγ. In contrast, the 
parental cells lack the MHC class I restricted presentation of the OVA derived SIINFEKL peptide. 
3.1.2.4 The truncated version of OVA is not secreted 
The clones expressing OVA-T were shown to present OVA derived SIINFEKL peptide 
(section 3.1.2.3) and to be susceptible to OVA specific CTL recognition (section 3.1.2.2), 
suggesting that the protein is expressed and processed. However, OVA-T could not be 
detected in whole cell protein samples, possibly due to proteasomal degradation (section 
3.1.2.1). To test this hypothesis the clones were cultured in the presence of 10 µM 
lactacystin for 13 h in order to block proteasomal activity. After preparing whole cell protein 
samples, OVA expression was analyzed by Western blot (Figure 3.10 A and B). The 
inhibition of the proteasome increased the detectable amount of OVA-F and allowed the 
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detection of the truncated OVA version at 37.6 kDa after extended exposition time, 
confirming the suggested high turnover of that protein (Figure 3.10, middle panel). 
In a next step, the culture supernatants of lactacystin treated, OVA expressing clones were 
analyzed by Western blot, in order to guarantee intracellular localization of OVA-T and at the 
same time secretion of OVA-F (Figure 3.10 C). The Western blot results demonstrated a 
strong OVA-F secretion which was unaffected by proteasome blockade. In contrast, OVA-T 
was not detectable in the culture supernatants even after lactacystin treatment and 20 min 
exposure time proving its intracellular localization. 
 
Figure 3.10: The truncated version of OVA is rapidly degraded by the proteasome and not 
secreted into the culture medium. 
The selected OVA transduced clones as well as the parental cell lines were treated with 10 µM 
Lactacystin for 13 h in order to block proteasomal degradation of the truncated OVA version. OVA 
expression level in protein lysates (A-B) as well as cell culture supernatants (C) was analyzed by 
Western blot. (A-B) Due to degradation, the truncated version of OVA (37.6 kDa) is only detectable 
after treatment with lactacystin and an extended exposure time of 20 minutes. (C) Analysis of the 
culture supernatants revealed that OVA-F is secreted and can be detected independently of 
proteasomal blockade by lactacystin. In contrast, OVA-T is not secreted into the culture medium even 
after lactacystin treatment and extended exposition time (20 minutes). m = marker. 
3.1.2.5 OVA transduced clones give rise to tumors in C57BL/6 mice 
In a final step, the OVA transduced clones were s.c. injected into C57BL/6 mice to determine 
the tumor take rate as well as the individual tumor growth curves. As shown in Figure 3.11, 
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all clones gave rise to tumors reaching tumor volumes between 1300 (M2KO/OVA-F) and 
1800 (B16F10 parental) mm3 16 days post tumor cell injection. All transduced clones, except 
for B16F10/OVA-T, showed a delayed tumor growth compared to the parental B16F10 cell 
line, probably due to the expression of the foreign, immunogenic antigen OVA. Nevertheless, 
the tumor take rate of all tested clones was 100 % which makes them a useful tool for 
subsequent in vivo experiments.   
 
Figure 3.11: Transduced B16F10 and M2KO derived clones give rise to tumors in vivo. 
C57BL/6 Ly5.1 mice (n = 7) were injected s.c. with B16F10/OVA or M2KO/OVA clones (2 x 10
5
) and 
tumor growth was monitored every 2-3 days. Error bars represent SEM within each animal collective. 
3.1.3 Establishment of ovalbumin and luciferase expressing B16F10 clones 
3.1.3.1 Luciferase expression of transduced cells in vitro 
In a final step, B16F10/OVA and M2KO/OVA clones were transduced using luciferase 
encoding retroviral particles and cultured in selection medium containing 1 µg/ml puromycin. 
After two weeks, individual clones were picked, expanded and the luciferase expression was 
analyzed by performing a luciferase assay. As shown in Figure 3.12 A, luciferase expression 
was detected in all clones (except for B16F10/OVA-F/Luci clone A2) as well as in the bulk 
cultures, but not in the parental OVA expressing clones B16F10/OVA-F and M2KO/OVA-F. 
An IFNү ELISpot assay was performed to select for those luciferase expressing clones 
which are equally recognized by OVA specific CTLs, thereby allowing a better comparison 
between the different clones in subsequent in vivo experiments. As expected, all clones 
were susceptible to OVA specific CTL recognition, whereas the parental B16F10 and M2KO 
cells were not. The clones finally selected for subsequent experiments, are B16F10/OVA-
F/Luci clone B1, B16F10/OVA-T/Luci clone A3, M2KO/OVA-F/Luci clone A3 and 
M2KO/OVA-T/Luci clone A1. For reasons of clarity, the specifications of the original clone 
designations omitted from now on and can be looked up in Figure 3.1. 
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Figure 3.12: B16F10/OVA and M2KO/OVA cells transduced with luciferase encoding retroviral 
particles express luciferase in vitro and are recognized by OVA specific CTLs. 
After generation of individual clones from luciferase transduced OVA expressing cells, the luciferase 
expression level (A) as well as the susceptibility to T cell recognition (B) was determined. (A) The 
cells were cultured in a 96-Well F bottom plate overnight and subsequently lyzed. After 5 minutes of 
incubation with luciferase substrate the light emission, which is proportional to luciferase activity was 
measured. (B) The clones (5 x 10
4
) were co-cultured with 10
3
 OVA specific CTLs overnight in order to 
perform an IFNγ ELISpot assay. Error bars represent SD of technical triplicates. 
3.1.3.2 Characterization of luciferase expression kinetics in vivo 
In a final validation step each of the selected clones were injected s.c. into C57BL/6 mice to 
determine tumor growth as well as the clone specific kinetics of luciferase expression in vivo. 
As shown in Figure 3.13 A, all clones gave rise to tumors with a tumor take rate of 100 %. 
However, remarkable differences in tumor growth were detected. Reduced tumor growth of 
M2KO/OVA-F/Luci, B16F10/OVA-F/Luci and M2KO/OVA-T/Luci were accompanied by 
higher luciferase expression levels compared to B16F10/OVA-F/Luci.  
The individual luciferase expression kinetics in Figure 3.13 B revealed the optimal imaging 
time for each cell line after D-luciferin injection. The kinetics show a highly variable substrate 
distribution phase within the first 12-20 minutes after D-luciferin injection, followed by a 
stable plateau (in between the vertical, dotted lines) and a variable substrate clearance 
phase. To obtain optimal quantitative results, imaging must occur during the plateau phase 
which is specific for each clone.  
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Figure 3.13: B16F10/OVA/Luci and M2KO/OVA/Luci clones form tumors in C57BL/6 
mice and show individual luciferase expression kinetics. 
(A) C57BL/6 Ly5.1 mice (n = 7-9) were injected s.c. with the finally selected OVA/Luci transduced 
clones (2 x 10
5
) and tumor growth was monitored every 2-4 days. Error bars represent SEM within 
each animal collective. (B) In order to monitor tumor growth by in vivo luminescence imaging, it is 
essential to determine for each clone its individual luciferase expression kinetic. C57BL/6 Ly5.1 (n = 
3) were injected s.c. with the luciferase expressing OVA transfectants (2 x 10
5
). Thirteen days post 
tumor cell injection, mice were sedated and injected i.p. with 300 µl D-luciferin (15 mg/ml). Up to 60 
minutes post substrate injection, the total Flux (p/s) was measured every two minutes to detect the 
clone specific luciferase expression plateau (% of max. Flux ≥ 95). Error bars represent SD within 
each animal collective. 
3.2 Generation of an OVA specific CD4+ T cell line 
In order to generate an OVA specific CD4+ T cell line that can be used to perform co-culture 
experiments with macrophages, three different strategies were implemented as already 
described in detail in section 2.2.12. Briefly, OVA specific CD4+ T cells were generated 
either through peptide immunization of C57BL/6 mice (C57BL/6 immunized), or by activation 
of OT-II splenocytes using IAb restricted peptide (OT-II peptide/feeder) or CD3/CD28 
Dynabeads (OT-II CD3/CD28 beads). T cell cultures were restimulated every 4 weeks by the 
addition of irradiated syngeneic feeder cells together with antigenic peptide. 
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3.2.1 Peptide immunization results in OVA specific T cell response 
C57BL/6 mice were immunized with IAb restricted OVA specific T cell epitope (OVA329-337 or 
OVA323-339) to prime OVA specific CD4
+ T cells in vivo, followed by T cell expansion in vitro. 
The presence of OVA specific CD4+ T cells was verified by culturing spleen cells of 
immunized mice in the presence of the respective peptide and measuring the number of 
IFNү producing cells using IFNү ELISpot assay. As shown in Figure 3.14 A, immunization 
using the core sequence of IAb restricted epitope (OVA329-337 [316]) did not result in T cell 
activation, even when high peptide concentrations (2 µg/ml) were used in the ELISpot assay. 
Between 156 and 210 IFNү spots were detected upon unspecific stimulation of splenocytes 
using 20 µg/ml ConA, showing that the assay itself worked. In contrast, IFNү producing, 
OVA specific CD4+ T cells were detected in 4 out of 5 mice immunized with the complete IAb 
restricted epitope (OVA323-339) (Figure 3.14 B). The number of IFNү secreting OVA specific 
CD4+ T cells was higher in splenocytes of mice sacrificed 13 days compared to 7 days post 
immunization. Remaining spleen cells, not needed for the ELISpot assay, were cultured in 
Complete T cell Medium and OVA323-339 peptide as described in section 2.2.12.1. After 
several weeks of culturing, T cells obtained from mice 7 days post immunization turned out 
to expand best and were compared to OT-II derived CD4+ T cell lines (section 3.2.2). 
 
Figure 3.14: Immunization of C57BL/6 mice with IA
b
 restricted OVA323-339 peptide results in OVA 
specific CD4
+
 T cell priming.  
(A) C57BL/6 were immunized s.c. with 100 µg OVA329-337 peptide (AAHAEINEA) diluted in Freund‘s 
Adjuvant. Thirteen days post immunization the mice were sacrificed and 1.5 x 10
6
 splenocytes were 
incubated with different OVA peptide concentrations to measure CD4
+
 T cell activation using IFNγ 
ELISpot assay. (B) C57BL/6 mice were immunized s.c. with 100 µg OVA323-339 peptide 
(ISQAVHAAHAEINEAGR) diluted in Freund‘s Adjuvant. Mice were sacrificed 7 or 13 days post 
immunization and 1.5 x 10
6
 splenocytes were incubated with 2 µg/ml of the corresponding OVA 
peptide. OVA specific CD4
+
 T cell activation was measured using IFNγ ELISpot assay. Error bars 
represent SEM of technical triplicates. 
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3.2.2 Testing of specificity and purity of established CD4+ T cell lines 
The OVA specific CD4+ T cell line generated from immunized C57BL/6 mice was compared 
to OT-II derived CD4+ T cell lines (generated as described in section 2.2.12) in terms of 
epitope specificity and purity. All three cell lines were generated from an individual mouse 
and restimulated once with irradiated syngeneic feeder cells and antigenic peptide prior to 
analysis of specificity and purity. The specificity was tested in an IFNү ELISpot assay using 
peptide loaded 771 B cell lymphoma cells as targets, as these cells can be easily kept in 
culture and express high levels of IAb. As shown in Figure 3.15 A, the maximum number of 
IFNү spots detectable with this assay (i.e. > 500 IFNү spots) was reached when the highest 
number of T cells (6250) was used. For each lower T cell number tested, the OT-II 
peptide/feeder cell line showed the highest number of IFNү secreting cells compared to the 
other T cell lines. As expected, only a low number of OVA specific CD4+ T cells were 
activated in the presence of 771 B cell lymphoma cells loaded with HBV core antigen control 
peptide (HBV) even though the highest T cell number was used, thereby emphasizing their 
high degree of specificity towards IAb restricted OVA peptide. 
To assess the purity of the OVA specific CD4+ T cell lines, the cells were stained using CD3, 
CD4 and CD8 specific monoclonal antibodies and analyzed by flow cytometry (Figure 3.15 
B, upper panel). The analysis revealed that only 48.6 % of the living, CD3+ OT-II 
peptide/feeder cells were also stained positive for CD4. The remaining 51.4 % of the living, 
CD3+ cell population consisted of CD8+ as well as CD4-CD8- cells. Similar frequencies were 
detected for the living, CD3+ OT-II CD3/CD28 beads cells, with the exception that no CD8+ T 
cells were present (resulting from CD4+ T cell isolation prior CD3/CD28 beads addition). The 
highest purity was detected for cells derived from the C57BL/6 immunized cell line where all 
living, CD3+ cells expressed CD4. For better characterization of the established T cell lines, 
the T cell receptor chain expression was analyzed (Figure 3.15 B, lower panel). As 
expected, all CD4+ cells of both OT-II derived cell lines expressed the T cell receptor chains 
Vα2.1 and Vβ5.1, which are known to be the OVA specific transgenic T cell receptors of 
OT-II mice. In contrast, only a small fraction (0.9 %) of C57BL/6 immunized CD4+ cells 
expressed both T cell receptor chains. The remaining cells belonged either to the 
Vα2.1+Vβ5.1- (53.7 %) or to the Vα2.1-Vβ5.1- (44.9 %) population, showing a high T cell 
receptor diversity within this CD4+ T cell line. 
Since the CD4+ T cell line established by peptide immunization of C57BL/6 mice was the 
only one consisting of pure CD4+ T cells, this cell line was used for subsequent co-culture 
experiments with PECs and TAMs. 
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Figure 3.15: Specificity and purity comparison of the different OVA specific CD4
+
 T cell lines. 
(A) Specificity of the generated T cell lines was tested in an IFNγ ELISpot assay. Therefore, 771 B 
cell lymphoma cells (5 x 10
4
) were loaded with 1 µg/ml OVA323-339 peptide or HBV core antigen128-140 
control peptide (HBV) and co-cultured with the different T cell lines for 16 h (highest T cell number: 
6250, followed by serial 1:2 dilution). The highest number of T cells was used for all negative controls 
included in the assay (HBV, T cells). Error bars represent SD of technical triplicates. (B) The T cell 
lines were stained using monoclonal antibodies specific for CD3, CD4, CD8 and the two T cell 
receptor chains Vα2.1 and Vβ5.1. The cells were subsequently analyzed by flow cytometry. Gating 
strategy: living cells → single cells (FSC-A vs. FSC-H) → CD3
+
 cells → CD4 vs. CD8 → TCR Vα2.1 
vs. TCR Vβ5.1 (within CD4
+
CD8
-
 cells). 
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3.3 Repolarization of M2-like PECs into immunostimulatory M1-like PECs in 
vitro 
As described in sections 1.1.4 and 1.2.4, the immunosuppressive tumor microenvironment 
still forms a major obstacle for successful cancer immunotherapy. In many tumor entities, 
TAMs with a M2-like phenotype contribute to the immunosuppressive tumor 
microenvironment by secreting inhibitory cytokines including IL-10 and TGF-β. Within this 
study several strategies to repolarize M2-like macrophages into immunostimulatory M1-like 
macrophages were investigated using PECs.  
3.3.1 Phenotypic analysis of in vitro polarized PECs 
In a first step, PECs were isolated from thioglycolate treated mice and analyzed by flow 
cytometry. Staining with F4/80 and CD11b specific monoclonal antibodies revealed co-
expression of the macrophage markers by more than 99 % of the cells (Figure 3.16). Next, 
PECs were polarized into M1-like or M2-like macrophages using LPS/IFNү or IL-4, 
respectively. Subsequently, the two phenotypes were characterized comprehensively by 
gene and protein expression analyses as well as functional assays.  
 
Figure 3.16: PECs contain a high percentage of macrophages. 
Four days after C57BL/6 mice were injected i.p. with 1 ml of a 3 % thioglycolate solution, PECs were 
isolated and stained with F4/80 and CD11b specific monoclonal antibodies for subsequent flow 
cytometric analysis. Left dot plot: Cell suspension immediately after isolation. Right dot plot: The 
cells were cultured for 2 h, non-adherent cells were washed off and adherent cells were harvested 
and stained. More than 99 % of all adherent PECs are F4/80
+
CD11b
+
 and thus can be considered as 
pure macrophages. Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → F4/80 vs. 
CD11b. 
As shown in Figure 3.17 A treatment of PECs with a combination of LPS and IFNү 
upregulated expression of the entire M1-associated gene panel within 4 h of stimulation as 
detected by qPCR. Some genes showed higher expression levels after prolonged 
stimulation periods (Stat1, Cd86, Cd80, Nos2), whereas expression of other M1-associated 
genes decreased after 24 h (Il6, Il12b) or 48 h (Il1b). Expression of Cxcl10 was stable 
throughout all tested time points. As expected, no M2-associated marker expression was 
observed upon stimulation with LPS/IFNγ, except for Il10 and Arg1 whose expression was 
transiently upregulated after 4 h or 24 h, respectively (Figure 3.17 B). On the other hand, 
IL-4 treatment of PECs decreased the expression of M1-associated genes being most 
pronounced after 24 h, with Cxcl9 and Cxcl10 showing strongest effects (Figure 3.17 A). 
Conversely, expression of M2-associated genes, such as Ym1, Fizz1, Arg1, Mrc1 and 
F
4
/8
0
CD11b
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Cd163 was induced upon IL-4 stimulation. Their upregulation became apparent within 4 h 
after incubation and was further increased upon prolonged stimulation (Figure 3.17 B).  
 
Figure 3.17: Gene expression analysis confirms polarization of in vitro polarized PECs. 
After isolation, PECs were polarized into M1-like (blue) or M2-like (orange) macrophages for 4 h, 24 h 
and 48 h by LPS/IFNү or IL-4 treatment, respectively. At each time point, RNA was isolated and the 
expression of M1- (A) and M2-associated genes (B) was measured using qPCR. The data obtained 
were first normalized to beta-actin (2
-∆Ct
) and subsequently normalized to expression data obtained 
from untreated PECs (2
-∆∆Ct
). (A) All M1-associated genes were upregulated in PECs treated with LPS 
and IFNγ, whereas most of the genes were downregulated in IL-4 treated PECs. (B) In contrast, most 
of the M2-associated genes were upregulated in PECs treated with IL-4 and downregulated in M1 
polarized PECs. Error bars represent 95 % CI of technical triplicates. One representative out of three 
experiments is shown. 
Next, the induced changes of M1/M2 in vitro polarization on protein level were analyzed by 
flow cytometry. Treatment with LPS/IFNγ for 48 h induced strong intracellular iNOS 
expression as well as surface expression of MHC II molecules, both representing classical 
M1-associated markers (Figure 3.18). As expected, expression of the M2-associated 
markers CD206 and Egr2 was decreased under these conditions. On the other hand, 
stimulation with IL-4 resulted in upregulated surface expression of the mannose receptor 
CD206 and in preserved Egr2 expression, whereas IAb surface expression became present 
on a small subpopulation of PECs. Similar results were observed also after shorter (24 h) 
and extended (72 h) time periods of polarization (supplementary Figure 6.4). In addition, 
polarization of PECs could be followed morphologically, as M1 like PECs appeared round 
shaped whereas M2 like PECs showed an elongated phenotype (Figure 3.19). 
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Figure 3.18: Protein expression analysis demonstrates successful polarization of PECs. 
PECs were polarized for 48 h, harvested, stained with iNOS, IA
b
, CD206 or Egr2 specific monoclonal 
antibodies and analyzed by flow cytometry. The percentage (upper panel) as well as the MFI (center) 
of marker positive cells is shown. In addition, the overlaid histograms are depicted in the lower panel. 
Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+ 
→ IA
b
 vs. FSC-H.
 
 
Figure 3.19: M1-like PECs differ phenotypically from M2-like PECs. 
PECs were isolated and polarized in M1-like or M2-like PECs by using IL-4 or LPS/IFNγ for 72 h. The 
cells were subsequently analyzed microscopically. M1-like PECs show a rounded cell shape whereas 
M2-like PECs are more elongated. 
0
20
40
60
80
100
%
 o
f 
IA
b
+
 c
e
lls
is
ot
yp
e
un
tre
at
ed
M
1-
lik
e
M
2-
lik
e
0
10000
20000
30000
40000
M
F
I 
o
f 
IA
b
+
 c
e
lls
C
o
u
n
t
0
20
40
60
80
100
%
 o
f 
C
D
2
0
6
+
 c
e
lls
un
st
ai
ne
d
un
tre
at
ed
M
1-
lik
e
M
2-
lik
e
0
200
400
600
800
M
F
I 
o
f 
C
D
2
0
6
+
 c
e
lls
M1-like M2-likeuntreatedunstained/isotype
0
20
40
60
80
100
%
 o
f 
E
g
r2
+
 c
e
lls
is
ot
yp
e
un
tre
at
ed
M
1-
lik
e
M
2-
lik
e
0
500
1000
1500
2000
2500
M
F
I 
o
f 
E
g
r2
+
 c
e
lls
0
20
40
60
80
100
%
 o
f 
iN
O
S
+
 c
e
lls
is
ot
yp
e
un
tre
at
ed
M
1-
lik
e
M
2-
lik
e
0
20000
40000
60000
80000
M
F
I 
o
f 
iN
O
S
+
 c
e
lls
iNOS
C
o
u
n
t
IAb
C
o
u
n
t
CD206
C
o
u
n
t
Egr2
iNOS IAb CD206 Egr2
untreated M1-like M2-like
4
0
 X
2
0
0
 X
Results 
83 
 
In a last step, cytokine secretion profiles of in vitro polarized PECs were analyzed using the 
LEGENDplex Mouse Inflammation Panel (Figure 3.20). This investigation was part of a 
collaboration project with the Center for Sepsis Control and Care (CSCC) in Jena and was 
performed by our collaborator Daniela Röll. The Multiplex assay includes 13 cytokines which 
are associated with a M1-like phenotype, except for IL-10 which is known to be secreted 
predominantly by M2-like macrophages. The results show that secretion of most of the 
proinflammatory cytokines (IFNβ, IFNү, IL-1α, IL-6, MCP-1, TNFα) was significantly 
increased after LPS/IFNү treatment when compared to both, untreated or IL-4 treated PECs. 
As the culture medium of polarized PECs was not exchanged prior cytokine measurement, it 
must be assumed that the detected IFNү is derived from the LPS/IFNү containing medium 
used for PECs polarization. Therefore, the measured IFNү levels only serve as internal 
positive control. Secretion of IL-12 and IL-27 was also increased in M1-like PECs but did not 
reach statistical significance. GM-CSF, IL-1β as well as IL-10 secretion was not affected by 
LPS/IFNү or IL-4 treatment. As IL-17A and IL-23 were not detected in any of the culture 
supernatants these cytokines were excluded from the analysis. 
In summary, these data demonstrate efficient in vitro polarization of PECs into macrophages 
with M1- or M2-like phenotype, as confirmed by quantitative gene and protein expression 
analyses as well as cytokine secretion analysis of M1- and M2-associated markers. 
 
Figure 3.20: Cytokine secretion of polarized PECs. 
The culture supernatants of 24 h polarized PECs were collected and analyzed using the LEGENDplex 
Mouse Inflammation Panel. The biological replicates (n = 3) are shown as individual dots and are 
connected with lines. PECs of 3-4 mice were pooled for each biological replicate. Significance was 
determined using One-way ANOVA with post-hoc Tukey test (95% CI, * p ≤ 0.05, ** p < 0.01, 
*** p ≤ 0.001). The presented data were generated jointly with Daniela Röll. 
3.3.2 Functional analysis of in vitro polarized PECs 
In order to analyze the functional capacities of putative M1- and M2- like PECs the 
phagocytic activity of polarized PECs using fluorescently labeled latex beads was measured. 
The whole assay was performed at 37 °C leading to phagocytosis mediated bead uptake. In 
comparison, PECs were incubated with beads at 4 °C, to control for unspecific binding of the 
beads to the cell surface (Figure 3.21 A). To guarantee proper quantification, the 
percentages of FITC+ cells in the 4 °C control group were subtracted from the percentages 
obtained through 37 °C incubation. 
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Figure 3.21: Differences in phagocytosis and pinocytosis confirm polarization of in vitro 
polarized PECs. 
PECs were isolated and polarized either into M1-like or M2-like macrophages for 72 h. Subsequently, 
phagocytic and pinocytic activity was determined by using fluorescent latex beads and FITC-dextran, 
respectively. (A) PECs were incubated with fluorescent latex beads at 4 °C or 37 °C and analyzed 
microscopically. (B) PECs incubated with latex beads were harvested at various time points and 
analyzed by flow cytometry (C) Similar to the phagocytic activity, M2-like PECs show a greater 
pinocytic potential compared to M1-like and M0 PECs when treated with FITC-dextran. For both 
assays, background values were determined upon incubation of cells with FITC labeled particles at 
4 °C and subtracted from the values measured after culturing at 37 °C. One out of three experiments 
with similar results is shown. Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → FITC
 
vs.
 
FSC-H. 
After incubation for 5 h, 68 % of M2-like PECs had taken up beads in comparison to 49.9 % 
of PECs polarized with LPS/IFNγ and 57.2 % of untreated macrophages (Figure 3.21 B, left). 
Moreover, after 12 h incubation M2-like PECs had taken up the double amount of beads 
compared to the LPS/IFNγ treated PECs as reflected by the MFI values (129,313 for M2-like 
macrophages versus MFI of 65,493 observed with M1 like PECs) (Figure 3.21 B, right). 
When the pinocytic activity of polarized PECs was analyzed using FITC-dextran [317, 318], 
IL-4 treated PECs turned out superior in pinocytosis compared to M1-like PECs (Figure 
4 °C 37 °C 
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3.21 C). This effect became evident within 60 min after addition of FITC-dextran, showing 
that 61.5 % of M2-like PECs and 37.6 % of M1-like PECs had pinocytosed the compound. 
After overnight incubation with FITC-dextran, all PECs had taken up the particles, regardless 
of their polarization status. However, the median fluorescence intensity values revealed that 
M2-like PECs had taken up 2.9 fold more of the compound (MFI: 5,179) compared to M1-like 
PECs (MFI: 1,762) (Figure 3.21 C, right). Of note, the pinocytic capacity of untreated PECs 
was inferior to M1-like and M2-like PECs at all time points measured. All in all, both assays 
clearly showed an increased phagocytic and pinocytic capacity of M2-like PECs compared to 
untreated or M1 polarized macrophages, thereby supporting the gene and protein 
expression data presented in section 3.3.1. 
3.3.3 Cognate interaction of CD4+ T cells with M2-like PECs 
Having observed that external addition of cytokines polarizes PECs in vitro, we next 
assessed whether cognate interaction with CD4+ T cells (generated through peptide 
immunization as described in section 2.2.12.1) would induce IFNү secretion by T cells and 
instruct PECs to acquire a M1-like phenotype. 
3.3.3.1 Susceptibility of polarized PECs to CD4+ T cell recognition 
First, the susceptibility of peptide loaded PECs to OVA specific CD4+ T cell recognition was 
examined. Therefore, PECs polarized for either 24 or 48 h were loaded with IAb restricted 
OVA peptide and co-cultured over night with OVA specific CD4+ T cells (Figure 3.22). As 
demonstrated by IFNγ ELISpot assays, peptide loaded PECs that had been polarized with 
LPS/IFNγ for 24 h were strongly recognized by OVA specific CD4+ T cells resulting in 
saturating spot numbers (i.e. > 500 IFNγ spots) (Figure 3.22, top left). In contrast, M2-like 
peptide-pulsed PECs were significantly less susceptible to CD4+ T cell recognition, similarly 
to untreated PECs loaded with antigenic peptide (119 and 100 spots, respectively). Flow 
cytometric analysis revealed IAb surface expression by 52.5 % of PECs polarized with 
LPS/IFNγ, whereas only 9.7 % of IL-4 stimulated PECs and 8.7 % of untreated PECs 
showed cell surface expression of IAb molecules (Figure 3.22, top right). When polarized for 
48 h, more than 90 % of LPS/IFNү treated PECs turned into IAb expressing cells and the 
magnitude of MHC II surface expression increased 4 fold compared to untreated PECs (MFI 
10350 vs. MFI 2586). As already observed with short term polarized PECs, maximal IFNγ 
spot formation was observed upon co-culture of T cells with peptide pulsed LPS/IFNγ treated 
macrophages. However, PECs treated for 48 h with IL-4 became less susceptible to CD4+ T 
cell recognition compared to untreated PECs (23 spots versus 52 spots) (Figure 3.22, 
bottom left), which differs from the results obtained with short term polarized PECs. Of note, 
although IL-4 polarization for 48 h induced M2-like PECs with a higher MHC II surface 
expression compared to untreated PECs (8.4 % versus 3.1 %), M2-like PECs appeared less 
susceptible to CD4+ T cell recognition, indicating that besides the amount of MHC II surface 
expression, further parameters impact on the T cell susceptibility of macrophages.  
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Figure 3.22: Susceptibility of polarized PECs to CD4
+
 T cell recognition.  
Polarized, peptide pulsed PECs were co-cultured with OVA specific CD4
+
 T cells for 24 or 48 h and 
subsequently analyzed using an IFNγ ELISpot assay. After 24 h, M2 polarized PECs demonstrate 
equal susceptibility to recognition by CD4
+ 
T cells compared to untreated PECs. However, 48 h after 
co-culturing, recognition of M2-like PECs was lower compared to untreated PECs. The staining of 
PECs using an IA
b
 specific monoclonal antibody demonstrates that this difference was not due to a 
lower frequency of IA
b
 expressing M2-like PECs. One out of three experiments with similar results is 
shown. Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+ 
→ IA
b
 vs. 
FSC-H. 
3.3.3.2 Cognate interaction with CD4+ T cells repolarizes M2-like PECs 
After showing that M2-like PECs efficiently interact with CD4+ T cells, despite their 
immunosuppressive phenotype and low MHC II expression, the next set of experiments 
should clarify whether this interaction would instruct PEC derived M2-like macrophages to 
acquire M1-like phenotype and function. Thus, PECs were polarized for 24 h into M2-like 
macrophages as confirmed by flow cytometry (Figure 3.23 A and C, upper panel), loaded 
with IAb restricted OVA peptide and co-cultured with OVA specific CD4+ T cells. 
Subsequently, PECs were analyzed for iNOS and IAb expression by flow cytometry. M2-like 
PECs co-cultured with CD4+ T cells in the presence of OVA peptide showed a strong 
upregulation of both M1-associated markers when compared to M2-like PECs loaded with 
control peptide or to PECs cultured without T cells (Figure 3.23 A, lower panel). Interestingly, 
repolarization of M2-like PECs by cognate interaction with CD4+ T cells was even more 
effective than polarization with LPS/IFNγ (compare with Figure 3.23 A, upper panel). 
Analysis performed on PECs 24 h after co-culture or treatment with LPS/IFNγ revealed that 
80.3 % of PECs had turned into MHC II positive PECs upon co-culture with CD4+ T cells, 
whereas only a 39.8 % of PECs showed IAb expression upon treatment with LPS/IFNγ. 
Assuming IFNγ released by the T cells upon recognition of the M2-like PECs to be the key 
mediator responsible for macrophage repolarization, the supernatants from the co-cultures 
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were collected to determine their IFNү concentrations by ELISA. As shown in Figure 3.23 B, 
the IFNγ concentration was increased 210 fold in supernatants of cultures that had included 
the OVA specific T cell epitope compared to supernatants from co-cultures with irrelevant 
epitope (HBV). 
 
Figure 3.23: Repolarization of M2-like PECs by CD4
+
 T cells. 
PECs were polarized with IL-4 for 24 h, loaded with 1 µg/ml IA
b
 restricted OVA peptide and 
subsequently co-cultured with ovalbumin specific CD4
+
 T cells for 24 h. (A) PECs were polarized by 
external cytokine addition (upper panel) or co-cultured with OVA specific CD4
+
 T cells (lower panel). 
Cells were harvested and stained with iNOS and IA
b
 specific monoclonal antibodies for flow cytometry 
analysis. Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+
 → iNOS/IA
b
 
vs. FSC-H. (B) Analysis of the co-culture supernatants by an IFNγ ELISA. Error bars represent SD of 
technical triplicates. (C) Gene expression analysis by qPCR after external cytokine addition (upper 
panel) or co-culture (lower panel). Data obtained by external cytokine addition were normalized to 
untreated PECs. Co-culture expression data were normalized to PECs w/o T cell addition. One out of 
three experiments with similar results is shown. Error bars represent 95 % CI of technical triplicates.  
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Next, we analyzed T cell mediated repolarization of M2-like PECs on gene expression level 
using the primer pairs described in Figure 3.17. The results show that all M1-associated 
genes were highly upregulated after co-culture with CD4+ T cells in presence of the OVA 
specific epitope (Figure 3.23 C, lower panel). In contrast, most of the M2-associated genes 
were downregulated (with the exception of Arg1 and Il10) when compared to M2-like PECs 
cultured with irrelevant peptide.  
As detected by flow cytometry as well as qPCR, the co-culture using the control peptide 
(HBV) repolarizes M2-like PECs slightly into M1-like macrophages, most likely due to the 
steady release of low amounts of IFNγ by the CD4+ T cell line even in the absence of its 
relevant peptide/MHC complex. This observation is additionally supported by the IFNү 
ELISA results (Figure 3.23 B), showing increased IFNү levels in co-cultures with CD4+ T 
cells and HBV core antigen derived control peptide compared to PECs only (w/o T cells). 
In a last step, it was tested whether the cognate interaction of M2-like PECs with CD4+ T 
cells would also result in a switch toward M1-like functionality. Therefore, PECs were 
polarized into M2-like macrophages, loaded with 5 µg/ml IAb restricted OVA peptide or 
irrelevant control peptide (HBV) and co-cultured with OVA specific CD4+ T cells for 24 h. 
Subsequently, FITC-dextran or fluorescent latex beads were added in order to test 
phagocytic or pinocytic activity, respectively. As expected, the percentage of PECs taking up 
FITC-dextran was significantly reduced in macrophages cultured with CD4+ T cells in the 
presence of the relevant peptide, pointing towards M1 repolarization (Figure 3.24 A, top). Of 
note, pinocytic activity remained unchanged in the presence of control peptide. However, the 
total amount of FITC-dextran taken up by macrophages was equal among the different 
groups (Figure 3.24 A, bottom).  
Similar results were detected after incubation of PECs with fluorescent latex beads. Already 
1 h after incubation, the proportion of FITC positive cells was significantly reduced among 
the population of M2-like PECs co-cultured with CD4+ T cells in the presence of relevant 
peptide compared to the PECs from the two control groups (Figure 3.24 B, top). These 
effects became even more pronounced after incubation for 3 h with beads. No differences in 
the total amount of phagocytosed beads were detected among the three groups of PECs 
(Figure 3.24 B, bottom), similarly to the observations made when analyzing pinocytotic 
capacity (Figure 3.24 A, bottom). 
In summary, these results clearly show that cognate interaction with CD4+ T cells can 
instruct M2-like PECs to acquire M1-like phenotype and function as shown by extensive 
gene expression analyses and functional phagocytosis and pinocytosis assays. The data 
provided a solid basis for subsequent studies, in which the cognate interaction between 
CD4+ T cells and TAMs was analyzed in vivo (see section 3.4). 
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Figure 3.24: Functional repolarization of M2-like PECs by CD4
+
 T cells. 
PECs were polarized with IL-4 for 24 h, loaded with 5 µg/ml IA
b
 restricted OVA peptide or irrelevant 
control peptide (HBV) and subsequently co-cultured with OVA specific CD4
+
 T cells for 24 h. Co-
cultured PECs were either incubated with FITC-dextran (A) or with fluorescent latex beads (B) for 1 h 
or 3 h and subsequently harvested for flow cytometric analysis. Both, phagocytic as well as pinocytic 
activity of PECs co-cultured with CD4
+ 
T cells and relevant peptide significantly decreased compared 
to the control groups. Statistical analysis was done by unpaired Student’s t-test (95% CI, * p ≤ 0.05, ** 
p < 0.01, *** p ≤ 0.001). Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → FITC vs. 
FSC-H. Error bars represent SD of biological triplicates. 
3.3.4 Identification of key transcription factors involved in PECs polarization 
The analysis of in vitro polarized PECs described in sections 3.3.1 and 3.3.2 were extended 
in order to identify the key transcription factors (TFs) mediating macrophage polarization. 
Identification of such TFs should reveal new insights into the metabolic and transcriptional 
reprogramming of macrophages and might be useful for the identification of therapeutic 
targets to reprogram M2 macrophages into the proinflammatory M1-like macrophages. 
Therefore, PECs were polarized either into a M1-like or a M2-like phenotype for 24 h, RNA 
was isolated and handed over to the Genomics and Proteomics Core Facility of the German 
Cancer Research Center (Heidelberg, Germany) to perform whole RNA sequencing. A 
detailed workflow as well as the purity and polarization check of isolated PECs is illustrated 
in Figure 3.25 A-C.  
The sequencing data were analyzed by our collaboration partners at the Center for Sepsis 
Control and Care in Jena by using their previously published tool, which enables the 
investigation of transcriptional regulation of gene expression profiles [319]. At the same time 
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they used their newly developed method based on mixed-integer-linear programming which 
integrates gene expression data into flux balance models (unpublished). Based on these 
methods, five TFs responsible for the regulation of signaling genes and metabolic genes in 
polarized macrophages were determined (section 3.3.4.2). In order to validate the functional 
relevance of the transcription factors in PEC polarization, their expression was either 
knocked down by siRNA transfection or upregulated by transfecting TF encoding plasmids. 
Thereafter, the polarization of the macrophages was analyzed by qPCR and measuring 
cytokine secretion (section 3.3.4.4).  
 
Figure 3.25: Experimental workflow for the generation of whole RNA sequencing data from 
polarized PECs.  
(A) Three mice were injected i.p. with 1 ml of 3 % thioglycolate solution. Four days later, PECs were 
isolated and polarized into M1-like or M2-like macrophages or left untreated (three wells per condition 
per mouse). After overnight polarization, the triplicate wells were pooled for subsequent RNA 
isolation. The pooling was necessary to obtain the required amount of RNA for whole RNA 
sequencing. (B) The purity of isolated macrophages was assessed by flow cytometry after staining 
with F4/80 and CD11b specific monoclonal antibodies. (C) After the polarization of macrophages was 
confirmed by qPCR, the RNA samples were sent for sequencing. As example, expression of Cxcl10 
and Fizz1 representing classical M1-like and M2-like markers, respectively are shown. Error bars 
represent SD of biological triplicates. 
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3.3.4.1 Correlation between RNA sequencing and qPCR data 
In a first validation, the obtained RNA sequencing data were compared and correlated with 
the respective qPCR data (see Figure 3.17) to ensure that both methods yielded comparable 
results. In Figure 3.26 A, Log(10)RPKM (reads per kilobase million) values obtained from 
RNA sequencing were compared to log(10)2-∆Ct values measured by qPCR 24 h after PECs 
polarization. Both methods yielded corresponding results considering the upregulation of 
genes in polarized macrophages compared to untreated PECs (marked in red). However, 
qPCR analysis revealed a higher sensitivity in detecting downregulated genes in polarized 
macrophages (marked in blue) which resulted in differences between the two datasets. 
The higher sensitivity of the qPCR method became even more apparent when the two 
datasets were plotted against each other, presenting each analyzed gene as an individual 
dot (Figure 3.26 B). Many genes with low expression level were located close to the y-axis 
(red dots showing little distribution across the x-axis) since the RNA sequencing sensitivity is 
not high enough to detect small differences in their expression level. In contrast, these small 
differences were still detected by qPCR as the same genes distribute throughout a wide 
range of the y-axis. 
 
Figure 3.26: Correlation between RNA sequencing and qPCR data. 
(A) Log(10)RPKM values obtained through RNA sequencing were compared to log(10)2
-∆Ct
 values 
measured by qPCR 24 h after PECs polarization. Genes significantly upregulated or downregulated 
compared to M0 are highlighted in red and blue, respectively. Genes with no significant change 
compared to M0 are marked in grey. (B) The correlation between RNA sequencing and qPCR data 
was illustrated by plotting the two datasets against each other. Each dot represents one gene. 
Numbers depicted in the graphs give the calculated coefficients of determination (R
2
). 
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In summary, both methods detected in 76 % (29/38) of all cases the same up- or 
downregulation compared to untreated PECs (Figure 3.26 A). In 18 % (7/38) of the cases, a 
downregulation was detected by qPCR, whereas no change in expression level was 
detected by RNA sequencing which can be explained by the aforementioned lower 
sensitivity of the latter method. Most importantly, the methods never showed contradictory 
results in terms of up- and downregulation of a given gene (e.g. upregulation detected by 
qPCR and downregulation detected by RNA sequencing) and as such support and 
supplement the qPCR data obtained from polarized PECs (Figure 3.17). 
3.3.4.2 In silico predicted TFs are highly expressed in M2-like PECs 
Based on the methods described in section 3.3.4, five TFs (CTCF, E2F1, MYC, PPARү and 
STAT6) important for maintaining a M2-like phenotype in IL-4 treated PECs were identified. 
Analysis of the RNA sequencing data demonstrated a strong downregulation of all five TFs 
in LPS/IFNү treated PECs compared to untreated cells (Figure 3.27 A). In contrast, the 
expression level in M2-like PECs was either upregulated (Ctcf, Myc and Pparg) or 
downregulated (E2f1 and Stat6) compared to M0, but consistently higher as in M1-like 
macrophages. 
 
Figure 3.27: Expression level and activity of selected transcription factors. 
PECs were polarized for 24 h into M1-like or M2-like macrophages and subsequently analyzed by 
RNA sequencing. (A) Z-scores and (B) activities of selected transcription factors revealed a higher 
expression level as well as a higher activity of all five factors in M2-like compared to M1-like PECs. 
Three biological replicates for each condition are shown. The presented data were generated jointly 
with Franziska Hörhold. 
Similar results were obtained when the TF activities were calculated and plotted in a 
heatmap as shown in Figure 3.27 B. The activity is an estimation of the overall impact of a 
TF on its target genes and can differ substantially from the expression level [320]. For 
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instance, the expression level of Stat6 is higher in untreated PECs compared to IL-4 treated 
cells, whereas the opposite is true for its calculated activity. Thus, the overall impact of 
STAT6 on its target genes is higher in M2-like PECs compared to untreated cells even 
though the expression level is lower.  
All five in silico predicted TFs demonstrated a high activity in M2-like PECs and a low activity 
in M1-like PECs, supporting the gene expression data presented in Figure 3.27 A and 
emphasizing their importance in maintaining the M2-like phenotype.  
3.3.4.3 Transfection of PECs with plasmids and siRNAs 
Strategies to experimentally validate the TFs predicted in silico involve on the one hand their 
overexpression and on the other hand their knockdown. In both strategies, transfection of 
PECs using either TF encoding plasmids (overexpression) or TF targeting siRNAs 
(knockdown) is required. However, macrophages are generally considered as hardly 
transfectable cells as they are equipped with a large amount of potent degradative enzymes 
that can disrupt integrity of the delivered nucleic acids [321].  
Based on that knowledge, PECs were transfected with a GFP encoding plasmid using 10 
reagents developed for transfection of primary “hard-to-transfect” cells. Most of the 
transfection reagents were tested using two different cell densities and varying 
DNA:transfection reagent ratios. The specific conditions as well as the percentages of GFP+ 
cells for all the tested approaches can be looked up in Table 6.1. As shown in Figure 3.28, 
only in 4 of 75 tested approaches the transfection efficiency exceeded 10 %. These included 
Lipo-LTX approach 3 (14.3 %), TransIT-2020 approach 1 and 2 (10.7 % and 11.1 %) and 
Viromer Red approach 5 (15.1 %), using 1 x 106 PECs. Even when GFP encoding RNA 
(pos. ctrl. RNA) in combination with Viromer Red was used, only 17.4 % of the macrophages 
were successfully transfected. In contrast, control transfection of B16F10 cells using the 
GFP encoding plasmid resulted in transfection efficiencies above 70 % for most of the 
transfection reagents, except for TurboFect (17.7 %) and Effectene (19.1 %), demonstrating 
that the plasmid as well as the reagents were working (supplementary Figure 6.5). 
As the establishment of additional transfection strategies like electroporation or viral 
transduction would have taken too long, the strategy of TF overexpression was not pursued 
further. 
Instead, the focus was placed on knocking down the TFs using siRNA pools. In order to find 
the most suitable transfection reagent to deliver siRNA to PECs, the cells were transfected 
with a fluorescently labelled (Cy3) siRNA testing four transfection reagents optimized for 
small RNA transfection. The transfection efficiency was determined by measuring the 
percentage of Cy3+ cells by flow cytometry 24, 48 and 72 h post transfection. The 
histograms in Figure 3.29 A revealed an almost 100 % transfection efficiency for all tested 
transfection reagents already 24 h post transfection using either 25 or 50 nM Cy3 coupled 
siRNA. However, increasing cytotoxicity during the course of transfection was observed, with 
Lipofectamine and Metafectene being the most cytotoxic reagents (Figure 3.29 B; % of living 
cells). Comparing the Cy3 MFI values of the two transfection reagents with less cytotoxic 
effects (DharmaFect4 and siLentFect) showed that more siRNA is taken up if transfection 
was performed with DharmaFect4, no matter which siRNA concentration was used (Figure 
3.29 B; MFI of Cy3+ cells). Due to its low cytotoxicity and high transfection efficiency, 
DharmaFect4 was selected for subsequent knockdown experiments.  
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Figure 3.28: Transfection of PECs with GFP encoding plasmid. 
Either 1 x 10
6
 or 2 x 10
6
 untreated PECs were transfected with a GFP encoding plasmid using 10 
different transfection reagents. For each reagent several transfection approaches were tested as 
recommended by the manufacturer and shown in more detail in Table 6.1. Macrophages were 
harvested and analyzed by flow cytometry 48 h post transfection. The numbers given within the 
graphs represent the percentages of GFP positive cells. Gating strategy: living cells → single cells 
(FSC-A vs. FSC-H) → GFP vs. FSC-H. 
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Figure 3.29: Transfection of PECs with siRNA using different transfection reagents.  
PECs were isolated from thioglycolate treated mice and dispensed in 6-Well plates (2 x 10
6
). Cells 
were transfected either with 25 nM or 50 nM of Cy3 coupled siRNA using DharmaFect4, 
Lipofectamine, Metafectene or siLentFect transfection reagent. (A) 24, 48 and 72 h post transfection, 
PECs were harvested and analyzed by flow cytometry. Gating strategy: living cells → single cells 
(FSC-A vs. FSC-H) → Cy3
+
 vs. FSC-H. (B) Table showing the percentages of living and Cy3
+
 cells as 
well as the median fluorescence intensity values (MFI) of Cy3
+
 cells. 
The results shown in Figure 3.29 demonstrated an efficient uptake of small RNA molecules 
by macrophages. However, as mentioned before macrophages are specialized in degrading 
internalized molecules rapidly. Therefore, it is possible that transfected small RNAs are a 
target for degradation, whereas the fluorescent dye Cy3 remains stable in the cytoplasm, 
thus leading to false positive results when transfection efficiency is determined by Cy3 
coupled siRNA. To rule out degradation of transfected small RNAs, a random miRNA which 
was available in the lab (miRNA-339-5p) was transfected into PECs. Small RNAs were 
isolated 24, 48 and 72 h post transfection and the presence of miRNA-339-5p was evaluated 
by qPCR. As shown in Figure 3.30, the detected endogenous expression of miRNA-339-5p 
measured in untreated PECs was low. As expected, the expression level measured in PECs 
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treated with the transfection reagent only (mock) was comparable to untreated PECs. In 
contrast, the detectable amount of miRNA-339-5p 24 h post PECs transfection was 
increased 2290 fold compared to the corresponding mock control, demonstrating successful 
transfection. As the miRNA was still detected in high quantities after prolonged culturing (48 
and 72 h post transfection), it can be concluded that internalized small RNAs are stable in 
PECs for at least 3 days.  
 
Figure 3.30: Transfected miRNA-339-5p is taken up by PECs and stable for at least 72 h.  
Unpolarized PECs were isolated from thioglycolate treated mice, dispensed in 6-Well plates (2 x 10
6
) 
and transfected with 25 µM of miRNA-339-5p using DharmaFect4 transfection reagent. 24, 48 and 
72 h post transfection, PECs were harvested for subsequent miRNA isolation. The presence of 
miRNA-339-5p was analyzed by qPCR using a miRNA-339-5p specific primer pair. The data were 
normalized to snoRNA202 which serves as internal control. Error bars represent SD of technical 
triplicates.  
3.3.4.4 Experimental validation of the in silico predicted transcription factors 
In a last step, the in silico predicted TFs were experimentally validated. As described above, 
all five TFs were predicted to be involved in maintenance of the M2-like phenotype. Hence, 
knocking down these proteins should induce a repolarization into proinflammatory M1-like 
PECs. To investigate changes in PEC polarization upon TF knock down, PECs were 
polarized into M2-like macrophages using IL-4, transfected with TF targeting siRNA pools 
and analyzed by measuring gene expression (Figure 3.31) as well as cytokine secretion 
(Figure 3.32). All the obtained qPCR data were normalized to the housekeeping gene Rpl19, 
as in silico predictions from various sources [322-327] demonstrated that this gene is almost 
not regulated by the five TFs, thereby guaranteeing stable expression after TF knockdown 
(Table 3.2). Additionally, Rpl19 expression was not affected by LPS/IFNү or IL-4 treatment, 
making it a suitable and reliable housekeeping gene for subsequent knockdown experiments 
(Table 3.2, log2 fold change). As pilot experiments demonstrated inefficient knock down of 
CTCF (data not shown), subsequent experiments were performed either by knocking down 
all five TFs (5 TFs) or only four of them, excluding Ctcf (4 TFs).  
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Table 3.2: In search of an appropriate housekeeping gene for qPCR analysis of 
polarized PECs. 
The BaseMean values were obtained from RNA sequencing data and serve as a measure of the 
expression level of a certain gene across all tested samples. The subsequent columns show whether 
the housekeeping genes are regulated by the different TFs. The numbers are based on in silico 
predicted as well as validated interactions between TFs and housekeeping genes (arbitrary unit: the 
higher the value the stronger the predicted regulation). The log(2) fold change values present the fold 
change expression between M1-like and M2-like PECs. A fold change of 0, showing that the 
housekeeping gene expression is not affected by LPS/IFNү or IL-4 treatment, would be ideal. The 
presented data were generated jointly with Franziska Hörhold. 
Gene Full Name 
Base 
Mean 
Ctcf E2f1 Myc Pparg Stat6 Sum 
log(2) 
fold 
change 
Actb actin beta 48061 0 3.2 3.5 0 0 6.7 0.39 
B2m beta-2 microglobulin 125058 0 1 2 0 0 3 1.96 
Gapdh 
glyceraldehyde-3-
phosphate dehydrogenase 
2239 0 0.7 1 0 0 1.7 2.45 
Gusb glucuronidase, beta 15590 0 0.7 2.5 0 0 3.2 -1.27 
Hmbs 
hydroxymethylbilane 
synthase 
409 0 0.7 2.5 0 0 3.2 -0.89 
Hprt 
hypoxanthine guanine 
phosphoribosyl transferase 
2361 0 0 2 0 0 2 0.28 
Ppia peptidylprolyl isomerase A 2894 0 1.2 2 0 0 3.2 0.06 
Rn18s 18S ribosomal RNA n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Rpl13a ribosomal protein L13a 4281 0.5 1.2 3.5 0 0 5.2 -0.08 
Rpl19 ribosomal protein L19 1777 0 1.2 1.5 0 0 2.7 -0.08 
Tbp TATA-box binding protein 559 0.5 0 1 0 0 1.5 0.25 
Ubc ubiquitin C 28430 0 1.2 0.7 0 0 1.9 1.25 
  
n.a. = not available 
The knockdown efficiency for the different TFs was measured on RNA level by qPCR 24 h or 
48 h post transfection as shown in Figure 3.31 A. In contrast to the results obtained in the 
aforementioned pre-experiments, the knockdown of all five TFs was successful and detected 
already 24 h after siRNA pool transfection. All TFs reached a log(2) 2-ΔΔCt value of -0.5 and lower 
which corresponds to a knockdown efficiency of at least 30 % compared to the samples treated 
with a negative control siPool (knockdown efficiency = 100 – 2 log(2) 2-ΔΔCt). In some cases (e.g. 
Myc and Pparg) knockdown efficiencies of 75 %, corresponding to a log(2) 2-ΔΔCt value of -2, 
were achieved. After 48 h the expression of all five TFs was still reduced when PECs were 
treated with all siRNA pools (5 TFs). In contrast, E2f1 expression increased again, reaching 
physiological conditions if the Ctcf targeting pool was not transfected (4 TFs). As expected, 
knocking down all five TFs resulted in strong induction of M1-associated gene expression within 
24 h of transfection (Figure 3.31 B). Some genes showed higher expression levels after 
prolonged transfection periods (Arg2, Il1b, Stat1) whereas expression of other genes decreased 
again after 48 h (Cxcl9, Cxcl10, Il12b, Nos2). In contrast expression of M2-associated genes 
was decreased upon siRNA transfection, except for Ppat and Tgfb1 whose expression was 
upregulated after 48 h. Interestingly, using only E2f1, Myc, Pparg and Stat6 targeting siRNA 
pools (knockdown of 4 TFs) resulted in almost the same gene expression patterns (Figure 
3.31 C). 
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Figure 3.31: Transcription factor knockdown results in M1-associated gene expression.  
PECs were polarized for 24 h into M2-like macrophages using IL-4 and subsequently transfected with 
siRNA pools targeting 5 (dark grey) or 4 (light grey) transcription factors. Ctcf, E2f1, Pparg and Stat6 
targeting siRNA pools were used in a final concentration of 10 nM, whereas the Myc targeting siRNA 
pool was used in a final concentration of 50 nM. (A) Gene expression analysis of the targeted 
transcription factors. (B-C) The expression of M1- and M2-associated genes was analyzed 24 and 
48 h post transfection. The presented data was first normalized to the housekeeping gene Rpl19 (2
-
ΔCt
) and subsequently normalized to the data obtained after transfecting the negative siRNA pool 
(2
-ΔΔCt
). The final concentration of the negative siRNA pool was 90 nM (5 TFs) or 80 nM (4 TFs). Error 
bars of qPCR data represent SD of technical triplicates. One representative out of three similar 
experiments is shown. 
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The gene expression analysis shown in Figure 3.31 revealed that knocking down Ctcf is not 
necessarily required for successful repolarization of M2-like PECs. Thus, the Ctcf targeting 
siRNA pool was excluded for subsequent experiments in which cytokine secretion of 
transfected PECs was analyzed. The measurement of the conditioned culture medium was 
done by Daniela Röll (Integrated Research and Treatment Center, Center for Sepsis Control 
and Care (CSCC), Jena, Germany) using the LEGENDplex Mouse Inflammation Panel. As 
already mentioned in section 3.3.1 all included cytokines, except for IL-10 are associated 
with a M1-like phenotype.  
 
Figure 3.32: Cytokine secretion of PECs post transcription factor knockdown. 
PECs were polarized with IL-4 for 24 h and transfected with siRNA pools targeting E2f1, Myc, Stat6 
and Pparg for 24, 48 and 72 h. E2f1, Pparg and Stat6 targeting siRNA pools were used in a final 
concentration of 10 nM, whereas the Myc targeting siRNA pool was used in a final concentration of 
50 nM. The final concentration of the negative siRNA pool was 80 nM. The culture medium was 
collected and analyzed using the LEGENDplex Mouse Inflammation Panel. The biological replicates 
(n = 3) are shown as individual dots and are connected with lines. PECs of 3-4 mice were pooled for 
each biological replicate. Significance was determined using paired Student’s t-test (95% CI, ns = not 
significant, * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001). nd = not detected. The presented data were 
generated jointly with Daniela Röll. 
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As shown in Figure 3.32, already 24 h after transfecting M2-like PECs the quantities of 
several M1-associated cytokines (IFNβ, IL-1α, IL-6, IL-27, MCP-1, TNFα) were increased in 
culture medium of cells treated with the TF targeting siRNA pools (combi siPool) compared 
to the culture medium of cells that received the negative siRNA pool (neg. combi siPool). 
The differences between the two groups became even more prominent after prolonged 
transfection periods resulting in significantly higher amounts of all aforementioned cytokines 
upon TF knock down (48 h or/and 72 h post transfection). Secretion of IL-10, the only M2-
associated cytokine within the tested panel was either not affected by TF knock down (24 h 
and 72 h) or decreased without reaching statistical significance (48 h). GM-CSF, IFNү and 
IL-1β secretion did not change upon TF knock down at any of the tested time points. 
In summary, these data demonstrate efficient in vitro repolarization of M2-like PECs into 
macrophages with M1-like phenotype mediated through TF knock down as confirmed by 
quantitative gene expression and cytokine secretion analysis. 
3.3.5 Identification of key miRNAs involved in PECs polarization 
In a next set of experiments, miRNA expression profiles of polarized PECs were generated 
in order to identify miRNAs involved in the process of polarization. Therefore, PECs were 
polarized either into M1-like or M2-like macrophages for 24 h using LPS/IFNү or IL-4, 
respectively. In addition, M2 polarized PECs were loaded with OVA323-339 epitope and 
subsequently co-cultured with ovalbumin specific CD4+ T cells (T cells + OVA peptide) to 
induce repolarization into M1-like macrophages as described in section 3.3.3. Small RNAs 
were isolated and handed over to the Genomics and Proteomics Core Facility of the German 
Cancer Research Center (Heidelberg, Germany) to perform small RNA sequencing. A 
detailed workflow illustrating all tested conditions is shown in Figure 3.33 A. The polarization 
of PECs upon cytokine treatment Figure 3.33 B as well as the repolarization upon co-culture 
with OVA specific CD4+ T cells Figure 3.33 C was confirmed by qPCR prior small RNA 
sequencing. In a first step, our collaboration partners at the Center for Sepsis Control and 
Care in Jena used the DESeq2 method [314] to identify differentially expressed miRNAs in 
each group (section 3.3.5.1). Next, the RNA sequencing data of previous experiments 
(section 3.3.4) were integrated in the analysis, thereby facilitating the identification of 
significantly enriched miRNAs as described in section 3.3.5.2. Finally, several significantly 
enriched miRNAs were transfected into PECs in order to validate their functional relevance 
in macrophage polarization (section 3.3.5.3).  
The results of these experiments could reveal new insights into the regulation of 
macrophage polarization mediated by miRNAs. Additionally, the small RNA expression 
profile of PECs repolarized by cognate interaction with CD4+ T cells was compared to that of 
PECs polarized by the addition of cytokines. Thereby it is possible to elucidate which 
changes in miRNA expression levels are dependent on T cell receptor signaling. 
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Figure 3.33: Experimental workflow for the generation of small RNA sequencing data from 
polarized PECs.  
(A) Three mice were injected i.p. with 1 ml of 3 % thioglycolate solution. Four days later, PECs were 
isolated and dispensed in 6-Well plates (2 x 10
6
). The cells were polarized into M1-like or M2-like 
macrophages or left untreated (three wells per condition per mouse). After overnight polarization, 
triplicate wells were pooled for subsequent miRNA isolation. Pooling was necessary to obtain the 
required amount of miRNA for small RNA sequencing. Additionally, some M2-like PECs were loaded 
with 5 µg/ml OVA323-339 peptide (T cells + OVA peptide) or HBV core antigen128-140 peptide (T cells + 
HBV peptide) and co-cultured using OVA specific CD4
+
 T cells for 24 h. Next, triplicate wells were 
pooled and miRNA was isolated. (B) Polarization of macrophages by cytokine addition as well as (C) 
successful repolarization into M1-like PECs upon co-culture with OVA specific CD4
+
 T cells was 
confirmed by qPCR. As example, expression of Cxcl10 and Fizz1 representing classical M1-like and 
M2-like markers, respectively are shown. Error bars represent SD of biological triplicates. 
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3.3.5.1 Differentially expressed miRNAs in polarized PECs 
 
Figure 3.34: Differentially expressed miRNAs in polarized PECs. 
PECs were left untreated or polarized for 24 h into M1-like or M2-like macrophages. In addition, 
M2-like PECs were loaded with OVA323-339 peptide (T cells + OVA peptide) or HBV core antigen 
peptide128-140 (T cells + HBV peptide) and co-cultured for 24 h with OVA specific CD4
+
 T cells. RNA 
expression was analyzed by whole RNA sequencing. Differentially expressed miRNAs were 
determined by using the DESeq2 software package [314]. The presented data were generated jointly 
with Franziska Hörhold. 
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As shown in Figure 3.34, the tested conditions (untreated, M1-like, M2-like etc.) were 
arranged into respective groups (e.g. M1-like vs. untreated) to determine differential gene 
expression using the DESeq2 software package [314]. A miRNA was only considered as 
significantly differentially expressed if the average expression level was high enough (base 
mean ≥ 97.034) and the p-value less or equal than 0.05. Each of the listed miRNAs is 
significantly differentially expressed in at least one of the groups. The z-scores of all 56 
differentially expressed miRNAs are shown in supplementary Figure 6.6. 
As shown in Figure 3.34, none of the 56 listed miRNAs was significantly differentially 
expressed when M2-like PECs were compared to untreated cells. In accordance with that, 
the signatures of differentially expressed genes within the two groups M1-like vs. untreated 
and M1-like vs. M2-like were similar. The same holds true if the signatures of the groups 
T cells + OVA peptide vs. M2-like and T cells + OVA peptide vs. untreated were compared. 
Of note, 29 miRNAs were significantly differentially expressed in the group M1-like vs. 
T cells + OVA peptide, clearly demonstrating that M1-like PECs polarized by external 
cytokine addition (LPS/IFNү) are different from M2-like PECs which were repolarized into 
M1-like by CD4+ T cells. Interestingly, such differences were not detected by gene 
expression analysis already described in Figure 3.23 C (upper vs. lower panel). 
3.3.5.2 Significantly enriched miRNAs in polarized PECs 
miRNAs significantly up- or downregulated in M1-like vs. untreated and M1-like vs. M2-like 
are of particular interest as they might be important in maintaining a M1-like or M2-like 
phenotype, respectively. To narrow down the number of miRNAs to be validated in 
subsequent in vitro experiments, the RNA sequencing data obtained from previous 
experiments (section 3.3.4) were incorporated in the bioinformatics analysis to identify 
significantly enriched miRNAs within these two groups.  
The first step to identify significantly enriched miRNAs was the collection of putative target 
genes of each differentially expressed miRNA using several prediction algorithms 
(Microcosm, miRanda, miRNAMap2, miRMap, miRDB, PITA, Pictar and TargetScan) as well 
as a database in which only validated targets are listed (MiRTarBase). A gene was only 
considered as target if a miRNA binding site was predicted by at least two of the 
aforementioned tools. Next, the fold change expression value of a miRNA within one of the 
groups (e.g. M1-like vs. M2-like) was compared to the fold change expression level of a 
certain differentially expressed target within the same group. Subsequently, the Fisher’s 
exact test determines whether enough targets show opposing expression fold changes 
compared to the miRNA expression fold change. For instance, if a miRNA is upregulated in 
M1-like vs. M2-like (positive fold change), a certain number of its targets must show a 
downregulation in RNA expression level when comparing M1-like vs. M2-like (negative fold 
change). Only then, a miRNA was considered to be significantly enriched. 
All of the 18 differentially expressed miRNAs in the group M1-like vs. untreated were 
identified to be significantly enriched. In the group M1-like vs. M2-like, 18 out of 19 
differentially expressed miRNAs were significantly enriched with miR-221-5p being the only 
exception. Combining the results obtained from both groups revealed a total of 22 miRNAs 
enriched in M1-like PECs compared to either untreated PECs or M2-like PECs or both. As 
shown in Figure 3.35, plotting the z-scores of these 22 miRNAs in a heatmap resulted in 3 
distinct clusters. The first cluster contains 6 miRNAs only upregulated in M1-like PECs, 
whereas the 7 miRNAs from the second cluster are upregulated in M1-like PECs and PECs 
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co-cultured with T cells and IAb restricted OVA peptide (323-339). In contrast, miRNAs from 
the third cluster were downregulated in M1-like PECs as well as in PECs co-cultured with T 
cells and OVA peptide. 
 
Figure 3.35: Significantly enriched miRNAs in PECs polarized by addition of cytokines or by 
cognate T cell interaction. The presented data were generated jointly with Franziska Hörhold. 
In a last step, several significantly enriched miRNAs were selected for further validation 
based on their expression levels (base mean) and fold change expression in M1-like vs. 
untreated and M1-like vs. M2-like (Table 3.3, bold and italicized). miRNAs with a high 
expression level and high fold changes were preferentially selected as these are most likely 
the miRNAs causing the strongest changes in macrophage polarization. 
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Table 3.3: miRNAs significantly enriched in polarized PECs 
The presented data were generated jointly with Franziska Hörhold. 
miRNA Base Mean 
log(2) 
fold change 
 M1-like vs. 
untreated 
M1-like vs. 
M2-like 
 mmu-miR-99b-3p 290,25 1.95 2.33 up
re
g
u
la
te
d
 in
  
M
1
-lik
e
 
mmu-miR-222-5p 98,37 0.64 0.65 
mmu-let-7e-5p 1963,41 1.38 1.73 
mmu-miR-99b-5p 7944,62 1.05 1.09 
mmu-miR-221-5p 4826,18 0.81 n.a. 
mmu-miR-200c-3p 156,91 n.a. 0.58 
mmu-let-7i-5p 315259,46 0.47 0.45 u
p
re
g
u
la
te
d
 in
  
M
1
-lik
e
 a
n
d
 T
 c
e
lls
 
+
 O
V
A
 p
e
p
tid
e
 
mmu-miR-210-3p 126,49 2.64 2.56 
mmu-miR-222-3p 3672,03 0.57 0.55 
mmu-miR-674-5p 210,19 1.9 1.64 
mmu-miR-146a-5p 27291,59 1.74 2.26 
mmu-miR-28a-3p 1473,67 0.47 0.52 
mmu-miR-361-5p 217,77 n.a. 0.46 
mmu-miR-107-3p 98,27 -0.72 n.a. 
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e
 
mmu-miR-27a-5p 2437,14 -0.75 -0.93 
mmu-miR-339-5p 255,71 -0.51 n.a. 
mmu-miR-181a-1-3p 213,54 n.a. -0.94 
mmu-miR-30e-3p 1653,18 -0.35 n.a. 
mmu-miR-744-5p 3323,79 n.a. -0.67 
mmu-miR-1198-5p 4230,84 -0.95 -0.88 
mmu-miR-27b-5p 292,09 -0.52 -0.66 
mmu-miR-27b-3p 174854,19 -0.32 -0.39 
          
n.a. = not available, since this miRNA was not differentially expressed in 
this comparison 
3.3.5.3 Experimental validation of significantly enriched miRNAs 
In a last step, the function of six miRNAs (miR-210-3p, miR-674-5p, miR-222-3p, let-7i-5p, 
miR-146a-5p and miR-28a-3p) which were upregulated in M2-like PECs upon CD4+ T cell 
co-culture (T cells + OVA peptide) was further investigated. As the same miRNAs were also 
differentially expressed in M1-like PECs, transfection of these miRNAs in M0 or M2-like 
PECs might mediate polarization towards a M1-like phenotype. 
To investigate changes in PEC polarization upon miRNA transfection, PECs were either left 
untreated (M0) or polarized into M2-like macrophages for 24 h using IL-4. Subsequently, a 
pool of the six miRNAs was transfected in which each miRNA had a final concentration of 
either 10 nM or 20 nM. The induced changes in macrophage polarization were analyzed 
48 h post transfection by measuring expression of M1- and M2-associated genes (Figure 
3.36). Similar to gene expression analysis after TF knockdown, all data obtained after 
miRNA transfection were first normalized to the housekeeping gene Rpl19 and subsequently 
to expression data obtained from cells treated with transfection reagent only (mock). As 
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shown in Table 6.2, miR-222-3p was the only miRNA predicted to have a binding site in the 
3’ UTR region of Rpl19. However, as this binding site was only predicted by one out of nine 
in silico prediction tools, Rpl19 was considered as a suitable housekeeping gene for gene 
expression analysis following transfection of the six miRNAs. 
 
Figure 3.36: miRNA transfection results in M1-associated gene expression.  
PECs were either left untreated (A) or polarized for 24 h into M2-like macrophages using IL-4 (B). 
Subsequently, the cells were transfected with a pool of miRNAs consisting of miR-210-3p, 
miR-674-5p, miR-222-3p, let-7i-5p, miR-146a-5p and miR-28a-3p, whereby each miRNA has a final 
concentration of either 10 or 20 nM. The expression of M1- and M2-associated genes was analyzed 
48 h post transfection. Error bars represent SD of technical triplicates. One representative out of two 
similar experiments is shown. n.d. = not detected. 
As expected, transfection of the miRNA pool in M0 PECs resulted in strong induction of M1-
associated gene expression 48 h post transfection, except for Ldha and Stat1 whose 
expression was slightly downregulated (Figure 3.36 A, left). Some genes showed higher 
expression levels after transfection with higher miRNA concentrations (Cd86, Cxcl9 and 
Cxcl10) whereas expression of other genes decreased (Il1b). Expression of Il12b and Nos2 
was not detectable. On the other hand, expression of several M2-associated genes was 
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downregulated upon miRNA transfection being most pronounced when using 20 nM of each 
miRNA, with Fizz1 and Ym1 showing strongest effects (Figure 3.36 A, right). Unexpectedly, 
expression of Mrc1 and Arg1, both representing typical M2-associated genes, were 
upregulated upon transfection with the pool containing 10 nM of each miRNA. Mrc1 was 
expressed even to higher extend when the miRNA concentration was increased, whereas 
Arg1 expression was downregulated. The second approach, in which M2-like PECs were 
transfected with the pool of miRNAs resulted in similar expression patterns (Figure 3.36 B), 
with some genes showing higher (Il1b, Il12b and Stat1) and others showing lower (Cxcl9, 
Cxcl10, Fizz1 and Ym1) expression (compare to Figure 3.36 A). 
In summary, these preliminary data demonstrate the potential of using only a small number 
of miRNAs to induce detectable changes in PEC polarization. However, additional analysis 
including cytokine secretion assays, flow cytometry analysis and functional assays are 
required to get a more comprehensive data set and to draw final conclusions. 
3.4 Interaction of OVA specific CD4+ T cells and TAMs 
As presented in section 3.3, OVA specific CD4+ T cells can efficiently interact with M2-like 
PECs inducing their repolarization in vitro, although these PECs showed a marked 
immunosuppressive phenotype and low MHC II expression. In a next set of experiments we 
investigated whether CD4+ T cell mediated repolarization would also occur among tumor 
associated macrophages in vivo. We therefore transferred OVA specific CD4+ T cells into 
syngenic M2KO/OVA-F tumor bearing mice and analyzed phenotypical changes of freshly 
isolated TAMs. 
3.4.1 Characterization of TAMs in OVA expressing B16F10 tumors 
In a first pilot experiment, B16F10/OVA-F cells expressing the full length OVA were used to 
determine TAM polarization at different tumor stages. Therefore, tumors generated in 
C57BL/6 mice upon s.c. injection were harvested and analyzed by flow cytometry either 12 
or 14 days post tumor cell inoculation. As shown in Figure 3.37 A, tumors in a later stage 
(14 days) were larger, whereas tumors in an earlier stage (12 days) were smaller than 
1000 mm3. Tumors in a later stage contained higher proportions of CD206+ (i.e. M2-like) 
TAMs (F4/80+CD11b+Gr1-), but equal proportions of IAb positive TAMs (i.e. M1-like) (Figure 
3.37 B, left). Of note, the IAb expression levels of TAMs were strongly reduced in larger 
tumors (Figure 3.37 B, right), thus pointing towards accumulation of CD206 positive TAMs 
with reduced IAb expression in these tumors. The absolute number of TAMs in the whole 
tumor was significantly higher in late stage tumors (8.6 x 105 cells) with a fold change 
increase of about 2.5 compared to early stage tumors (3.3 x 105 cells) (Figure 3.37 C). 
Strikingly, CD206 expressing TAMs increased 4.6 fold whereas IAb expressing TAMs did 
only increase 2.3 fold, showing that M2-like TAMs accumulated twice as much compared to 
M1-like TAMs (Figure 3.37 D). 
These results show that TAMs with reduced expression of a typical M1-like marker (IAb) and 
increased expression of a well characterized M2-like marker (CD206) are present in higher 
frequencies and total numbers in late stage B16F10/OVA-F tumors compared to tumors in 
an earlier stage. 
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Figure 3.37: Analysis of TAMs in different B16F10/OVA-F tumor stages. 
C57BL/6 mice were injected s.c. with 2 x 10
5
 B16F10/OVA-F cells. Twelve or 14 days post tumor cell 
injection, tumors were isolated and analyzed by flow cytometry. (A) Correlation between tumor weight 
and tumor volume of all analyzed tumors. Early and late stage tumors are separated by the vertical 
dotted line. (B) Percentages and median fluorescence intensity values of CD206 and IA
b
 expressing 
TAMs. (C) Total numbers and fold change increase of TAMs. (D) Total numbers and fold change 
increase of CD206 or IA
b
 expressing TAMs. Error bars represent SEM within each animal collective. 
Statistical analysis was done by unpaired Student’s t-test (95% CI, ns: not significant, * p ≤ 0.05, 
** p < 0.01, *** p ≤ 0.001). Gating strategy: CD45+ → living cells → single cells (FSC-A vs. FSC-H) → 
F4/80
+
CD11b
+
Gr1
-
 → CD206 vs. IA
b
. 
3.4.2 Peptide loaded TAMs stimulate OVA specific CD4+ T cells ex vivo 
In the next set of experiments, we assessed the capacity of TAMs to take up B16F10 
derived OVA in the tumor microenvironment and present MHC restricted OVA epitopes to 
OVA specific CD4+ T cells. This process might induce polarization of TAMs into M1-like 
phenotype thereby facilitating CTL mediated tumor attack (compare detailed explanation in 
section 1.5). 
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Figure 3.38: Peptide loaded TAMs stimulate OVA specific CD4
+
 T cells ex vivo. 
C57BL/6 mice were injected s.c. with either 2 x 10
5
 B16F10 or B16F10/OVA-F cells. (A) Fourteen 
days after tumor inoculation, 10
4
 TAMs from each tumor were isolated by FACS and co-cultured with 
the OVA specific CD4
+
 T cells (1.5 x 10
5
 cells). After 48 h, the culture supernatants were collected 
and analyzed using IFNγ ELISA. As positive controls, B16F10 derived TAMs were loaded with 
1 µg/ml IA
b
 restricted OVA323-339 epitope for 1 h prior co-culture (peptide loaded TAMs) or CD4
+
 T cells 
were cultured in the presence of 20 µg/ml ConA (ConA). As negative controls, CD4
+
 T cells were 
cultured with (peptide) or without (medium) 1 µg/ml OVA323-339 peptide. * indicate saturated signal 
intensity. (B) Twelve days post tumor cell injection, 5 x 10
4
 TAMs were co-cultured with OVA specific 
CD4
+
 T cells (10
5 
cells). IFNγ secretion by CD4
+
 T cells was measured 24 h after co-culture using 
IFNγ ELISpot assay. Sort strategy: CD45
+
 → single cells (FSC-A vs. FSC-H) → living cells → 
F4/80
+
CD11b
+
. (C) Thirteen days after tumor cell injection, tumors were isolated, stained with 
monoclonal antibodies and analyzed by flow cytometry. Gating strategy: CD45
+
 → single cells (FSC-A 
vs. FSC-H) → living cells → (F4/80
+
CD11b
+
) → FSC-H/Marker vs. H2-K
b
 SIINFEKL. 
To investigate OVA engulfment and epitope presentation by TAMs, B16F10 or 
B16F10/OVA-F tumors were isolated from C57BL/6 mice between 12 and 14 days post 
tumor cell injection. The tumors were stained using monoclonal antibodies and TAMs were 
subsequently sorted to perform co-culture experiments with OVA specific CD4+ T cells or 
analyzed by flow cytometry. As measured by IFNү ELISA, peptide (OVA323-339) loaded 
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B16F10 derived TAMs stimulated strong IFNү secretion of OVA specific CD4+ T cells (T cell 
line established as described in section 2.2.12.1), showing that IAb expression on TAMs was 
sufficient to facilitate interaction with CD4 TCRs (Figure 3.38 A). However, co-culturing CD4+ 
T cells with TAMs from either B16F10 or B16F10/OVA-F tumors in the absence of synthetic 
peptide resulted in comparable IFNү concentrations with 304.3 or 270.9 pg/ml, respectively. 
Similar results were obtained when the experiment was repeated using an IFNү ELISpot as 
readout, demonstrating that TAMs sorted from OVA expressing tumors failed to stimulate 
OVA specific CD4+ T cells (Figure 3.38 B). 
In a next attempt, different cell populations in B16F10 and B16F10/OVA-F tumors were 
analyzed by flow cytometry using a H2-Kb SIINFEKL specific antibody in order to check OVA 
uptake and MHC I restricted presentation of the CTL epitope SIINFEKL (Figure 3.38 C). 
Staining of B16F10 tumors resulted in binding of the H2-Kb SIINFEKL antibody to 5.1 % of 
living cells. The same percentage was detected when the corresponding isotype control 
antibody was used (data not shown), indicating unspecific binding of the antibody. Staining 
of OVA-F expressing tumors revealed an increase of 0.6 % H2-Kb SIINFEKL positive cells. 
Analysis of the individual cell populations showed only a small increase of H2-Kb SIINFEKL 
expression in CD3+ T cells (1.2 %) and CD11c+ dendritic cells (0.4 %) in B16F10/OVA-F 
tumors compared to the parental tumors. In contrast, even lower frequencies of H2-Kb 
SIINFEKL positive cells were observed in B16F10/OVA-F tumors when macrophages 
(14.8 % vs. 13.9 %) or B cells (1.2 % vs. 1.1 %) were analyzed. Due to the fact that the 
antibody binds unspecifically and the staining did not result in a clear and separated 
population, the results should be treated with caution. The same H2-Kb SIINFEKL specific 
antibody was used to analyze OVA expression in B16F10 OVA transduced clones (see 
Figure 3.9), demonstrating that the antibody in principle works fine. 
In summary, the data demonstrate that peptide pulsed TAMs isolated from B16F10 tumors 
have the capability to stimulate OVA specific CD4+ T cells (Figure 3.38 A and B). However, 
TAMs from OVA expressing tumors that were not loaded with IAb restricted OVA epitope 
failed to activate OVA specific CD4+ T cells. In addition MHC I restricted OVA epitope 
presentation by TAMs was not detectable by flow cytometry (Figure 3.38 C). 
3.4.3 Infiltration of adoptively transferred CD4+ T cells in B16F10 tumors 
As demonstrated in section 3.3.3.2, OVA specific CD4+ T cells facilitated efficient 
repolarization of peptide pulsed M2-like PECs into immunostimulatory M1-like macrophages 
in vitro. Additionally, TAMs isolated from B16F10 tumors had the capability to stimulate CD4+ 
T cells ex vivo as described in section 3.4.2. Based on these results, a set of experiments 
were performed to analyze the effects of adoptively transferred OVA specific CD4+ T cells on 
TAM polarization in tumor bearing C57BL/6 Ly5.1 mice. 
Pilot experiments showed that cells of the generated OVA specific CD4+ T cell line (section 
2.2.12.1) which was used for co-culture experiments with PECs and TAMs were not able to 
infiltrate into the tumors and into the draining lymph nodes (dLNs) (data not shown). Thus, 
CD4+ T cells of TCR transgenic OT-II mice were isolated and pre-activated with either IAb 
restricted OVA323-339 peptide or CD3/CD28 beads in the presence of IL-2 for 3 days, 
respectively. To assess the capability of these pre-activated CD4+ T cells to secrete IFNү 
upon target cell recognition, an IFNү ELISpot assay using peptide loaded (OVA323-339) 771 B 
cell lymphoma cells as targets was performed. As shown in Figure 3.39 A, CD4+ T cells pre-
activated with peptide or CD3/CD28 beads secreted IFNү upon co-culture with OVA323-339 
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loaded targets, whereas naïve CD4+ T cells which were freshly isolated from OT-II mice did 
not. Both pre-activation strategies resulted in highly specific CD4+ T cells only secreting IFNү 
in the presence of target cells loaded with IAb restricted OVA epitope as demonstrated by 
the included negative controls (T cells only (T cells) and target cells loaded with HBV core 
antigen control peptide128-140 (HBV)). Subsequent analysis of various T cell activation (CD25 
and CD44) and adhesion molecules (LFA-1, CD2 and VLA-4) by flow cytometry revealed 
that at least 96 % of pre-activated CD4+ T cells were positive for all the markers tested (data 
not shown). All naïve CD4+ T cells (≥ 98.3 %) were stained positive for the adhesion 
molecules LFA-1, CD2 and VLA-4. In contrast, the percentage of naïve CD4+ T cells 
expressing CD25 (5.6 %) or CD44 (13 %) was low (data not shown). Analysis of the MFI 
values revealed a higher expression level of all tested markers on the surface of peptide pre-
activated CD4+ T cells compared to CD3/CD28 pre-activated or naïve cells (Figure 3.39 B). 
For instance, peptide pre-activated CD4+ T cells (MFI: 78522) showed a 35.5 fold higher 
CD25 (low affinity IL-2 receptor α chain) expression level compared to naïve T cells 
(MFI: 2213) and a 2.25 fold increase when compared to cells pre-activated with CD3/CD28 
beads (MFI: 34802). 
 
Figure 3.39: Expression of activation markers and specificity of pre-activated OT-II cells. 
(A) OT-II splenocytes were isolated and either cultured in the presence of 1 µg/ml IA
b
 restricted 
OVA323-339 peptide (peptide pre-activated CD4 T cells) or positively selected for CD4
+
 T cells and 
incubated with CD3/CD28 beads (CD3/CD28 beads). Three days after incubation, peptide pre-
activated CD4
+
 T cells were purified by positive selection and co-cultured with peptide loaded 
(1 µg/ml) 771 B cell lymphoma cells (5 x 10
4
) over night. CD4
+
 T cells pre-activated with CD3/CD28 
beads were co-cultured without any further purification. IFNγ secretion was detected by IFNγ ELISpot 
assay. For comparison, freshly isolated OT-II splenocytes underwent positive CD4 selection and were 
included in the assay (naive). The highest T cell number used within the assay was 2.5 x 10
4
 followed 
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by serial 1:2 dilutions. Error bars represent SD of technical triplicates. (B) CD4
+
 T cells were stained 
with monoclonal antibodies specific for T cell activation markers as well as adhesion molecules and 
subsequently analyzed by flow cytometry. MFI values of the positive populations were normalized to 
the corresponding MFI value obtained for naive T cells. Gating strategy: single cells (FSC-A vs. 
FSC-H) → living cells → CD3
+
 → CD4
+
CD8
-
 → marker vs. FSC-H.  
In a next step, the infiltration of OVA specific CD4+ T cells into B16F10/OVA-F tumors, 
draining lymph nodes (dLNs) and spleens was analyzed. Therefore, 5 x 106 pre-activated or 
naïve CD4+ T cells were injected i.v. into B16F10/OVA-F tumor bearing mice ten days after 
tumor cell injection (Figure 3.40 A). Four days later, tumors, spleens and dLNs were 
harvested to prepare single cell suspensions for subsequent flow cytometry analysis. The 
cells were stained using monoclonal antibodies specific for the congenic markers CD45.1 or 
CD45.2, facilitating differentiation between adoptively transferred (CD45.2+) and 
endogenous CD4+ T cells (CD45.1+). As shown in the upper panel of Figure 3.40 B, the 
percentage of adoptively transferred CD4+ T cells (CD3+CD4+CD45.2+) in spleens and dLNs 
was significantly higher when mice received peptide pre-activated T cells compared to 
CD3/CD28 pre-activated or naïve T cells. Most importantly, the percentage of CD45.2+ T 
cells within the CD3+CD4+ cell population in tumors of mice that received peptide pre-
activated CD4+ T cells (35.2 %) was 3 fold higher compared to mice that received 
CD3/CD28 pre-activated cells (12.5 %). Naïve CD4+ T cells only accounted for 3 % of all 
CD3+CD4+ cells detected in the tumors. Thus, the capacity of the T cells to infiltrate into the 
different organs and the tumor correlated with the surface expression level of the tested 
activation and adhesion molecules (compare to Figure 3.39 B).  
The absolute quantification demonstrated that around 1.5 x 106 peptide pre-activated CD4+ 
T cells reached the spleen, whereas only 6.2 x 104 had the capability to infiltrate into the 
tumors (Figure 3.40 B, lower panel). However, this absolute number is still higher compared 
to the number of CD3/CD28 pre-activated (1.4 x 104) or naïve CD4+ T cells (3.2 x 104) that 
reached the tumor.  
In summary, these results demonstrate the importance of upregulating activation and 
adhesion markers by T cell pre-activation to enable T cell infiltration into tumors. The peptide 
pre-activated CD4+ T cells showed superior tumor infiltration capacity compared to 
CD3/CD28 pre-activated or naïve T cells and were used for subsequent experiments. 
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Figure 3.40: Infiltration of adoptively transferred OVA specific CD4
+
 T cells into spleens, dLNs 
and tumors of B16F10/OVA-F tumor bearing mice. 
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 5-7) were injected s.c. with 2 x 10
5
 
B16F10/OVA-F cells. Ten days after tumor inoculation, mice were injected i.v. with 5 x 10
6
 
OVA specific CD4
+
 T cells obtained from OT-II splenocytes. CD4
+
 T cells were either injected without 
pre-activation (naïve = n) or after incubation with 1 µg/ml OVA323-339 peptide (peptide = p) or 
CD3/CD28 beads (CD3/CD28 beads = b) for 3 days. Mice that did not receive any T cells served as 
control groups (w/o ACT = c). Infiltration of CD45.2
+
CD4
+
CD8
-
 cells into spleens, dLNs and tumors 
was analyzed by flow cytometry four days after adoptive cellular therapy. (B) Infiltration of adoptively 
transferred T cells into spleens, dLNs and tumors presented as percentage of CD45.2
+
 within 
CD3
+
CD4
+
 cells (upper panel) or as total cell numbers (lower panel). Error bars represent SEM within 
each animal collective. Significance was determined using One-way ANOVA with post-hoc Tukey test 
(95% CI, ns: not significant, * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001). Gating strategy: CD45+ → living 
cells → single cells (FSC-A vs. FSC-H) → CD3
+
CD4
+
 → CD45.1 vs. CD45.2. 
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3.4.4 Adoptive transfer of specific CD4+ T cells affects TAM phenotype 
Within the next experiments the polarization of TAMs in OVA expressing B16F10 tumors 
upon transfer of OVA specific CD4+ T cells was analyzed. Therefore, C57BL/6 Ly5.1 mice 
were injected with the IAb deficient, OVA-F expressing B16F10 clone (M2KO/OVA-F). Ten 
days post tumor cell injection, peptide pre-activated CD4+ T cells were injected i.v. and T cell 
infiltration as well as TAM polarization was analyzed four days later (Figure 3.41 A). As 
shown in Figure 3.41 B, the tumor bearing mice were distributed into two groups with equal 
mean tumor sizes prior adoptive T cell transfer (Day 10), thereby avoiding differences in 
TAM polarization between these groups due to different tumor sizes. Mice within the control 
group (c = w/o adoptive cellular therapy (ACT)) did not receive T cells, whereas mice of the 
second group were injected with 5 x 106 peptide pre-activated CD4+ T cells (p). Tumor 
weight measurement of harvested tumors on day 14 revealed a lower mean tumor weight in 
mice treated with T cells (546 mg) compared to control mice (640 mg). Analysis of TILs 
(CD45+) from these tumors showed that on average 2.7 x 104 transferred T cells (CD4+CD8-
CD45.2+) had reached the tumor, thereby representing 19.3 % of the CD4+CD8- TIL 
compartment (Figure 3.41 C). In contrast, no CD45.2+ cells were detected in tumors from 
control mice. Deeper analysis of the TIL compartment demonstrated equal frequencies of 
TAMs (F4/80+CD11b+Gr1-) in both groups (c = 34.2 % and p = 32.1 %) (Figure 3.41 D, left). 
However, the frequency of CD206+ TAMs (Figure 3.41 D, middle) as well as the CD206 
surface expression intensity (Figure 3.41 D, right) of these cells was significantly decreased 
in tumors of mice adoptively transferred with peptide pre-activated CD4+ T cells. At the same 
time, IAb surface expression was significantly enhanced on TAMs from tumors of treated 
mice compared to tumors from control mice (Figure 3.41 D, right), although the overall 
frequency of IAb positive TAMs was unchanged between both groups of mice (Figure 3.41 D, 
middle). No correlation between the percentage of transferred CD4+ T cells and the 
percentage of CD206 (r2 = 0.13) or IAb (r2 = 0.0) expressing TAMs within the tumors of 
treated mice was detected. Thus, tumors harboring high numbers of transferred CD4+ T cells 
are not necessarily showing lower percentages of CD206+ cells or higher percentages of IAb+ 
cells. Nevertheless, these data indicate that adoptive transfer of CD4+ T cells can induce 
polarization of TAMs towards a M1-like phenotype. As shown in supplementary Figure 6.7, 
comparable results were obtained when CD4+ T cells were transferred into C57BL/6 Ly5.1 
mice bearing an OVA expressing pancreatic tumor (PDAC/OVA-F). However, no changes in 
TAM polarization upon T cell transfer were detected if the breast cancer model EO771/OVA-
F was used (supplementary Figure 6.8).  
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Figure 3.41: Polarization of TAMs in M2KO/OVA-F tumors after adoptive transfer of OVA 
specific CD4
+
 T cells.  
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 10) were injected s.c. with 2 x 10
5
 M2KO/OVA-F 
cells. Ten days post tumor inoculation mice were injected i.v. with 5 x 10
6
 peptide pre-activated OVA 
specific CD4
+
 T cells. Mice were sacrificed on day 14 and tumors were analyzed by flow cytometry. 
Control mice (c) did not receive CD4
+
 T cells. (B) Tumor volume and tumor weight 10 and 14 days 
after tumor cell injection, respectively. (C) Infiltration of adoptively transferred T cells into tumors 
presented as percentage of CD45.2
+
 within CD4
+
CD8
-
 cells or as total numbers within tumors. Error 
bars represent SEM within each animal collective. Gating strategy: CD45
+
 → living cells → single 
cells (FSC-A vs. FSC-H) → CD4
+
CD8
-
 → CD45.1 vs. CD45.2. (D) Percentages of TAMs 
(F4/80
+
CD11b
+
Gr1
-
) within CD45
+
 cells as well as percentages and MFI values of CD206 and IA
b
 
expressing cells within TAMs are shown. Error bars represent SEM within each animal collective. 
Statistical analysis was done by unpaired Student’s t-test (95% CI, ns: not significant, * p ≤ 0.05, 
** p < 0.01, *** p ≤ 0.001). Gating strategy: CD45+ → living cells → single cells (FSC-A vs. FSC-H) → 
F4/80
+
CD11b
+
Gr1
-
 → CD206 vs. IA
b
. 
In a next step, the aforementioned experiment was repeated using the M2KO clone instead 
of M2KO/OVA-F cells to investigate whether the observed changes in TAM polarization were 
OVA dependent (Figure 3.42 A). As shown in Figure 3.42 B, the mean tumor volumes of the 
two groups was almost identical 10 days post tumor cell injection, with 334.8 mm3 in the 
control group (c) and 338.6 mm3 in the treated group (p). Similar to the observation of the 
first experiment (Figure 3.41 B), M2KO tumor bearing mice treated with CD4+ T cells 
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(631.8 mg) showed a slightly lower mean tumor weight compared to the control group 
(754.5 mg) four days post adoptive T cell transfer (Figure 3.42 B, right). As shown in Figure 
3.42 C (left) the percentage of infiltrated transferred CD4+ T cells in M2KO tumors (22.1 %) 
was as high as in M2KO/OVA-F tumors (19.3 %). However, the average absolute number of 
transferred CD4+ T cells reaching the M2KO tumors (1.5 x 104) was significantly lower 
compared to M2KO/OVA-F tumors (2.7 x 104) (Figure 3.42 C, right). Most importantly, the 
differences in TAM polarization observed in M2KO/OVA-F tumors upon adoptive transfer of 
OVA specific CD4+ T cells were not detectable in TAMs from M2KO tumors lacking OVA 
expression as demonstrated in Figure 3.42 D. 
 
Figure 3.42: Polarization of TAMs in M2KO tumors after adoptive transfer of OVA specific CD4
+
 
T cells.  
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 11) were injected s.c. with 2 x 10
5
 M2KO cells. 
Ten days post tumor injection mice were injected i.v. with 5 x 10
6
 peptide pre-activated OVA specific 
CD4
+
 T cells. Mice were sacrificed on day 14 and tumors were analyzed by flow cytometry. Control 
mice (c) did not receive CD4
+
 T cells. (B) Tumor volume and tumor weight 10 and 14 days after tumor 
cell injection, respectively. (C) Infiltration of adoptively transferred T cells into tumors presented as 
percentage of CD45.2
+
 within CD4
+
CD8
-
 cells or as total numbers within tumors. Error bars represent 
SEM within each animal collective. Gating strategy: CD45
+
 → living cells → single cells (FSC-A vs. 
FSC-H) → CD4
+
CD8
-
 → CD45.1 vs. CD45.2. (D) Percentages of TAMs (F4/80
+
CD11b
+
Gr1
-
) within 
CD45
+
 cells as well as percentages and MFI values of CD206 and IA
b
 expressing cells within TAMs 
are shown. Error bars represent SEM within each animal collective. Statistical analysis was done by 
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unpaired Student’s t-test (95% CI, ns: not significant, * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001). Gating 
strategy: CD45
+
 → living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+
Gr1
-
 → CD206 vs. 
IA
b
. 
Finally, TAMs of M2KO/OVA-F tumors were sorted four days after adoptive T cell transfer for 
subsequent RNA isolation and gene expression analysis by qPCR (Figure 3.43 A). The 
average tumor volume and tumor weight 10 and 14 days after tumor cell injection, 
respectively, was similar between the two groups (Figure 3.43 B). As shown in Figure 3.43 C 
(left), treatment of M2KO/OVA-F tumor bearing mice with pre-activated OVA specific CD4+ T 
cells upregulated expression of M1-associated genes, with Arg2, Il1b, Cd86, Cxcl10 and 
Nos2 expression being significantly increased compared to TAMs of control mice. 
Expression of the other M1-associated genes Stat1, Cxcl9 and Il12 did not change upon 
CD4+ T cell transfer. In contrast, no significant up- or downregulation was detected for any of 
the tested M2-associated genes (Figure 3.43 C, right).  
 
Figure 3.43: Gene expression analysis of TAMs in M2KO/OVA-F tumors after adoptive transfer 
of OVA specific CD4
+
 T cells. 
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 10) were injected s.c. with 2 x 10
5
 M2KO/OVA-F 
cells. Ten days post tumor inoculation mice were injected i.v. with 5 x 10
6
 peptide pre-activated OVA 
specific CD4
+
 T cells. Mice were sacrificed on day 14 and RNA of sorted TAMs (F4/80
+
CD11b
+
Gr1
-
) 
was isolated to perform qPCR. Control mice (c) did not receive CD4
+
 T cells. (B) Tumor volume and 
tumor weight 10 and 14 days after tumor cell injection, respectively. (C) Gene expression analysis of 
sorted TAMs. The data were normalized to Rpl19 expression level which served as housekeeping 
gene. The box and whiskers plots extend from the smallest to the largest values and show the 
median, the 25th as well as 75th percentiles. Significance was determined using unpaired Student’s t-
test with Bonferroni-Holm p-value correction (95% confidence interval (CI), ns: not significant, 
* p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001). Sort strategy: CD45+ → single cells (FSC-A vs. FSC-H) → living 
cells → F4/80
+
CD11b
+
Gr1
-
. 
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In summary, these results show that the adoptive transfer of CD4+ T cells can repolarize 
immunosuppressive M2-like macrophages into M1-like macrophages with increased 
expression levels of M1-associated genes. These effects are dependent on the presence of 
OVA-F, as changes in macrophage polarization were not observed in the microenvironment 
of OVA negative tumors. As the tumor cell line is deficient in MHC II expression, a direct 
activation of adoptively transferred OVA specific CD4+ T cells by OVA323-339 presenting 
B16F10 cells can be excluded. Instead, these results suggest a cognate interaction between 
APCs which took up OVA-F and presented IAb restricted OVA epitopes to the transferred 
CD4+ T cells that in turn became activated and secreted IFNү, thereby changing 
macrophage polarization.  
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4 Discussion 
4.1 Generation of IAb deficient B16F10 cells using the CRISPR/Cas9 system 
Parts of the following paragraph have been taken from reference [307] and were originally 
written by myself. The CRISPR/Cas9 based technology was demonstrated to outperform 
other genome editing strategies such as zinc finger nucleases (ZFNs) or transcription 
activator-like effector nucleases (TALENs) in frequency and precision [328]. The Cas9 
nuclease in combination with a single guide RNA targeting the gene of interest was already 
applied in various settings and resulted in high knockout (KO) efficiencies. Transfection of 
haploid embryonic stem cells with ten-eleven translocation methylcytosine dioxygenase 1 
(Tet1) targeting guide RNAs achieved a knockout efficiency of 50 % [329]. Yu and 
colleagues even demonstrated a 100 % KO efficiency after injecting a guide RNA and in 
vitro transcribed Cas9 mRNA in Drosophila embryos [330]. The KO efficiencies of our five 
IAb targeting guide RNAs ranged from 13.2 % to 45.6 %, indicating that the on-target 
mutagenesis is highly dependent on the guide RNA sequence (Figure 3.3). Similar variations 
in the efficiencies of guide RNAs have been reported in several other studies. Targeting of 
the β2 microglobulin (B2M) gene in HEK293T cells was reported to ablate B2M surface 
expression in 7 % to 48 % of transfected cells depending on the guide RNA [331]. Another 
study was using two guide RNAs to target the AAVS1 locus in HEK293T cells, human 
chronic myelogenous leukemia K562 cells and human induced pluripotent stem cells and 
demonstrated varying target gene KO rates of 10 % to 25 %, 13 % to 38 % and 2 % to 4 %, 
respectively [332]. The understanding of the relationship between on-target activity and the 
sequence characteristics of a certain guide RNA still remains limited. However, recent 
studies demonstrated that the nucleotide composition (e.g. GC content) and the secondary 
structure of a guide RNA as well as the genomic context of the target site (besides the well-
established importance of the protospacer adjacent motif (PAM) sequence) are features 
which are associated with DNA cleavage efficiency [333, 334].   
Our functional in vitro analysis clearly showed that our finally selected IAb KO clone had lost 
susceptibility to recognition by CD4+ T cells (Figure 3.5). The absence of MHC II did not alter 
the tumor growth behavior in vivo when compared to the parental B16F10 cell line (Figure 
3.5). Even though we did not observe any phenotypical changes of our generated KO 
clones, we cannot rule out any off-target mutations induced by one of the guide RNAs. 
Single and double mismatches of guide RNAs have been reported to occur at varying 
frequencies dependent on their position within the guide RNA/DNA duplex. Of note, studies 
using human cell-based reporter assays revealed that some off-target sites have 
comparable mutagenesis frequencies than the once detected at the on-target site [335]. We 
maximized specificity of our guide RNAs by selecting guide sequences with high on-target 
scores and at least 3 base pair mismatches to any predicted off-target sequence in the 
genome. Several strategies to reduce off-target mutagenesis and increase Cas9 specificity 
have been developed. The use of truncated guide RNAs (<20 nucleotides in length) was 
shown to result in fewer cleavages at off-target sites without reducing on-target editing 
efficiencies [336]. Kleinstiver and colleagues developed Cas9 variants harboring amino acid 
exchanges at DNA contact sites. These so called high fidelity Cas9 nucleases reduced off-
target events and retained on-target activities comparable to WT Cas9 [337]. Other authors 
Discussion 
120 
 
generated fusion proteins composed of catalytically inactive Cas9 and FokI nuclease 
(fCas9). As a consequence, the induction of DNA double-strand breaks requires the 
association of two fCas9 fusion proteins binding their respective target sites (15 or 25 base 
pairs apart from each other) [338]. DNA cleavage using this strategy is dependent on 
simultaneous binding of two guide RNAs to their respective target sites, thereby reducing 
undesired off-target modifications. A similar approach is implemented by mutating the 
nuclease domains of Cas9 to create DNA “nickases” which introduce single-strand instead of 
double-strand breaks [339]. Thus, the use of paired Cas9 nickases, both binding specifically 
to their respective target site is required for cooperative genome editing and to induce 
double-strand breaks. Ran and colleagues demonstrated a 50 – 1000 fold reduction of off-
target activity in different cell lines when paired Cas9 nickases were used compared to WT 
Cas9 [339]. In contrast to the aforementioned techniques, Cas9 nickases generate sticky 
ends instead of blunt ends making them an attractive tool for subsequent gene integration.  
Our analysis of CRISPR/Cas9 (guide #4) induced mutations in the finally selected IAb KO 
clone revealed the same 11 bp deletion in all tested bacterial colonies (Table 3.1). As the 
parental cell line B16F10 has been shown to be near tetraploid, we would have expected to 
identify four different mutations (one mutation on each chromosome 17 on which the H2-Ab1 
gene is located). However, fluorescence in situ hybridization (FISH) of the IAb KO clone 
using mouse chromosome 17 painting probes demonstrated a marked chromosomal 
instability which resulted in a variety of hybridization patterns (data not shown; FISH analysis 
was done by CHROMBIOS, Nußdorf, Germany). In most of the cells, three intact copies of 
chromosome 17 and a small translocated segment of chromosome 17 close to the 
centromere of an unidentified chromosome were observed. In the other cells, additional 
variations of chromosome 17 were detected which included a fusion of two chromosomes, 
two copies of the translocated chromosome, an additional abnormal chromosome, only two 
copies of the chromosome or cells with four copies of the chromosome. These data suggest 
that our selected IAb KO clone had only a single chromosome 17 at the time of guide RNA 
transfection, thus resulting in a single mutation. Subsequent culturing of the clone provided 
advantageous conditions for chromosome duplications and translocations as observed in the 
FISH analysis. Even though the interpretation of the mutation analyses has not yet been 
clarified, the CRISPR/Cas9 system has proven to be an efficient and straight forward 
strategy to generate murine MHC II KO cell clones which represent an ideal tool to 
investigate anti-tumor CD4+ T cell responses that function independently of MHC surface 
expression by the tumor. 
4.2 Establishment of OVA and luciferase expressing B16F10 clones 
Ovalbumin (OVA) is a non-inhibitory serpin representing the major protein found in egg white 
[340]. The identification of MHC I [341] and MHC II [342] restricted T cell epitopes and the 
availability of T cell receptor transgenic mice for both OVA specific CD4+ (OT-II mice) [342, 
343] and CD8+ T cells (OT-I mice) [344] have made it an attractive model antigen to analyze 
antigen-specific immune responses in C57BL/6 mice. The native, full length OVA contains a 
signal peptide (amino acids 22 – 48) which is not cleaved and facilitates membrane 
translocation by forming an amphipathic hairpin structure [315, 345]. Most studies 
investigating antigen-specific immune responses against OVA expressing tumor cells make 
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use of the secreted, full length OVA protein, thereby neglecting the fact that most tumor-
associated antigens are not secreted under physiological conditions. Within this study we 
were aiming for the clarification of whether anti-tumor CD4+ T cell responses are dependent 
on secreted antigen or not. Therefore, we generated B16F10 clones expressing either the 
full length, secreted OVA (OVA-F) or a truncated version of OVA (OVA-T) lacking the signal 
peptide (not secreted). The different clones generated from transduced B16F10 cells 
expressed OVA-F and OVA-T in variable quantities as demonstrated by qPCR analysis 
(Figure 3.6). Moreover, the presence of full length OVA in whole cell protein samples as well 
as in culture supernatants was confirmed by Western blot analysis (Figure 3.10). However, 
OVA-T was only detected after blocking proteasomal degradation, indicating a rapid turnover 
of the truncated protein due to the lacking signal peptide (Figure 3.10). Indeed, several 
studies reported similar results and even determined the half-life of OVA-T and OVA-F. In 
whole cell protein samples of HEK293T cells and DCs transduced with OVA encoding 
lentiviral vectors, Western blot analysis revealed a strong signal of OVA-F at the expected 
protein size [346]. In contrast, the truncated version of OVA, lacking the first 48 amino acids, 
was almost not detected. Shen and colleagues generated stable fibroblast transfectants 
expressing either OVA-F or OVA-T and performed pulse-chase experiments after 35S 
metabolic labeling [347]. They found that the full length OVA protein had a half-life of around 
280 min. In contrast, OVA-T had a half-life of only 40 min, suggesting a rapid degradation as 
observed in our experiments. All OVA transduced clones gave rise to tumors after s.c. 
injection into C57BL/6 mice in our study. However, the tumor growth was significantly 
delayed compared to the parental B16F10 cell line (except for B16F10/OVA-T) (Figure 3.11). 
The expression of the xenogenic antigen OVA by murine tumor cells was shown to be 
associated with delayed tumor growth in several studies [348, 349]. Moreover, Gilfillan and 
colleagues demonstrated a rejection of MC-38/OVA tumors in an antigen dependent manner 
mediated by endogenous CD8+ T cells [350]. 
In a next step, the OVA expressing B16F10 clones were transduced with luciferase encoding 
retroviral particles which allows subsequent tumor growth monitoring by in vivo 
bioluminescence imaging. After injecting the different luciferase expressing clones into 
C57BL/6 mice we observed remarkable differences in tumor growth (Figure 3.13). Reduced 
tumor growth was accompanied by higher luciferase expression levels (Figure 3.12). In 
addition, 4 out of 5 luciferase expressing EO771 clones were completely rejected after s.c. 
injection into C57BL/6 mice, whereas the parental cell line showed a continuous tumor 
growth (data not shown). The growing EO771/OVA clone had a significantly lower luciferase 
expression than the rejected clones (data not shown). Similar result were already reported 
[351] and indicate an immune mediated rejection of luciferase expressing tumors in 
immunocompetent mice. The identification of luciferase specific CD8 T cell epitopes and the 
presence of luciferase specific CD8+ T cells in C57BL/6 mice support this assumption [352]. 
4.3 Generation of an OVA specific CD4+ T cell line 
The generation of murine antigen specific T cell lines usually involves the immunization of 
mice with the respective antigen in combination with an adjuvant. In this study we immunized 
C57BL/6 mice s.c. with the IAb restricted OVA epitope323-339 in combination with complete 
Freund’s Adjuvant. The culture of splenocytes from immunized mice in the presence of 
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synthetic IAb restricted OVA peptide resulted in IFNү release by activated OVA specific CD4+ 
T cells, indicating successful in vivo T cell priming (Figure 3.14). In contrast, no OVA specific 
CD4+ T cells were detected ex vivo among splenocytes of mice immunized with the IAb 
restricted OVA epitope core sequence (aa 329 – 337 [316]), suggesting that application of 
the core sequence was not sufficient to induce T cell priming in vivo. The splenocytes of 
mice immunized with the epitope core sequence died after several days of culturing in the 
presence of the respective peptide and IL-2. In contrast, immunization with OVA 
epitope323-339 and subsequent culturing for several weeks allowed the generation of a 
polyclonal, OVA specific CD4+ T cell line. Moreover, we generated two additional OVA 
specific CD4+ T cell lines by culturing splenocytes from TCR transgenic OT-II mice in the 
presence of IAb restricted OVA epitope323-339 or CD3/CD28 Dynabeads. The T cell cultures 
were restimulated every 4 weeks by adding irradiated syngeneic feeder cells together with 
antigenic peptide. As all CD4+ T cells in OT-II mice express the same OVA specific TCR 
recognizing IAb restricted OVA epitope323-339, an OVA specific CD4
+ T cell line can be 
generated without the need of in vivo immunization. The three CD4+ T cell lines showed a 
high degree of specificity for the IAb restricted OVA epitope and equal numbers of activated 
T cells (i.e. secreting IFNү) upon co-culture with peptide loaded 771 B cell lymphoma cells, 
demonstrating that the different strategies to generate a CD4+ T cell line worked equally well 
(Figure 3.15). However, staining with monoclonal antibodies specific for CD3, CD4 and CD8 
revealed high frequencies of double negative (CD4-CD8-) CD3+ T cells in both T cell lines 
generated from OT-II splenocytes (Figure 3.15). In contrast, 99.9 % of CD3+ T cells of the T 
cell line generated through peptide immunization of C57BL/6 mice were CD4+CD8-. Of note, 
double negative CD3+ T cells were already observed in freshly isolated splenocytes of OT-II 
mice (data not shown), a phenomenon which was to my knowledge not explicitly reported 
yet. However, flow cytometry stainings of OT-II splenocytes using CD4 and CD8 specific 
antibodies were shown in different studies and at least indicate the presence of double 
negative T cells (as the authors do not comment on their gating strategy it is difficult to 
interpret the data) [353, 354]. Moreover, high frequencies of abnormal T cell populations, 
such as double negative T cells have been detected in the periphery and secondary 
lymphoid tissues of T cell receptor transgenic mice [355]. Boehmer and colleagues 
described a double negative T cell lineage in HY-transgenic mice which was thymus 
dependent but did not require positive selection for emigration from the thymus [356]. Even 
though the origin of this T cell lineage is still not completely understood, these results 
suggest that the expression of a TCR transgene influences thymocyte development and 
probably affect the different selection processes involved in T cell differentiation.  
4.4 Phenotypic and functional analysis of in vitro polarized PECs 
Macrophages are a subset of myeloid cells that show phenotypic and functional plasticity. 
Depending on the environmental signals they can differentiate in M1-like and M2-like 
macrophages which are involved in a variety of processes such as tumor growth inhibition 
and promotion, respectively. Even though the concept of classically (M1) and alternatively 
(M2) macrophages is generally accepted, the two polarization states should only be 
considered as two extremes within a spectrum of phenotypes. In this study, the two 
phenotypes of polarized macrophages were comprehensively analyzed by gene and protein 
expression analysis as well as functional assays. As a source of macrophages we used 
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thioglycolate elicited peritoneal exudate cells (PECs) which were already used in a variety of 
studies investigating macrophage polarization [357]. Flow cytometry analysis of PECs 
revealed surface expression of CD11b and F4/80 on more than 99 % of the cells, making 
these cells suitable for subsequent analysis of macrophage polarization (Figure 3.16). 
Our gene expression analysis confirmed successful polarization of PECs upon treatment 
with LPS/IFNү or IL-4 (Figure 3.17). Treatment of PECs with IL-4 decreased the expression 
of M1-associated genes and induced expression of M2-associated genes within 4 h of 
stimulation. On the other hand, LPS/IFNү treatment upregulated expression of the entire M1-
associated gene panel within 4 h of stimulation. A similar expression pattern has been 
described already for LPS treated murine PECs [358]. As expected, no M2-associated 
marker expression was observed upon stimulation with LPS/IFNγ, except for Il10 and Arg1 
whose expression was transiently upregulated after 4 h or 24 h, respectively. Even though 
expression of arginase 1 is typically associated with alternative macrophage polarization, 
several studies reported that both macrophage phenotypes express the enzyme, albeit in 
different amounts. IL-4 or IL-13 mediated arginase 1 expression in alternatively activated 
macrophages requires binding of STAT6 to an enhancer element of the arginase 1 gene 
[359]. In contrast, intracellular bacteria have been shown to promote arginase 1 expression 
in chronically infected M1-like macrophages through STAT6 independent TLR pathways 
[360]. Sonoki and colleagues demonstrated that the expression of arginase 1 in rat 
peritoneal macrophages was induced in a CCAAT/enhancer-binding protein beta (C/EBPβ) 
dependent manner upon treatment with LPS [361]. In accordance with our results, 
arginase 1 expression was shown to be induced more slowly than Nos2 expression and 
reached a maximum 12 h post LPS treatment. Interestingly, comparable results have been 
reported for LPS treated murine PECs in which arginase activity increased even up to 4 days 
[362]. In summary, these data suggest that arginase 1 expression is induced in classically 
activated macrophages to decrease arginine availability for Nos2, thereby avoiding 
overproduction of nitric oxide which is toxic to host tissues. 
Due to its immunosuppressive properties, IL-10 is mainly associated with M2-like 
macrophages. However, IL-10 expression is controlled by various signaling pathways and 
was reported to be present also in M1-like macrophages, albeit in lower levels compared to 
M2-like macrophages. Similar to the data we obtained, LPS treatment of murine PECs was 
shown to induce Il10 expression after 6 h of culturing [363], but was significantly 
downregulated compared to untreated PECs upon stimulation for 48 h [357]. Indeed, MyD88 
and TRIF dependent TLR signaling, including LPS induced TLR4 signaling were reported to 
induce IL-10 production in bone marrow-derived macrophages (BMMs) [364]. Following TLR 
stimulation, activation of extracellular signal-regulated kinase (ERK) and p38 is required for 
inducing Il10 expression in macrophages [365]. IL-10 can act in a negative feedback loop to 
regulate its own production by inducing dual specificity protein phosphatase 1 (DUSP1) 
expression. DUSP1 inactivates the kinase p38 by dephosphorylation, thereby limiting IL-10 
production [366]. In addition, IFNү signaling was shown to inhibit ERK and p38 dependent 
IL-10 production in macrophages [367]. Taken together, the described signaling events 
taking place in macrophages upon stimulation with LPS and IFNү explain the transient 
upregulation of Il10 within the first 24 h of stimulation. Further, the observation that IFNү can 
inhibit IL-10 production and that IL-10 acts in a negative feedback loop to reduce its own 
expression might explain Il10 downregulation after extended stimulation periods. 
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4.5 Repolarization of M2-like macrophages by CD4+ T cells 
4.5.1 Reprogramming of M2-like PECs by CD4+ T cells in vitro 
Having observed that external addition of cytokines polarizes PECs in vitro, we next 
assessed whether cognate interaction with CD4+ T cells would induce IFNү secretion by T 
cells and instruct PECs to acquire a M1-like phenotype. Repolarization of M2-like 
macrophages by CD4+ T cells was already demonstrated in principle with peptide loaded 
macrophages in vitro [368]. In a study from Heusinkveld and colleagues, the authors 
polarized human peripheral blood derived macrophages towards a M2-like phenotype by 
culturing them with culture supernatant of cervical cancer cell lines. Afterwards, they co-
cultured peptide-pulsed M2-like macrophages with different HPV specific CD4+ T cell clones 
which resulted in T cell activation accompanied by secretion of IFNү. The co-cultured 
macrophages expressed high levels of M1-like associated genes (Cd86, Cd83 and Il12) and 
secreted only low amounts of IL-10, indicating a polarization towards the M1-like phenotype. 
However, our analyses of macrophages upon cognate interaction with CD4+ T cells was 
more comprehensive and included detailed gene and protein expression analyses as well as 
functional assays.  
In a first step we showed that peptide loaded IL-4 induced M2-like PECs are susceptible to 
the recognition by OVA specific CD4+ T cells (Figure 3.22). Our data demonstrated that M2-
like PECs were significantly less susceptible to CD4+ T cell recognition compared to M1-like 
macrophages, which is at first glance in line with the low MHC II surface expression 
observed on M2-like PECs. However, M2-like PECs were also less susceptible to CD4+ T 
cell recognition than untreated macrophages, even though they had a slightly higher IAb 
surface expression. These results indicate that besides the amount of MHC II surface 
expression, further parameters impact on the T cell susceptibility of macrophages. Indeed, 
M2-like macrophages are known to impair T cell activity by a variety of mechanisms such as 
the release of immunosuppressive cytokines (e.g. IL-10 and TGF-β). Moreover, M2 
polarized macrophages overexpress the tryptophan degrading enzyme IDO1, thereby 
depriving T cells of tryptophan and suppressing their activation and proliferation [185]. The 
expression of arginase 1 by M2-like macrophages further inhibits antigen-specific T cell 
responses by depriving the cells of the semi-essential amino acid L-arginine [188]. We could 
demonstrate that M2-like PECs efficiently induced IFNү secretion by CD4+ T cells, despite 
their immunosuppressive phenotype. Next, we showed that M2-like macrophages can be 
instructed to acquire a M1-like phenotype upon cognate interaction with CD4+ T cells 
(section 3.3.3.2). Peptide-pulsed M2-like PECs co-cultured with CD4+ T cells in the presence 
of OVA peptide showed a strong upregulation of M1-associated markers when compared to 
M2-like PECs loaded with control peptide or to PECs cultured without T cells (Figure 3.23). 
In contrast, most of the M2-associated genes were downregulated (with the exception of 
Arg1 and Il10) when compared to M2-like PECs cultured with irrelevant peptide. As 
discussed above (section 4.4), the upregulation of the two immunosuppressive molecules 
IL-10 and arginase 1 can be explained at least in part by the signaling events taking place 
during macrophage repolarization. The IFNү concentration in the supernatants of cultures 
that had included the OVA specific T cell epitope was increased 210 fold compared to 
supernatants from co-cultures with irrelevant epitope (HBV), suggesting that IFNү release by 
activated T cells represents the key mediator for macrophage repolarization. Besides 
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detecting successful repolarization of M2-like PECs by comprehensive gene and protein 
expression analyses, we could also observe a switch towards M1-like functionality. M2-like 
PECs co-cultured with CD4+ T cells in the presence of relevant peptide showed a lower 
phagocytic capacity than PECs from the two control groups (Figure 3.24). Taken together, 
these results clearly show that cognate interaction with CD4+ T cells can instruct M2-like 
PECs to acquire M1-like phenotype and function. 
4.5.2 Characterization of TAMs in Ova expressing B16F10 tumors 
We showed that OVA expressing B16F10 tumors in a later stage of development contain 
higher proportions of CD206+ (i.e. M2-like) TAMs with significantly reduced IAb expression 
levels compared to tumors in an earlier stage of development (Figure 3.37). These results 
are in accordance with the assumption that macrophages infiltrating into the tumor 
microenvironment are exposed to a variety of cytokines released by tumor cells or stroma 
cells, inducing their polarization into an immunosuppressive M2-like phenotype [180, 181]. In 
a next set of experiments, we wanted to show that TAMs from OVA expressing tumors took 
up the secreted OVA and present IAb restricted epitopes to CD4+ T cells. This was already 
demonstrated in principle in a myeloma tumor model secreting immunoglobulin L chain V 
region (detailed explanation of these studies are given in section 4.5.3) [210, 211]. However, 
in our tumor model TAMs isolated from OVA expressing tumors could not activate OVA 
specific CD4+ T cells to a higher extend than TAMs isolated from OVA negative parental 
tumors (Figure 3.38). This was not due to a lack of MHC II surface expression, as we could 
demonstrate that peptide pulsed TAMs isolated from B16F10 tumors have the capability to 
stimulate OVA specific CD4+ T cells, showing that IAb expression on TAMs was sufficient to 
facilitate interaction with CD4 TCRs (Figure 3.38). However, our results do not necessarily 
mean that the secreted OVA was not taken up and processed by TAMs. As isolation of 
TAMs from B16F10 tumors by MACS separation yielded insufficient purity, we were 
dependent on performing fluorescence activated cell sorting. Therefore, the tumors were 
enzymatically digested for 1 h at 37 °C using collagenase D, DNAse I and TLCK which might 
affect peptide/MHC complex stability. Subsequently, the cell suspensions were stained with 
monoclonal antibodies and resuspended in FACS buffer. As the TIL infiltration in B16F10 
tumors is low, each tumor sample was sorted for at least 1 h to obtain a sufficient number of 
TAMs. Thus, the sorted macrophages were not in contact with dying or OVA secreting tumor 
cells within the last hours before performing the co-culture experiment, suggesting that 
already dissociated peptide or internalized peptide/MHC complexes cannot be replaced by 
new OVA epitope binding IAb molecules during that time. It has been reported that the 
dissociation half-life of peptide/MHC II complexes can vary between 30 min and several 
days [369]. The predicted IC50 value of the IA
b restricted OVA peptide (aa 323-339; 
ISQAVHAAHAEINEAGR) using the NetMHCII algorithm is 339.4 nM, showing that 339.4 nM 
of this peptide are sufficient to inhibit 50 % of a reference peptide binding [370]. Peptides 
with binding affinities below 50 nM are usually considered as strong binders [371], as it is 
more likely that these peptides remain bound to the respective MHC II molecule. Thus, the 
IAb restricted OVA epitope can be considered as a weak binder, which is probably 
associated with a shorter half-live of the peptide/MHC complex. Therefore, the assumed 
short half-life of OVA epitope MHC II complexes and the absence of OVA before the co-
culture assay might explain our observations.  
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4.5.3 Reprogramming of M2-like TAMs by adoptive CD4+ T cell transfer 
Finally, we investigated whether TAA specific CD4+ T cells would mediate a repolarization of 
TAMs in IAb deficient B16F10 tumors. This was already demonstrated in principle using s.c. 
injected, Matrigel embedded MOPC315 myeloma cells in an Id-specific T cell receptor 
transgenic immunodeficient mouse model. The severe combined immunodeficiency (SCID) 
mice, in which the CD4+ T cells recognize a MHC II restricted tumor-specific peptide (Id) 
derived from the secreted immunoglobulin L chain of MOPC315 myeloma cells, have been 
shown to reject s.c. injected MOPC315 cells. As MOPC315 cells lack the expression of 
MHC II they are not a direct target of Id-specific CD4+ T cells. Nevertheless, the anti-tumor 
effects have been reported to be CD4+ T cell mediated, as the tumor rejection was not 
dependent on the presence of B cells or CTLs [372]. Ten years after the generation of the 
TCR transgenic SCID mouse system, Corthay and colleagues demonstrated that Id-specific 
CD4+ T cells become activated upon co-culture with MOPC315 derived TAMs in vitro, thus 
showing that the macrophages took up the secreted TAA and presented TAA derived 
peptides [210]. Further, the authors detected IFNү secretion by Id-specific CD4+ T cells upon 
interaction with TAMs in vivo and subsequent upregulation of MHC II surface expression on 
TAMs. Finally, the authors could show that MOPC315 tumor rejection was mediated by a 
collaboration of macrophages and TAA specific CD4+ T cells. This study nicely 
demonstrated that TAMs can activate IFNү secretion by endogenous Id-specific CD4+ T cells 
in vivo but did not further investigate changes in macrophage polarization. However, in a 
follow-up study a few years later, the authors used the same transgenic mouse model and 
observed CD4+ T cell mediated polarization of TAMs towards a tumoricidal M1 phenotype 
secreting proinflammatory cytokines (IL-6, IL-1β, CXCL9 and CXCL10) [211]. Even though in 
vitro cultured MOPC315 cells lack the expression of MHC II, they might induce surface 
expression under certain in vivo conditions which would facilitate direct tumor cell killing by 
CD4+ T cells. By repeating some of the above mentioned experiments using MHC II deficient 
MOPC315 cells, Tveita and colleagues demonstrated that tumor rejection was not 
dependent on MHC II expression on tumor cells, thereby further supporting the indirect CD4+ 
T cell mediated tumor cell killing [373]. In another study, the authors injected a mixture of 
TAA positive and TAA negative MOPC315 cells into the TCR transgenic mice to investigate 
whether the indirect tumor cell killing mediated by CD4+ T cells would also result in 
bystander killing of TAA negative MOPC315 cells [374]. The authors frequently observed an 
outgrowth of TAA negative tumor cells, even in the presence of large excess of TAA positive 
cells. They further demonstrated that the CD4+ T cell/Macrophage mediated tumor cell killing 
is restricted to areas of TAA positive MOPC315 cells, thus allowing the escape of TAA 
negative tumor cells. Moreover, it was reported that some TAA positive MOPC315 tumor 
cells persist in a dormant state and eventually grow out to form tumors [375]. The authors 
demonstrated that these tumor cells could escape by impairing indirect TAA antigen 
presentation by macrophages through modulating the quaternary structure of the TAA. 
Taken together, these studies demonstrated that endogenous TAA specific CD4+ T cells can 
indirectly mediate tumor rejection by polarizing macrophages in an “artificial” tumor 
microenvironment (Matrigel containing cytokines such as CCL2, CXCL9, IL-15, IL-18, LIF, 
VEGF, TGFβ) using TCR transgenic immunodeficient mice. In contrast, we are the first who 
comprehensively investigate TAM polarization in a “natural” TME upon adoptive transfer of 
OVA specific CD4+ T cells into tumor bearing immunocompetent mice.   
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The absolute quantification of tumor infiltrated lymphocytes upon adoptive T cell transfer 
revealed that only a very small number of transferred CD4+ T cells reached the tumor 
(Figure 3.40). Indeed, it is well known that tumor cells exert a variety of mechanisms to 
exclude T cells from the TME. Tumor cells can secrete the proangiogenic factor VEGF, 
which is at least in part responsible for the establishment of an abnormal tumor vasculature, 
thereby impairing T cell trafficking into the TME [376, 377]. Blocking the VEGF/VEGFR axis 
by anti-VEGF antibodies was reported to normalize the tumor vasculature and increase the 
infiltration of adoptively transferred T cells into B16 tumors [378]. Further, Klug and 
colleagues showed that neoadjuvant local low-dose gamma irradiation stimulated iNOS 
expression in TAMs which induced vascular normalization and facilitated enhanced T cell 
recruitment [212]. Besides modulating the vasculature, tumor cells can build up physical 
(e.g. collagen deposits) as well as metabolic (anaerobic glucose poor environment) barriers 
which inhibit T cell migration and T cell functionality, respectively [379]. Genetically 
engineered T cells, expressing tumor-specific chemokine receptors might overcome these 
barriers. Indeed, transduction of CAR T cells with the chemokine receptor CCR2b was 
demonstrated to result in significantly higher T cell infiltration into the TME of CCL2 secreting 
tumor cells [380]. 
Even though only a low number of transferred T cells reached the M2KO/OVA tumors in our 
experiments, we could demonstrate that the adoptive transfer of CD4+ T cells mediated a 
repolarization of immunosuppressive M2-like TAMs into M1-like macrophages with 
decreased CD206 surface expression and increased expression levels of M1-associated 
genes (Arg2, Il1b, Cd86, Cxcl10 and Nos2) (Figure 3.41 and Figure 3.43). Moreover, we 
showed that these effects are dependent on the presence of OVA, as changes in 
macrophage polarization were not observed in the microenvironment of OVA negative 
tumors (Figure 3.42). A direct activation of adoptively transferred OVA specific CD4+ T cells 
by OVA323-339 presenting B16F10 cells can be excluded as we were using our established IA
b 
deficient tumor cell line. Instead, our results suggest a cognate interaction between APCs 
which took up OVA and presented IAb restricted OVA epitopes to the transferred CD4+ T 
cells that in turn became activated and secreted IFNү, thereby changing macrophage 
polarization. As macrophages are present within the TME of M2KO/OVA tumors in high 
frequencies (Figure 3.41) and typically have a high phagocytic capacity (especially M2-like 
macrophages as demonstrated in Figure 3.21), we assume that these cells could be 
particularly important in presenting OVA epitopes (as illustrated in Figure 4.1). 
However, so far we cannot rule out that also other APCs, such as B cells and DCs take up 
OVA and present IAb restricted epitopes to transferred CD4+ T cells. The role of DCs in 
presenting TAAs is well known and several studies reported that DCs can take up TAAs and 
present MHC I and MHC II restricted TAAs derived epitopes to CD8+ and CD4+ T cells, 
respectively [381-383]. In contrast, it is still unclear whether B cells are physiologically 
relevant APCs in the TME. Peptide-pulsed (SIINFEKL) B cells injected in syngeneic 
C57BL/6 mice have been reported to induce OVA specific T cell tolerance [384]. Another 
study demonstrated that the presence of B cells blocked an anti-tumor response in vivo after 
vaccination with irradiated tumor cells [385]. However, as soon as resting B cells become 
activated by CD4+ T cells through CD40-CD40L interaction, they upregulate the surface 
expression of co-stimulatory molecules and MHC molecules. These B cells have an 
enhanced capacity to present antigenic peptides and to activate T cells and might play a role 
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in presenting TAAs in the TME [386, 387]. Thus, more comprehensive analyses are required 
to investigate the individual contribution of the different APCs in mediating TAM 
repolarization. 
 
Figure 4.1: Proposed model of TAM repolarization upon adoptive CD4
+
 T cell transfer. 
B16F10 cells (dark red) are injected subcutaneously into C57BL/6J mice to induce tumor growth. 
Tumor infiltrating M2-like macrophages (blue) engulf ovalbumin released by tumor cells and present 
MHC class II (IA
b
) restricted OVA epitopes to adoptively transferred OVA specific CD4
+
 T helper cells 
(orange). The activated CD4
+
 T helper cells secrete IFNγ which induces macrophages to polarize to 
proinflammatory M1 (light red). 
4.6 Modulation of macrophage polarization by transcription factor knock 
down 
Extensive research has led to a better understanding of the signaling pathways that underlie 
macrophage polarization. However, the exact TF mediated control is still not fully elucidated. 
In this study, our collaboration partners combined TF binding information with RNA 
expression profiles and identified five TFs required to retain the M2-like phenotype. The 
expression of the five identified TFs CTCF, E2F1, MYC, PPARү and STAT6 was significantly 
downregulated in LPS/IFNү treated PECs compared to untreated cells (Figure 3.27 A). In 
contrast, the expression level in M2-like PECs was either upregulated (Ctcf, Myc and Pparg) 
or downregulated (E2f1 and Stat6) compared to M0, but consistently higher as in M1-like 
macrophages. Moreover, all five in silico predicted TFs demonstrated a high activity in 
M2-like PECs and a low activity in M1-like PECs (Figure 3.27 B), supporting the detected 
differences in gene expression levels and emphasizing their importance in maintaining the 
M2-like phenotype. Transfection of Ctcf, E2f1, Myc, Pparg and Stat6 targeting siRNAs into 
M2 polarized PECs resulted in strong upregulation of M1-associated genes and in 
H2Kb/OVA peptide IAb/OVA peptide OVA329-337 specific TCR
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downregulated expression of M2-associated genes compared to M2-like PECs treated with 
negative control siRNA. Further, the secretion of proinflammatory cytokines, such as IL-6, 
TNFα, IL-1α and IFNβ was significantly increased upon TF knockdown. Almost the same 
expression profiles were detected when the experiment was repeated excluding Ctcf 
targeting siRNAs, suggesting that knockdown of CTCF was not required for the observed 
effects. Taken together, our data provide strong evidence for the importance of these TFs in 
maintaining a M2-like phenotype in IL-4 stimulated PECs. 
The next paragraphs will give an overview of the known functions of the five identified TFs in 
the process of macrophage polarization. Moreover, published results in accordance with as 
well as disparate from our data will be discussed. 
STAT6 (Signal transducer and activator of transcription 6) 
The important role of STATs in regulating macrophage polarization has been well-
established. While STAT1 is a pivotal TF to induce IFNү mediated M1 polarization, STAT6 is 
required to drive alternative activation of macrophages in the presence of IL4 and/or IL-13. 
Expression of many M2-associated genes, such as Fizz1, Arg1, Mrc1 and Ym1 is regulated 
by STAT6 and accompanied by modifications of the chromatin structure and epigenetic 
changes [388]. siRNA mediated knockdown of STAT6 in murine PECs inhibited the induction 
of M2-associated genes upon treatment with IL-4 [215]. In accordance with these data, the 
overexpression of STAT6 in RAW264.7 cells significantly decreased the percentage of CD86 
positive cells, whereas M2 marker expression was increased [389]. Moreover, IL-4 induced 
inhibition of proinflammatory gene expression is largely mediated by STAT6 [388, 390]. 
STAT6 was reported to directly and/or indirectly suppress IFNү mediated STAT1 expression 
[390-392], and STAT6 knockout mice lose IL-4 induced inhibition of the IFNү/STAT1 
signaling pathway [393]. Further, siRNA knockdown of STAT6 in M1-like RAW264.7 cells 
abrogated IL-4 induced inhibition of Nos2 gene expression [394]. In addition, STAT6 is 
known to modulate expression of other TFs involved in macrophage polarization. For 
instance, expression of Krüppel-like factor (KLF4), an essential factor for IL-4 induced M2-
like polarization was shown to be dependent on STAT6 in RAW264.7 cells [395]. Both TFs 
were found to cooperate to induce M2 marker gene expression. Taken together, the 
importance of STAT6 in inducing and maintaining a M2-like phenotype in murine 
macrophages was demonstrated in various experimental settings. Therefore, the 
identification of STAT6 in our study as one of the five key TFs involved in M2 polarization 
using the mixed-integer-linear programming approach is in accordance with present 
knowledge. 
PPARү (Peroxisome proliferator-activated receptor gamma) 
The human genome encodes for three PPAR subtypes, PPARα, -ү and –δ which are 
expressed in various cell types and tissues [396]. PPARs control virtually all processes of 
fatty acid metabolism, including fatty acid synthesis, storage, transport and their oxidation. 
PPARү was found to be expressed mainly in adrenal glands, spleens and adipose tissue 
and has major functions in regulating lipid metabolism in macrophages and adipocyte 
differentiation. In macrophages, PPARү is constitutively expressed and can be induced upon 
stimulation with IL-4 and/or IL-13. Already 20 years ago, Ricote and colleagues 
demonstrated that activated PPARү inhibits the expression of TFs (STAT, AP-1 and NK-κB) 
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involved in classical macrophage activation [397]. Consistent with these findings, 
macrophages with Pparg deletion were shown to have an impaired capacity to acquire a M2 
phenotype [398]. Further, it was demonstrated that treatment of primary human monocytes 
with PPARү agonists enhanced the activation of M2-associated gene expression [138]. 
Treatment of murine PECs with different PPARү agonists significantly increased CD206 
surface expression and enhanced the phagocytic activity of macrophages, both of which are 
typical features for alternative macrophage activation [399]. Moreover, the authors 
demonstrated that the treatment of macrophages with a PPARү antagonist prevents IL-13 
induced M2-like polarization. Interestingly, STAT6 has been shown to interact with PPARү, 
thereby enhancing PPARү target gene expression [400]. Thus, crosstalk between IL-4 
induced STAT6 and PPARү is probably required for optimal M2 polarization.   
As mentioned earlier (see section 1.2.3), M2 macrophages predominantly use fatty acid 
oxidation as it is best suited for permanent energy supply required for processes like tissue 
repair or remodeling [173]. Several studies demonstrated that transcriptional regulation of 
PPARү and its coactivator PGC-1β are indispensable for the uptake and oxidation of fatty 
acids [398, 401]. Macrophages isolated from mice with macrophage specific PPARү deletion 
showed a significantly reduced fatty acid oxidation compared to macrophages from WT 
mice, demonstrating that oxidative metabolism in M2 macrophages is dependent on PPARү 
[398]. Our results further emphasize the importance of PPARү in inducing and maintaining 
M2-like polarization and are in line with the current state of knowledge. 
CTCF (CCCTC-binding factor) 
CTCF is a highly conserved DNA binding zinc finger nuclease and plays an important role in 
the regulation of several cellular processes such as transcriptional activation/repression and 
imprinting [402]. In contrast to the well-established role of STAT6 and PPARү in regulating 
macrophage polarization, very little is known about the expression and function of CTCF in 
macrophages. In a study from Nikolic and colleagues, the authors crossed LysM-Cre mice 
with mice carrying a Ctcf floxed allele to generate a mouse model with myeloid cell specific 
Ctcf deletion [403]. The absence of Ctcf had no significant effects on macrophage 
frequencies in the peritoneum and the spleens. However, macrophage differentiation from 
bone marrow derived LysM-Cre Ctcff/f precursors was significantly reduced in vitro. Even 
though CTCF was previously reported to be involved in the regulation of MHC II molecule 
expression [404], the authors could not observe any changes in MHC II surface expression 
on macrophages. Ctcf deletion in bone marrow derived macrophages had no significant 
impact on surface expression of CD86, CD206 and CD16/32. Further, Ctcf deficient 
macrophages had similar phagocytic capacity than macrophages from WT mice. 
Interestingly, secretion of the M2-associated cytokine IL-10 and the M1-associated cytokine 
TNF was significantly decreased in bone marrow derived macrophages isolated from LysM-
Cre Ctcff/f mice compared to macrophages from WT mice upon treatment with TLR ligands. 
Whole RNA sequencing comparing gene expression of Ctcf deficient macrophages with WT 
macrophages revealed 617 differentially expressed genes. Genes which were significantly 
downregulated in Ctcf deficient macrophages included both, M1-associated (Nos2, Cxcl10) 
and M2-associated genes (Vegfa). Taken together, these data demonstrate that CTCF is 
involved in the regulation of macrophage differentiation and modulates expression of a vast 
amount of genes. However, the role of CTCF in macrophage polarization is still ambiguous 
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as Ctcf deficiency was associated with reduced levels of M1-like and M2-like associated 
genes.  
In contrast, the results shown in this thesis present a clear association between Ctcf 
expression and alternative macrophage activation. Ctcf expression in IL-4 treated PECs was 
upregulated compared to untreated PECs, but significantly downregulated upon treatment 
with LPS/IFNү. Further, CTCF activity in M1-like PECs was significantly reduced compared 
to untreated and M2-like macrophages. However, our results demonstrated that macrophage 
repolarization upon knockdown of only four TFs (excluding CTCF) was as efficient as knock 
down of all five TFs. These results indicate that in our experimental setting CTCF was not 
required to maintain a M2-like phenotype. However, to make sure that CTCF is indeed 
dispensable for maintaining a M2-like phenotype we would need to perform single 
knockdown experiments, in which only CTCF expression is reduced without knocking down 
any other TFs. It might well be that CTCF is dependent on one of the four TFs and can only 
fulfill its functions if their expression is not reduced by siRNA pools. Nevertheless, our results 
provide a good basis for deeper analysis of CTCF expression and its importance in 
macrophage polarization. 
E2F1 (E2F transcription factor 1)  
E2F1 target genes are involved in cell cycle progression, differentiation, DNA replication and 
repair. Thus, E2F1 is a key transcription factor regulating cellular proliferation and its activity 
in tumor cells is often altered [405]. Whereas the role of E2F1 in controlling the cell cycle 
was investigated comprehensively throughout the last 30 years, almost nothing is known 
about its function in macrophages. E2F1 binding motifs were found to be overrepresented in 
genomic loci that are bound by the NF-κB subunit RELA, suggesting a cooperative 
regulatory function of these two TFs [406]. Moreover, E2F1 together with RELA were shown 
to be rapidly recruited to the promoter regions of proinflammatory cytokine encoding genes 
(e.g. TNFα and IL-1β) upon treatment of THP-1 cells with LPS. siRNA mediated knockdown 
of E2F1 impaired the expression of these LPS induced genes indicating that E2F1 is 
required to fully activate NF-κB target genes. Similar to these observations, inhibition of 
E2F1 in J77A4.1 macrophages and subsequent stimulation with LPS resulted in reduced 
IL-6 and TNFα production [407]. In accordance with these findings, stimulation of bone 
marrow derived macrophages from E2f1 knockout mice with different TLR ligands resulted in 
reduced expression of proinflammatory cytokines (IL-1β, IL-6, IL-12, TNF-α) compared to 
macrophages from control mice [408]. These results further emphasize the role of E2F1 in 
regulating the inflammatory response to TLR ligands in macrophages. 
In contrast to the results described above, our analyses of macrophage polarization upon 
siRNA mediated knockdown of E2F1, MYC, CTCF, STAT6 and PPARү revealed a 
significant upregulation of proinflammatory genes (Cxcl9, Cxcl10, Il1b and Il12b), suggesting 
that E2F1 is involved in repressing rather than activating their transcription. The discrepancy 
between our observations and previously published data might be explained by the different 
experimental approaches applied. While the published results are mainly based on data 
obtained from macrophages treated with LPS after siRNA mediated E2F1 knockdown, our 
results were generated by knocking down E2F1 in M2 polarized cells. Hence, the published 
data investigated the impact of E2F1 deficiency on TLR signaling, whereas we investigated 
the impact of reduced E2F1 expression in IL-4 induced M2 macrophages. It must be 
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assumed that the regulatory function of E2F1 on its target genes is in great part dependent 
on the activated signaling pathway (TLR4 signaling induced by LPS vs. JAK/STAT signaling 
induced by IL-4), which could explain the observed discrepancies between our results and 
published data. 
Myc 
Myc is a proto-oncogene involved in a variety of cellular processes (e.g. cell growth and 
apoptosis) and has been shown to be frequently mutated and/or deregulated in cancer cells 
[409]. MYC was reported to be required for alternative macrophage polarization. The 
transcription factor expression and its translocation into the nucleus is induced upon 
stimulation of macrophages with IL-4 [214]. Expression of Myc in BMMs stimulated with IL-4 
was shown to be increased 3-fold compared to untreated cells, whereas it was decreased 9-
fold in M1-like macrophages [410]. Many M2-associated genes are directly or indirectly 
controlled by MYC. Of note, treatment of IL-4 stimulated macrophages with MYC inhibitor 
abrogated Pparg and Stat6 expression, showing that both TFs are regulated by MYC and 
emphasizing the essential role of MYC in M2 polarization [214]. 
IL-4 induced M2-like macrophages typically have an enhanced migratory capacity, which is 
in accordance with their important function in wound healing. Hao and colleagues 
demonstrated that siRNA mediated MYC knockdown impairs cell migration in IL-4 treated 
RAW264.7 cells, thereby further supporting the role of MYC in maintaining M2-associated 
functionality [411]. Moreover, overexpression of a truncated MYC version (MYC-nick) in 
BMMs was accompanied by upregulation of M2-associated genes and increased 
phagocytosis [412]. Taken together, these results highlight the significance of MYC in 
inducing and maintaining alternative macrophage activation, being involved in controlling 
M2-associated gene expression and functionality. Our data further support the importance of 
MYC, as we could demonstrate that siRNA mediated knockdown of MYC in M2-like PECs 
was associated with increased expression of M1-associated genes and proinflammatory 
cytokine expression.  
4.7 Modulation of macrophage polarization through miRNA transfection 
This part of the study focused on the identification of key miRNAs inducing classical 
activation of macrophages. We identified 56 significantly differentially expressed miRNAs in 
PECs upon treatment with LPS/IFNү or IL-4 or CD4+ T cell mediated repolarization (Figure 
3.34). In the two groups M1-like vs. untreated and M1-like vs. M2.like, we detected 18 and 
19 differentially expressed miRNAs, respectively. After incorporating the RNA sequencing 
data of polarized PECs in the bioinformatics analysis, significantly enriched miRNAs were 
identified. Combining the results obtained from both groups revealed a total of 22 miRNAs 
enriched in M1-like PECs compared to either untreated PECs or M2-like PECs or both. 
These significantly enriched miRNAs can be arranged into three distinct clusters (Figure 
3.35). One cluster contained miRNAs downregulated in M1-like PECs as well as in PECs co-
cultured with OVA specific T cells. The other two clusters encompassed miRNAs either 
upregulated in M1-like PECs only or upregulated in M1-like PECs and PECs co-cultured with 
OVA specific T cells. Finally, six miRNAs (miR-210-3p, miR-674-5p, miR-222-3p, let-7i-5p, 
miR-146a-5p and miR-28a-3p) which were upregulated in both, M1-like (LPS/IFNү) 
macrophages and M2-like PECs upon co-culture with OVA specific CD4+ T cells were 
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selected for subsequent validation as these are the miRNAs supposed to be important for 
inducing a M1-like phenotype. Transfection of all six miRNAs in untreated or M2-like PECs 
resulted in strong induction of M1-associated gene expression and downregulation of M2-
associated genes (Figure 3.36). Unexpectedly, expression of Mrc1 (Cd206) and Arg1, both 
representing typical M2-associated genes, was upregulated in some of the tested conditions. 
Several studies investigated the expression profiles of miRNAs in polarized macrophages. 
Zhang and colleagues performed miRNA microarray analysis with LPS/IFNү or IL-4 treated 
BMMs and identified a total of 109 differentially expressed miRNAs [413]. Of note, 104 of 
these miRNAs were upregulated in M1-like macrophages compared to M2, whereas only 
five were downregulated. Of the six miRNAs we have selected, miR-146a was the only one 
upregulated in M1-like macrophages in their data set, whereas the other five miRNAs were 
not differentially expressed. In another study, Lu and colleagues performed small RNA 
sequencing with in vitro polarized BMMs [414]. They identified a total of 31 differentially 
expressed miRNAs, with 24 being upregulated in M1-like macrophages. Three of our six 
finally selected miRNAs were detected in their data set as well (miR-146a, miR-210 and 
miR-222) and were shown to be upregulated in M1-like BMMs. Qi and colleagues used 
thioglycolate elicited PECs treated with LPS and subsequently identified differentially 
expressed miRNAs by microRNA arrays [415]. They reported a LPS induced upregulation of 
miR-146 and miR-210, which is in accordance with our data. Unfortunately, the authors did 
not further comment on their microRNA array results but immediately selected miR-210 for 
further analyses.  
Taken together, three of our differentially expressed and significantly enriched miRNAs, 
namely miR-210, miR-222 and miR-146a have been reported to be upregulated in M1-like 
macrophages in at least one of the studies. However, differential expression of miR-674, 
Let-7i and miR-28a was not detected. In line with our results, the studies identified more 
upregulated than downregulated miRNAs in M1-like macrophages compared to M2-like. In 
the following, known functions of our six finally selected miRNAs are described. 
miR-210-3p 
Several studies identified a strong upregulation of miR-210-3p expression in LPS treated 
BMMs [416] and PECs [415], suggesting an important role of miR-210-3p in M1-like 
macrophages. However, the expression of proinflammatory cytokines in macrophages 
transfected with miR-210 mimics was shown to be significantly reduced after LPS treatment 
[415]. In accordance with this observation, transfection of macrophages with miR-210 
inhibitor and subsequent LPS stimulation resulted in significant upregulation of these 
cytokines. Our target prediction analysis revealed putative binding sites of miR-210-3p in the 
3’UTR of NFKB1 (subunit of NF-κB). Indeed, Qi and colleagues demonstrated that NF-κB is 
a direct target of miR-210, explaining the induced negative regulation of proinflammatory 
cytokine secretion in LPS treated cells [415]. Taken together, miR-210 expression is induced 
in LPS treated macrophages and acts in a negative feedback loop by targeting TLR 
signaling, thereby inhibiting proinflammatory cytokine secretion.  
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miR-146a-5p 
The substantial effects of miR-146-5p on macrophage polarization have been reported in 
several studies. In accordance with our results, treatment of macrophages with LPS has 
been shown to result in a strong NF-κB dependent upregulation of miR-146a [162]. Of note, 
miR-146a has been demonstrated to target TRAF6 and IRAK1 mRNA, both of which are 
adapter molecules downstream of cytokine and TLR signaling pathways. Thus, miR-146a 
expression is induced in classically activated macrophages to control cytokine and TLR 
signaling in a negative feedback loop and reduce the release of proinflammatory cytokines 
similar to miR-210-3p as described above [162]. In accordance with these results, inhibition 
of miR-146a in polarized PECs promoted the expression of M1-associated genes (Il6 and 
Il1b) and decreased expression of M2-associated genes (Pdgf and Arg1). Furthermore, 
miR-146a transfected RAW264.7 cells mixed with 4T1 cells and injected subcutaneously 
(s.c.) into BALB/c mice significantly promoted tumor growth [163]. 
miR-674-5p 
The targets and functions of miR-674-5p are largely unknown, which is supported by the fact 
that only five publications including the term “miR-674-5p” can be found when using the  
PubMed search engine (https://www.ncbi.nlm.nih.gov/pubmed/; accessed: 19.08.18). None 
of these publications is dealing with miR-674-5p expression in the context of macrophages in 
general or macrophage polarization in particular. Thus, miR-647-5p is described in this 
thesis for the first time as miRNA differentially expressed in polarized macrophages. Our 
target prediction analysis revealed 1038 target genes (predicted by at least two prediction 
tools) with putative binding sites for miR-647-5p. The predicted targets include genes 
involved in fatty acid metabolism (Abcd1) and purin biosynthesis (Gart), both representing 
processes known to be enhanced in M2-like macrophages [417]. Thus, miR-674-5p 
expression in M1-like macrophages might be required to downregulate these processes. Our 
experimental validation indicates that this miRNA plays a role in repolarizing M2-like 
macrophages. However, more comprehensive analyses as briefly described in section 5 are 
required to make a final statement. 
miR-222-3p 
In LNCaP prostate carcinoma cells, stimulation of the NF-κB pathway by TNFα was shown 
to enhance miR-222 expression [418]. Inhibiting the NF-κB pathway in PC3 prostate 
carcinoma cells and U87 glioblastoma cells resulted in decreased expression levels of 
miR-222. These results demonstrate that miR-222 expression is dependent on NF-κB 
signaling, which is in accordance with our data showing a significant upregulation of miR-222 
in LPS/IFNү treated macrophages. After co-transfecting miR-222-3p in combination with the 
other five identified miRNAs into M2-like PECs we could detect a repolarization towards the 
M1-like phenotype with several proinflammatory cytokines being upregulated. In contrast to 
our results, a study from Ying and colleagues demonstrated polarization of human U937 
cells into M2-like macrophages upon transfecting miR-222-3p mimics [419]. However, it can 
be assumed that the function of miRNAs between different species (and even different cell 
lines of the same species as observed by Theresa Kordaß) can differ substantially even 
though their sequences are often highly conserved. A study investigating the function of 
miR-222-3p in murine macrophages has not been published yet. 
Discussion 
135 
 
let-7i-5p 
Ten different mature let-7 miRNAs have been identified until today in both, human and mice 
[420]. Whereas the whole mature sequence of let-7a is identical across animal species, 
other members of this family share only the seed sequences. The role of let-7 miRNAs in 
macrophage polarization was already described for let-7c and let-7b. Let-7c was 
demonstrated to be significantly higher expressed in M2-like BMMs compared to M1-like 
BMMs [421]. Further, LPS induced repolarization of M2-like macrophages decreased the 
expression of let-7c. Transfection with let-7c mimics induced polarization towards a M2-like 
phenotype with reduced expression of proinflammatory cytokines compared to control 
transfections. These results demonstrated that let-7c suppresses M1-like polarization and 
can promote M2-like polarization. The same holds true for let-7b, which was shown to be 
expressed to significantly higher extent in IL-4 induced human peripheral blood derived 
macrophages compared to LPS/IFNү treated or untreated macrophages [422]. 
The expression and function of let-7i in macrophages has not been described so far. 
However, it was reported that let-7i targets and downregulates expression of TLR4 in human 
biliary epithelia cells (cholangiocytes) [423]. At the same time, activation of TLR4 signaling 
by LPS treatment resulted in decreased let-7i expression levels. Similar regulatory effects of 
let-7i on TLR4 expression were observed in the human monocytic cell line THP-1 [424]. In 
contrast to the LPS induced downregulation of let-7i expression observed in cholangiocytes, 
our miRNA expression data showed a significant upregulation of this miRNA in PECs treated 
with LPS/IFNү. Moreover, none of the nine miRNA target prediction tools predicted a TLR4 
binding site for let-7i, indicating that regulatory functions of let-7i differ between mice and 
humans. Indeed, the let-7i binding site in the human TLR4 3’UTR sequence is absent in 
mice [425]. 
miR-28a-3p 
Not a single publication including the term “miR-28a-3p” can be found by the PubMed search 
engine and only three publications including the term “miR-28a” are listed in the underlying 
databases (https://www.ncbi.nlm.nih.gov/pubmed/; accessed: 20.08.18). None of these 
publications were dealing with the role of miR-28a in macrophage polarization. Therefore, 
this thesis describes for the first time differential expression of miRNA-28a-3p in polarized 
macrophages. 
Taken together, two of our six finally selected miRNAs have well-known functions in 
macrophage polarization (miR-210-3p and miR-146a-5p). The role of the remaining four 
miRNAs is either largely (miR-222-3p) or completely (miR-674-5p, let-7i-5p and miR-28a-3p) 
unknown. miR-210-3p and miR-146a-5p have been reported to act in a negative feedback 
loop to inhibit proinflammatory cytokine secretion by macrophages. Therefore, it seems 
contradictory to use these miRNAs in an attempt to repolarize M2-like macrophages into a 
M1-like phenotype. However, our enrichment analysis (see section 3.3.5.2) not only 
guarantees that the selected miRNAs are upregulated after LPS/IFNү treatment, but also 
ensures that the predicted targets of these miRNAs are significantly downregulated in M1-
like PECs. Thus, these two miRNAs might have a dual role in macrophage polarization. On 
the one hand they are responsible for fine tuning of NF-κB expression in LPS induced 
macrophages to prevent excessive release of proinflammatory cytokines and on the other 
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hand they might facilitate maintenance of the M1-like phenotype by downregulating M2-
associated genes. Even though our results indicate that the remaining four miRNA 
candidates are important in inducing and maintaining a M1-like phenotype, more 
comprehensive analyses are required to rule out similar negative feedback loops.    
In addition to the analysis of differentially miRNA expression in PECs polarized with 
cytokines, we also included samples of M2-like PECs repolarized by cognate interaction with 
OVA specific CD4+ T cells. Our in vitro data clearly demonstrate T cell mediated 
reprogramming of these macrophages into an immunostimulatory M1-like phenotype 
(section 3.3.3). Our gene and protein expression analyses revealed that the repolarized 
macrophages very much resemble the classically activated macrophages (LPS/IFNү). Thus, 
we would have expected very similar miRNA expression profiles between these two groups. 
However, 29 miRNAs were significantly differentially expressed in the group M1-like vs. M2-
like after co-culture with T cells + OVA peptide, clearly demonstrating that M1-like PECs 
polarized by external cytokine addition (LPS/IFNү) are different from M2-like PECs which 
were repolarized into M1-like by CD4+ T cells (section 3.3.5.1). Of note, the difference in the 
miRNA expression profiles between these two groups was higher than between IL-4 induced 
M2-like and LPS/IFNү induced M1-like PECs. These differences are most likely attributed to 
the fact that a repolarization by cognate T cell interaction incorporates other signaling 
pathways than the polarization by external cytokine addition. Stimulation of macrophages 
with LPS/IFNү activates TLR4 and JAK/STAT signaling pathways, eventually leading to the 
activation of TFs such as STAT1, STAT2, IRF-1, NF-κB, AP-1, IRF-7 and IRF-3 [144-146]. In 
contrast, cognate interaction of M2-like macrophages with CD4+ T cells might activate 
signaling pathways associated with engagement of CD86 and CD80 by CD28 and CTLA-4. 
Moreover, due to the release of IFNү by activated CD4+ T cells JAK/STAT signaling 
pathways become activated. Eventually, the activation of distinct TFs as well as the crosstalk 
between the activated signaling pathways will determine miRNA expression and probably 
explain the observed differences between LPS/IFNү induced PECs and M2-like PECs 
repolarized through cognate CD4+ T cell interaction. 
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5 Summary and outlook 
This thesis demonstrates reprogramming of immunosuppressive M2-like macrophages upon 
MHC II restricted interaction with CD4+ T cells, transcription factor knockdown and miRNA 
transfection. 
In the first part of the project we demonstrated that cognate interaction between M2-like 
PECs and CD4+ T cells was accompanied by IFNү release of activated CD4+ T cells, thereby 
instructing macrophage repolarization towards a M1 phenotype. Upon adoptive transfer of 
OVA specific CD4+ T cells into C57BL/6 mice bearing IAb deficient OVA expressing tumors, 
partial repolarization of TAMs freshly isolated from explanted tumors was observed, 
suggesting that interaction between OVA specific CD4+ T cells and TAMs can shift the 
M1/M2 balance towards M1 also in vivo. However, to make sure that the observed 
macrophage repolarization is exclusively mediated by cognate interaction between CD4+ 
T cells and macrophages, we would need to repeat our experiments in transgenic mice with 
IAb deficient macrophages [426]. In such a mouse model, the absence of TAM repolarization 
upon adoptive transfer of CD4+ T cells would proof that the cognate interaction between 
macrophages and transferred CD4+ T cells is required. Moreover, it would be interesting to 
repeat the adoptive T cell transfer experiments with our B16F10 transfectant clone 
expressing a truncated version of OVA (not secreted). These results could clarify whether 
the CD4+ T cell mediated changes in TAM polarization are dependent on the secretion of 
tumor associated antigens or not. In the second part of the thesis we identified five TFs 
(CTCF, E2F1, MYC, PPARү and STAT6) associated with the induction and maintenance of 
the M2 phenotype. siRNA mediated TF knockdown induced the expression of 
proinflammatory cytokines in M2-like PECs. Further, M2-like macrophages expressed 
elevated levels of M1-associated genes and lower levels of M2-associated genes. As we 
knocked down all five TF simultaneously, it is difficult to determine to what extend each 
individual TF contributes to the observed repolarization. However, the on-going analysis of 
RNA sequencing data from M2-like PECs transfected with each TF targeting siRNA 
individually will finally clarify the exact functions of each TF in the process of macrophage 
polarization. Nevertheless, the data we have obtained so far reveal already new insights into 
the transcriptional reprogramming of macrophages and might be useful for the identification 
of therapeutic targets to reprogram M2 macrophages into the proinflammatory M1-like 
macrophages. Finally, small RNA sequencing of in vitro polarized PECs revealed 19 
miRNAs differentially expressed between M1-like and M2-like PECs. Six miRNAs highly 
expressed in M1-like PECs were selected for further validation. Transfection of these 
miRNAs into M2-like or untreated PECs resulted in significant upregulation of M1-associated 
genes, whereas M2-associated genes were downregulated. Our data indicate that 
repolarizing M2-like macrophages by a pool of miRNAs is in principle possible. However, 
future experiments should include individual transfections of each miRNA into M2-like PECs, 
thus allowing for better interpretation of the function of the different miRNAs. In addition, 
more comprehensive analyses (cytokine secretion, phagocytosis assays, protein expression) 
and proper negative controls (pool of negative control miRNAs) are required to draw final 
conclusions.
Appendix 
138 
 
6 Appendix 
 
Figure 6.1: Vector chart of PX458. 
 
Figure 6.2: Analysis of IAb surface expression on B16F10 derived transfectant clones.  
IA
b
 surface expression of individual B16F10 derived clones transfected either with guide #1 or guide 
#4 encoding vector and of parental B16F10 cells after treatment with IFNγ and subsequent staining 
with IA
b
 specific monoclonal antibody. Untreated (B16F10 w_o) and unstained B16F10 cells served 
as background controls, whereas parental B16F10 cells treated with IFNγ (B16F10 + IFNg) served as 
positive control. Designations of clones are depicted in the column at the right. This figure legend was 
taken from reference [307] and was originally written by myself. 
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Figure 6.3: Transduced cell lines stably integrated the OVA encoding sequence. 
B16F10 or M2KO cells were transduced using lentiviral particles encoding for OVA. Both bulk cultures 
stably integrated OVA in their genome as confirmed by PCR and subsequent agarose gel 
electrophoresis. Expected product size for full length OVA is 229 bp and for truncated OVA 323 bp.  
 
Figure 6.4: Surface protein expression analysis of polarized PECs. 
PECs were isolated, purified and polarized either into M1-like (LPS + IFNγ) or M2-like (IL-4) 
macrophages 4 days after thioglycolate injection. After 24, 48 and 72 h of polarization, the cells were 
harvested, stained with (A) iNOS, (B) IA
b
 or (C) CD206 specific monoclonal antibodies and analyzed 
by flow cytometry. Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+
 → 
CD206/Egr2 vs. FSC-H 
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Table 6.1: Transfection of PECs with GFP encoding plasmid. 
Detailed depiction of all tested transfection approaches of PECs using 10 different transfection 
reagents. The corresponding results are illustrated in Figure 3.28. 
Reagent Approach 
Cell 
number 
TR [µl] DNA [µg] 
living cells 
[%] 
GFP+ cells 
[%] 
L
ip
o
fe
c
ta
m
in
e
 L
T
X
 
untreated 1 x 10
6
 0 0 87 0 
mock 1 1 x 10
6
 6 0 69.2 0.6 
mock 2 1 x 10
6
 15 0 71.4 1 
1 1 x 10
6
 6 2.5 4.4 3.6 
2 1 x 10
6
 9 2.5 0.6 3.2 
3 1 x 10
6
 12 2.5 0.2 14.3 
4 1 x 10
6
 15 2.5 0.2 0 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 6 0 89.8 0.1 
mock 2 2 x 10
6
 15 0 88.8 0.5 
1 2 x 10
6
 6 2.5 22.1 3.6 
2 2 x 10
6
 9 2.5 3.5 0.8 
3 2 x 10
6
 12 2.5 0.7 1.2 
4 2 x 10
6
 15 2.5 0.3 2.5 
L
ip
o
fe
c
ta
m
in
e
 3
0
0
0
 untreated 1 x 10
6
 0 0 87 0 
mock 1 1 x 10
6
 3.75 0 88.9 0.1 
mock 2 1 x 10
6
 7.5 0 89 0.3 
1 1 x 10
6
 3.75 2.5 5.4 1.4 
2 1 x 10
6
 7.5 2.5 0.4 2.3 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 3.75 0 92.9 0.1 
mock 2 2 x 10
6
 7.5 0 93.1 0.1 
1 2 x 10
6
 3.75 2.5 29.3 1.2 
2 2 x 10
6
 7.5 2.5 1.4 5.3 
P
ro
m
o
F
e
c
ti
n
 
untreated 1 x 10
6
 0 0 87 0 
mock 1 1 x 10
6
 1.5 0 86.3 0.4 
mock 2 1 x 10
6
 6 0 84.9 1 
1 1 x 10
6
 3 1.5 74.3 0.9 
2 1 x 10
6
 1.5 1.5 81.5 0.2 
3 1 x 10
6
 4.5 1.5 69.7 1.3 
4 1 x 10
6
 6 1.5 63.6 2.1 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 1.5 0 91.3 0.1 
mock 2 2 x 10
6
 6 0 91 0.2 
1 2 x 10
6
 3 1.5 83.5 0.2 
2 2 x 10
6
 1.5 1.5 84.6 0.1 
3 2 x 10
6
 4.5 1.5 81 0.5 
4 2 x 10
6
 6 1.5 78.2 0.8 
T
ra
n
s
IT
-X
2
 
untreated 1 x 10
6
 0 0 87 0 
mock 1 1 x 10
6
 7.5 0 88.2 1.5 
mock 2 1 x 10
6
 15 0 70.4 0.5 
1 1 x 10
6
 7.5 2.5 0.8 2.5 
2 1 x 10
6
 15 2.5 0.1 0 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 7.5 0 92 0.4 
mock 2 2 x 10
6
 15 0 80.7 0.1 
1 2 x 10
6
 7.5 2.5 3.7 2.5 
2 2 x 10
6
 15 2.5 0.3 0 
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Reagent Approach 
Cell 
number 
TR [µl] DNA [µg] 
living cells 
[%] 
GFP+ cells 
[%] 
T
ra
n
s
IT
-2
0
2
0
 
untreated 1 x 10
6
 0 0 87 0 
mock 1 1 x 10
6
 2.5 0 89.4 0.5 
mock 2 1 x 10
6
 7.5 0 90.5 0.8 
1 1 x 10
6
 7.5 2.5 45.8 10.7 
2 1 x 10
6
 2.5 2.5 50.5 11.1 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 2.5 0 92 0.2 
mock 2 2 x 10
6
 7.5 0 92.7 0.3 
1 2 x 10
6
 7.5 2.5 72.2 4.6 
2 2 x 10
6
 2.5 2.5 71.2 3.3 
T
u
rb
o
F
e
c
t 
untreated 1 x 10
6
 0 0 87 0 
mock 1 1 x 10
6
 4 0 84.6 0.3 
mock 2 1 x 10
6
 8 0 81.7 0.4 
1 1 x 10
6
 6 4 78 0.6 
2 1 x 10
6
 4 4 76.7 0.3 
3 1 x 10
6
 8 4 73.9 0.6 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 4 0 92.6 0.1 
mock 2 2 x 10
6
 8 0 88.7 0.2 
1 2 x 10
6
 6 4 83.4 0.1 
2 2 x 10
6
 4 4 81.8 0 
3 2 x 10
6
 8 4 82.4 0.1 
V
ir
o
m
e
r 
R
e
d
 
untreated 1 x 10
6
 0 0 87 0 
mock 1 x 10
6
 200 0 82.6 0.5 
1 1 x 10
6
 40 0.4 81.9 0.4 
2 1 x 10
6
 100 1 74.4 0.7 
3 1 x 10
6
 200 2 55.9 2.7 
4 1 x 10
6
 300 3 44.8 6.9 
5 1 x 10
6
 400 4 39.4 15.1 
untreated 1 x 10
6
 0 0 87 0 
mock 1 2 x 10
6
 40 0 90.8 0.1 
mock 2 2 x 10
6
 400 0 90.3 0.1 
1 2 x 10
6
 40 0.4 85.7 0.1 
2 2 x 10
6
 100 1 82 0.2 
3 2 x 10
6
 200 2 72.8 1.2 
4 2 x 10
6
 300 3 62.5 4.1 
5 2 x 10
6
 400 4 60.7 7.6 
DNA 2 x 10
6
 pos. Ctrl. 
DNA 
- 80.6 0.4 
RNA 2 x 10
6
 pos. Ctrl. 
RNA 
- 89.1 17.4 
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Reagent Approach 
Cell 
number 
TR [µl] DNA [µg] 
living cells 
[%] 
GFP+ cells 
[%] 
E
ff
e
c
te
n
e
 
untreated 2 x 10
6
 0 0 89.4 0 
mock 1 2 x 10
6
 2 0 90.7 0 
mock 2 2 x 10
6
 40 0 85.1 0.2 
1 2 x 10
6
 10 0.4 89.9 0 
2 2 x 10
6
 20 0.4 85.7 0.1 
3 2 x 10
6
 4 0.4 90.7 0 
4 2 x 10
6
 5 0.2 88.5 0 
5 2 x 10
6
 10 0.2 88.8 0 
6 2 x 10
6
 2 0.2 82.8 0 
7 2 x 10
6
 15 0.6 79.2 0.1 
8 2 x 10
6
 30 0.6 80.5 0.3 
9 2 x 10
6
 6 0.6 89.2 0.1 
10 2 x 10
6
 40 0.8 77.5 0.9 
11 2 x 10
6
 8 0.8 87.5 0 
12 2 x 10
6
 20 0.8 75.9 0.5 
D
h
a
rm
a
fe
c
t 
D
u
o
 
untreated 2 x 10
6
 0 0 89.4 0 
mock 1 2 x 10
6
 1 0 92.4 0 
mock 2 2 x 10
6
 12 0 85.4 0 
1 2 x 10
6
 4 2 18.7 0.2 
2 2 x 10
6
 2 2 48.2 0.1 
3 2 x 10
6
 6 2 6.1 0.4 
4 2 x 10
6
 2 1 45.6 0.1 
5 2 x 10
6
 1 1 62.3 0 
6 2 x 10
6
 3 1 25.4 0.2 
7 2 x 10
6
 8 4 1.9 0.8 
8 2 x 10
6
 4 4 11.9 0.2 
9 2 x 10
6
 10 4 0.5 1.6 
M
e
ta
fe
c
te
n
e
 P
ro
 
untreated 2 x 10
6
 0 0 89.4 0 
mock 1 2 x 10
6
 2 0 76.1 0 
mock 2 2 x 10
6
 25 0 32.2 0.9 
1 2 x 10
6
 2 1 84.5 0 
2 2 x 10
6
 5 1 77.7 0 
3 2 x 10
6
 7 1 76.3 0.1 
4 2 x 10
6
 4 2 64 0.3 
5 2 x 10
6
 10 2 55.8 0.8 
6 2 x 10
6
 14 2 77.1 0.1 
7 2 x 10
6
 8 4 37.3 6.6 
8 2 x 10
6
 20 4 48 1.9 
9 2 x 10
6
 28 4 67.7 2.3 
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Figure 6.5: Control transfections of B16F10 cells using a GFP encoding plasmid. 
B16F10 cells (2 x 10
5
) were seeded into a 6-Well plate and transfected with a GFP encoding plasmid 
using the standard protocol provided by the manufacturer. The cells were harvested and analyzed by 
flow cytometry 48 h after transfection. The numbers given within the graphs represent the 
percentages of GFP positive cells. Gating strategy: living cells → single cells (FSC-A vs. FSC-H) → 
GFP vs. FSC-H. 
Table 6.2: In search of an appropriate housekeeping gene for qPCR analysis of 
polarized PECs after miRNA transfection. 
The BaseMean serve as a measure of the expression level of a certain miRNA across all tested 
samples. The subsequent columns show whether the housekeeping genes are regulated by one of 
the miRNAs. The numbers show how many of the following tools predict an interaction between 
miRNA and housekeeping gene: MiRTarBase (validated miRNA targets), Microcosm, miRanda, 
miRNAMap2, miRMap, miRDB, PITA, Pictar and TargetScan (miRNA-target prediction tools). The 
log(2) fold change values present the fold change expression between M1-like and M2-like PECs.  
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Hprt 2361 2 0 0 0 1 0 0 1 0 0 0 0 1 0 5 0.28* 
Actb 48061 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0.38* 
Tbp 559 1 1 0 1 1 1 1 2 1 1 1 3 1 1 16 0.24* 
Ppia 2894 0 0 0 0 0 1 0 1 0 0 0 0 0 1 3 0.06 
Rpl13a 4281 0 1 0 0 0 0 0 1 0 0 0 0 0 0 2 -0.08 
Gusb 15590 1 0 1 2 0 0 0 1 1 0 0 2 0 1 9 -1.27* 
B2m 125058 0 0 0 0 0 0 0 0 1 0 1 0 0 0 2 1.96 
Hmbs 409 1 0 0 1 0 0 0 0 1 0 0 0 1 0 4 -0.89* 
Rn18s n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Gapdh 2239 2 0 0 0 0 0 0 0 0 0 0 0 1 0 3 2.44* 
Ubc 28430 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1.25* 
Rpl19 1777 0 0 0 0 0 1 0 0 0 0 0 1 1 0 3 -0.08 
n.a. = not available; * p ≤ 0.05 
GFP
C
o
u
n
t
TurboFect PromoFectin Viromer TransIT-2020
EffecteneTransIT-X2Lipo-30001Lipo-LTX1
mocktransfectedunstained
0 0 0 0
0 0 0 0
17.7 94 72.8 84.4
99.3 99.2 99.6 19.1
0.5 0.4 0.8 0.3
1.5 0.7 0.7 0
1only around 30 % of the cells survived
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Figure 6.6: Z-scores of differentially expressed miRNAs in polarized PECs. 
 
miRNA
mmu-miR-186-5p
mmu-miR-142a-3p
mmu-miR-142a-5p
mmu-miR-149-5p
mmu-miR-28a-3p
mmu-miR-30e-5p
mmu-miR-361-5p
mmu-miR-378a-5p
mmu-miR-32-5p
mmu-miR-378a-3p
mmu-miR-34a-5p
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mmu-miR-222-3p
mmu-miR-150-5p
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Figure 6.7: Infiltration of adoptively transferred OVA specific CD4
+
 T cells and polarization of 
TAMs in PDAC/OVA-F tumor bearing mice. 
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 6) were injected s.c. with 2 x 10
6
 PDAC/OVA-F 
cells. Ten days after tumor inoculation, mice were injected i.v. with 5 x 10
6
 peptide pre-activated OVA 
specific CD4
+
 T cells (p). Mice were sacrificed four days later and tumors were analyzed by flow 
cytometry. Control mice (c) did not receive CD4
+
 T cells. (B) Tumor volume 10 and 14 days after 
tumor cell injection. (C) Infiltration of adoptively transferred T cells into tumors presented as 
percentage of CD45.2
+
 within CD3
+
CD4
+
 cells. Gating strategy: CD45
+
 → living cells → single cells 
(FSC-A vs. FSC-H) → CD3
+
CD4
+
 → CD45.1 vs. CD45.2. (D) Percentages of TAMs 
(F4/80
+
CD11b
+
Gr1
-
) within CD45
+
 cells as well as percentages and MFI values of CD206 and IA
b
 
expressing TAMs. Error bars represent SEM within each animal collective. Statistical analysis was 
done by unpaired Student’s t-test (95% CI, ns: not significant, * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001). 
Gating strategy: CD45
+
 → living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+
Gr1
-
 → 
CD206 vs. IA
b
.   
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Figure 6.8: Polarization of TAMs in EO771/OVA-F tumors upon ACT with CD4
+
 T cells. 
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 7-8) were injected s.c. with 2 x 10
6
 
EO771/OVA-F cells. Thirteen days post tumor inoculation, mice were injected i.v. with 5 x 10
6
 peptide 
pre-activated OVA-specific CD4
+
 T cells. Mice were sacrificed on day 17 and tumors were analyzed 
by flow cytometry. Control mice (c) did not receive CD4
+
 T cells. (B) Tumor volume and tumor weight 
13 and 17 days post tumor cell injection, respectively. (C) Four days post i.v. injection tumors were 
analyzed by flow cytometry. Percentages of TAMs (F4/80
+
CD11b
+
Gr1
-
) within CD45
+
 cells as well as 
percentages and MFI values of CD206 and IA
b
 expressing cells within TAMs are shown. (D) Total 
numbers of CD45
+
 cells, TAMs, CD206 as well as IA
b
 expressing TAMs (upper panel) within 
EO771/OVA-F tumors after ACT. Corresponding tumor weight normalizations are depicted in the 
lower panel. Error bars represent SEM within each animal collective. Statistical analysis was done by 
unpaired Student’s t-test (95% CI, ns: not significant, * p ≤ 0.05, ** p < 0.01, *** p ≤ 0.001).  Gating 
strategy: CD45
+
 → living cells → single cells (FSC-A vs. FSC-H) → F4/80
+
CD11b
+
Gr1
-
 → CD206 vs. 
IA
b
. 
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Figure 6.9: Survival of B16F10/OVA-F tumor bearing mice after adoptive T cell transfer with 
OVA specific CD4
+
 and CD8
+
 T cells. 
(A) Experimental workflow: C57BL/6 Ly5.1 mice (n = 7 - 8) were injected s.c. with 2 x 10
5
 
B16F10/OVA-F cells. Eight days after tumor inoculation, mice were injected i.v. either with 5 x 10
6
 
peptide pre-activated OVA specific CD8
+
 T cells or a combination of OVA specific CD4
+
 and CD8
+
 T 
cells (5 x 10
6
 each). Mice not receiving any T cells served as control group (control). (B) Tumor 
volume of the different treatment groups eight days after tumor cell injection. (C) Kaplan-Meier 
survival curves of mice treated either with CD8
+
 T cells alone or a combination of CD4
+
 and CD8
+
 T 
cells. Significance was determined using log-rank test. (D) Tumor growth of individual tumors within 
each group. Error bars represent SEM within each animal collective. 
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Figure 6.10: Tumor rechallenge of mice after adoptive transfer 
C57BL/6 Ly5.1 mice that rejected the B16F10/OVA-F tumor completely (n = 3) as well as a control 
group of mice (n = 6) were injected s.c. with either 2 x 10
5
 B16F10/OVA-F cells 11 weeks post T cell 
transfer (A) or 2 x 10
5
 B16F10 cells 21 weeks post T cell transfer (B). Error bars represent SEM within 
each animal collective. 
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